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Abstract
In this thesis, we consider interim sample size adjustment in clinical trials with
multiple co-primary continuous endpoints. We aim to answer two questions: First, how to
adjust a sample size in clinical trial with multiple continuous co-primary endpoints using
adaptive and group sequential design. Second, how to construct a test in order to control
the family-wise type I error rate and maintain the power, even if the correlation ρ between
endpoints is not known.
To answer the first question, we conduct K different interim tests, each for one
endpoint and each at levelα/K (i.e. Bonferroni adjustment). To answer the second question,
either we perform a sample size re-estimation in which the results of the interim analysis
are used to estimate one or more nuisance parameters, and this information is used to
determine the sample size for the rest of the trial or the inverse normal combination test
type approach; or we conduct a group sequential test where we monitor the information,
and the information is adjusted to allow the correlation ρ to be estimated at each stage or
the inverse normal combination test type approach.
We show that both methods control the family-wise type I error α and maintain
the power and that the group sequential methodology seems to be more powerful, as this
depends on the spending function.
xx
Chapter 1
Introduction and Background
1.1 Introduction
The following problem is the main focus of this thesis: Suppose we have a study with two
treatment groups, E (experimental) and C (control), which are to be compared in a parallel
group randomised phase III clinical trial, and the same study has also K co-primary end-
points. We want to control the family-wise type I error rate, which is defined as the prob-
ability of falsely rejecting at least one null hypothesis among K hypotheses. We also want
to control the power, knowing that it will depend on some nuisance parameters. Somehow
we want to use interim data to modify the sample size to fix the power.
To resolve this problem, we will consider statistical methods for dealing with interim
data. They will be sample size re-estimation, the group sequential approach and the inverse
normal combination test procedure. Before reviewing these methods in more detail in the
context of a single endpoint in the next chapter, this chapter gives some background on the
concepts used throughout this thesis. Section 1.2 describes some of these concepts, Section
1.3 presents the concept of multiple endpoints, Section 1.4 describes the general framework
of the analysis and Section 1.5 presents a summary.
Chapter 2 provides a literature review of the methods in the context of a single end-
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point. Section 2.1 provides a background on the sample size re-estimation procedure with a
single endpoint. This method enables the use of interim analyses of data to estimate one or
more nuisance parameters. Following each interim analysis, this estimate is used to deter-
mine the sample size for the remainder of the trial. Section 2.2 describes the inverse normal
combination test method in the context of a single endpoint. This procedure enables the
combination of interim data and final data at the final analysis. As is described, this analy-
sis method can be used along with the sample size re-estimation approach. In Section 2.3,
the group sequential design method is described, again in the setting of analysis of a single
endpoint. This method allows a series of interim analyses to be conducted. As described
below an error spending function can be used to ensure type I error control. Finally, in
Section 2.4, the group sequential design inverse normal combination test method with a
single endpoint is presented. This approach integrates the inverse normal combination test
method into classical group sequential testing approach.
Chapter 3 presents the idea of sample size reestimation in the context of multiple
co-primary endpoints. Section 3.1 presents a sample size reestimation approach for this
setting, Section 3.2 describes the inverse normal combination tests method with multiple
co-primary endpoints with sample size re-estimation and Section 3.3 presents a summary
of the findings.
Chapter 4 describes group sequential designs in the context of multiple endpoints.
The method uses specified stopping rules and a spending function based on the information
at each interim analysis. This information is adjusted to allow for the estimated correlation,
ρ, between test statistics at each stage.
Chapter 5 presents the group sequential inverse normal combination tests procedure
with multiple co-primary endpoints. The method integrates the concept of an inverse nor-
mal combination tests approach into the group sequential designs procedure described in
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Chapter 4.
Finally, Chapter 6 provides a discussion of the main features of the new method-
ologies introduced, summarises their properties and offers a conclusion. Limitations of the
current work and suggestions for further work are also highlighted in this chapter.
3
1.2 Concepts
This section gives background and introduces some concepts and statistical tools required
in the rest of this thesis. Notation and key terms are defined in Subsection 1.2.1, background
on clinical trials is given in Subsection 1.2.2, whilst Subsections 1.2.3 to 1.2.8 give details
of the normal distribution, nuisance parameters, one-sided tests, fixed sample Z-tests, fixed
sample t-tests and p-values respectively. Finally, motivation for sequential analysis is given
in Subsection 1.2.9.
1.2.1 Notation and Definition of terms
The following notation is used throughout this thesis.
(i) K represents the total number of co-primary endpoints; there are K endpoints. These
will generally be labelled as k = 1,2,...,K.
(ii) J denotes total maximum number of stages or looks. The interim stages will generally
be indexed by j, j = 1,...,J.
(iii) E denotes the experimental randomised, independently, identically distributed group
and C represents the control randomised, independently, identically distributed group.
(iv) nEj (nCj) denotes the total number of randomised patients in group E (C) up to and
including the jth stage and nEJ (nCJ ) represents a maximum sample size specified
in advance. To simplify the notation, we assume that each group has equal sample
size nEj = nCj , and denote this by nj . We finally assume that each group has a
maximum sample size of nJ and we denote this by N.
(v) XijkE represents the random variable of the kth endpoint for the ith subject in group E
at stage j (k = 1, ..., K, i = 1, ..., nEj, j = 1, ..., J) and XijkC represents the random
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variable of the kth endpoint for the ith subject in group C at stage j (k = 1, ..., K, i =
1, ..., nCj, j = 1, ..., J).
(vi) E(XijkE) = θkE denotes the mean response for subjects receiving the experiment
treatment E, and E(XijkC) = θkC represents the mean response for subjects receiving
the control intervention C.
(vii) θk represents the mean difference between the two groups on the kth endpoint.
(viii) H0k : θk = 0 is the null hypothesis for endpoint k.
(ix) δk is chosen to be a clinically important difference (or effect size) of interest and the
alternative hypothesis is H1k : θk = δk.
(x) σ2Ek (σ2Ck ) represents the variance for response variable XijkE (XijkC). For simplic-
ity, a common variance for endpoint k is considered i.e. σ2Ek = σ2Ck = σ2k.
(xi) ρk1k2 = corr(Xijk1, Xijk2) denotes the correlation between Xijk1 and Xijk2 .
(xii) Σ denotes the variance covariance matrix between endpoints.
Throughout this thesis, the term group sequential design will describe a sequential
clinical trial that includes a series of interim analyses with the possibility of stopping the
trial at each analysis. The term sample size re-estimation will describe a trial in which
data are used at one or more interim analyses to estimate nuisance parameters with this
information used to determine the sample size for the remainder of the trial. Finally, the
term inverse normal combination test will describe a trial that uses the inverse normal p-
value combination function (Bauer (1989)) to combine data from a number of stages.
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1.2.2 Clinical trials
1.2.2.1 Definition and Phases of a clinical trial
Pocock (2004) defines a clinical trial as any form of planned experiment that involves
patients and is designed to elucidate the most appropriate treatment of future patients with
a given medical condition. In conducting a clinical trial, one uses results based on a limited
sample of patients to make inferences about how a treatment should be conducted among
the general population of patients who will require treatment in the future. The clinical
evaluation of a new drug is usually divided into four phases. The characteristics of each
phase can differ between therapeutic areas, but can roughly be outlined as follows:
- Phase I includes the first experiments in human beings (often healthy volunteers).
Such trials are primarily concerned with drug safety, not efficacy, and the first objec-
tive is to determine how much of a drug can be given without causing serious side-
effects. Studies of drug metabolism and bioavailability are also considered within
this phase. Finally, in Phase I, studies of multiple doses are performed to determine
the appropriate dose schedules for use in Phase II.
- In Phase II, the experimental treatment is first studied in patients with a view to an
initial assessment of efficacy. This phase is also often used for identifying a safe and
effective dose level for further development.
- In Phase III, a full-scale evaluation of a treatment is undertaken. The first objective
is to compare the new drug, which has been shown as reasonably effective, with a
placebo control or the current standard treatment(s) for the same condition in a large
trial involving a substantial number of patients.
- Finally, Phase IV, also called the post-marketing surveillance phase, is undertaken to
monitor for adverse effects and also includes additional large-scale, long-term studies
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of morbidity and mortality. It is sometimes used to describe promotion exercises with
the objective of bringing the new drug to the attention of a large number of clinicians.
The adaptive and sequential methods used in Phase III clinical trials are the main focus of
this thesis. The primary goal in a Phase III clinical trial is usually to confirm whether or
not the experimental drug (E) is efficacious compared to control (C). In a single setting,
assume that the true treatment effect is θE for the experimental drug and θC for the control,
and that a positive value of θE or θC indicates that the treatment has been useful to the
patient. The treatment effect θ = θE−θC can then be assessed in a statistical hypothesis test
context, where the null hypothesis H0 : θ = 0, is tested against the alternative hypothesis
H1 : θ > 0. It is a regulatory requirement to control the type I error rate, the probability of
falsely rejecting the null hypothesis, at some pre-specified level α. One-sided tests of α =
0.025 are usually required by regulators, which correspond to α = 0.05 for two-sided tests.
Also, with regard to the power at a certain value of the treatment effect θ = δ, it is necessary
to make sure that it is at least 1 - β. β is the type II error, i.e the probability of failing to
reject the false null hypothesis. Popular choices for β are β = 0.1 and β = 0.2.
1.2.2.2 Clinical trials context
This thesis deals with sequential sample size re-estimation, with and without early stopping,
conducted in the context of a randomised clinical trial. In fact, randomised controlled
trials, where patients are randomly assigned to one of several treatment groups, are the
gold standard for the evaluation of a new therapy. The purpose of randomisation is to
avoid bias that may arise due to unexpected variations in patients’ characteristics that may
result from less formal (ad hoc) allocation methods. In this type of trial, the probability of
receiving a certain treatment is known, but it is not predictable what treatment each patient
will receive.
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The thesis also deals sample size re-estimation conducted in the context of a blinded
randomised clinical trial. Day and Altman (2000) explain that in controlled trials the term
blinding, and in particular double blinding, usually refers to keeping study participants
and those collecting and analysing clinical data unaware of the assigned treatment, so that
they should not be influenced by that knowledge. Julious (2004) argues that blinding is
important as it removes any systematic bias there may be in treatment assessment and
allocation during the conduct of the trial. This forms the basis for regulatory authorities
when deciding whether to approve a new drug.
1.2.3 Normal distribution
This thesis deals with sequential sample size re-estimation in clinical trials (with and with-
out early stopping) with multiple continuous endpoints that follow normal distributions. In
probability theory, the normal (or Gaussian) distribution is a continuous probability distri-
bution and plays a central role in statistics.
In the setting of a single random variable X , the probability density function of a
normal distribution is defined by
f(x) =
1√
2πσ2
e
−(x−θ)2
2σ2 (1.1)
for ∞ < x <∞. The probability density function is dependent on two parameters,
mean θ and standard deviation σ, where ∞ < θ <∞ and σ > 0.
The expected value is
E(X) =
∫ ∞
−∞
xf(x)dx = θ (1.2)
and the variance is
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V ar(X) =
∫ ∞
−∞
(x− θ)2f(x)dx = σ2 (1.3)
where f(x) is defined in Eq. (1.1).
Conventionally, N(θ, σ2) is used to indicate that a random variable X follows a
normal distribution with mean θ and variance σ2.
The standard normal distribution is a special case of the normal distribution where
θ = 0 and σ2 = 1. Its density function is usually given by
φ(x) =
1√
2π
e
−x2
2 (1.4)
and its distribution function is given by
Φ(x) =
∫ x
−∞
φ(x) =
1√
2π
e
−µ2
2 dµ. (1.5)
The variance defined in Eq. (1.3) is called the population variance in the sense that
the concept of population can be extended to continuous random variables with infinite
populations. However, in many practical situations, the true variance of a population is not
known in advance and must be estimated on a sample of the population. Suppose we have
a series of n measurements of a random variable X written as xi, where i = 1, 2, ..., n. The
estimate sample variance is defined by
s2 =
1
n− 1
n∑
i=1
(xi − x)2 (1.6)
where x denote the sample mean of X .
The variance is calculated from the squares of the observations. This means that it
is not in the same units as the observations, which limits its use as a descriptive statistic
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(Bland (2000)). The answer to this is to take the square root, which will then have the
same units as the observations and the mean. The square root of the variance is called the
standard deviation, usually denoted by s. Thus
s =
√√√√ 1
n− 1
n∑
i=1
(xi − x)2. (1.7)
Again, in the setting of two random variables X and Y , the probability density
function of a normal distribution is defined by
f(x, y) =
1
2πσxσy
√
1− ρ2 exp(−
1
2
Q(x, y)) (1.8)
where the quadratic form
Q(x, y) =
1
1− ρ2 [(
x− θ1
σx
)2 + (
y − θ2
σy
)2 − 2ρ(x− θ1)(y − θ2)
σxσy
]
gives the density function of a bivariate normal distribution. Note that the parame-
ters σ2x, σ
2
y , and ρ must satisfy σ2x > 0, σ2y > 0, and 0 < ρ < 1.
The correlation, ρ is defined as a bivariate analysis that measures the relation be-
tween two or more variables such that systematic changes in the value of one variable are
accompanied by systematic changes in the other (Bobko (2001)). In statistics, the value
of the correlation coefficient is +1 in the case of a perfect positive (increasing) linear rela-
tionship (correlation), - 1 in the case of a perfect decreasing (negative) linear relationship
(anticorrelation). As the correlation coefficient value goes towards 0, the relationship be-
tween the two variables will be weaker (closer to uncorrelated).
Suppose we have a series of n measurements of two random variables X and Y
written as xi and yi, where i = 1, 2, . . . , n, then the sample correlation coefficient can be
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used to estimate the population correlation ρ between X and Y. The sample correlation
coefficient is written
ρxy =
∑n
i=1(xi − x)(yi − y)
(
∑n
i=1(xi − x)2)(
∑n
i=1(yi − y)2)
(1.9)
where x and y are the sample means of X and Y.
This can also be written as
ρxy =
∑n
i=1(xi − x)(yi − y)
(n− 1)sxsy
where sx and sy are the sample standard deviations of X and Y as defined in Eq.
(1.7).
The correlation coefficient defined in Eq. (1.9) is called Pearson correlation. It is
widely used in statistics and is the one we consider in this thesis. It measure the degree
of the relationship between linear related variables. Other types of correlations include
Kendall rank correlation and Spearman correlation; however, they are not discussed here
as they are non-parametric tests used to measure the strength of dependence between two
variables for the first and the degree of association between two variables for the second
(Bland (2000)).
1.2.4 Nuisance parameter
In statistics, a nuisance parameter is defined as any parameter that is not of immediate
interest but must be accounted for in the analysis of those parameters that are of interest
(Basu (1977)). In other words, a parameter is a nuisance parameter in the sense that we are
not interested in its value, but its value modifies the distribution of our observations. For
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example, if we are interested in the mean θ, the variance σ2 defined in Eq. (1.6) and the
correlation ρxy defined in Eq. (1.9) are nuisance parameters.
The variance σ2 and the correlation ρxy may cease to be a nuisance if they become
the object of the study. In general, a nuisance parameter is any parameter that interferes on
the analysis of another.
To treat nuisance parameter in this thesis, we are going to use interim analysis to
estimate the values of the nuisance parameter considered before the study begins, and this
value is used to determine the parameter of interest (e.g. the sample size) for the rest of the
trial or at interim stage.
1.2.5 One-sided test
Throughout this thesis, tests are conducted for the difference in the mean response of
two treatments θ when observations are normally distributed with common, known (or
unknown) variance σ2.
The null hypothesis H0 : θ = 0 expresses that both treatments are equal. The
alternative hypothesis H1 : θ > 0 corresponds to one treatment being greater than the
other.
Suppose we have a standardised test statistic Z, which is normally distributed under
H0, and a fixed sample test rejects H0 if Z > c for a constant c. The type I error probability
is defined as the probability of wrongly rejecting the null hypothesis,
α = Pr(Z > c|θ = 0). (1.10)
The power of a test is the probability of rejecting the null hypothesis when it is false.
It depends on the specific value of θ, denoted by δ, that is
12
Power = Pr(Z > c|θ = δ) = 1− β (1.11)
where δ represents a treatment difference that needs to be detected with high prob-
ability and β represents the type II error probability at θ = δ.
1.2.6 Fixed Sample Z-test
We consider a fixed sample test for a single endpoint. Let XiE and XiC i = 1,2,...,n, be
the ith observations of samples E and C. We assume that XiE (XiC) is normally distributed
with mean θE (θC) and a common and known variance σ2 i.e., XiE ∼ N(θE , σ2) (XiC ∼
N(θC , σ
2)), and that all observations are independent. We are interested in testing a null
hypothesis that the two means are equal against an alternative hypothesis that the difference
in means is a positive constant:
H0 : θE − θC = 0
H1 : θE − θC > 0
If n subjects are allocated to each treatment, the standardised statistic (see Jennison
and Turnbull (2000a), p. 22) is given by :
Z =
1√
(2nσ2)
(
n∑
i=1
XiE −
n∑
i=1
XiC)
∼ N((θE − θC)
√
{n/(2σ2)}, 1). (1.12)
The information for θE − θC is:
I =
n
2σ2
. (1.13)
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So, underH0 where θE = θC , Z ∼ N(0, 1), and to satisfy the type I error probability
requirement, we need:
Pr(Z > c|θ = 0) = α (1.14)
where
c = Φ−1(1− α) (1.15)
represents the quintile of a normal distribution and Φ denotes the standard normal
cumulative distribution function. The one-sided test with type I error probability α rejects
H0 if Z > c.
To satisfy the power requirement, we also need :
Pr(Z > c|θ = δ) = 1− β (1.16)
where Z ∼ N(θ√I, 1) and θ = δ. We denote µ∗ = θ√I and call it the non-
centrality parameter. The power defined in Eq. (1.16) is now expressed by:
1− β = Pr{Z − µ∗ > c− µ∗|θ = δ}
1− β = Pr{−Z + µ∗ ≤ −c+ µ∗|θ = δ}
1− β = Φ(−c + µ∗)
Φ−1(1− β) = −c + µ∗
µ∗ = c+ Φ−1(1− β).
The sample size n that satisfying the power requirement can be derived by replacing
µ∗ by θ
√
n
2σ2
and c by Φ−1(1− α) in the above expression, giving:
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n =
2(Φ−1(1− α)− Φ−1(1− β))2σ2
θ2
. (1.17)
Although we have based our test on the standardised test statistic Z, this is not the
only possibility. Another test statistic is called the score statistic. It is defined in this case
as:
S = Z
√
I (1.18)
where Z denotes the standardised test statistic and I the information. Under H0, the
score statistic is normally distributed with mean 0 and variance I
S ∼ N(0, I). (1.19)
Under H1, the score statistic is normally distributed with mean θI and variance I
S ∼ N(θI, I). (1.20)
1.2.7 Fixed sample t-test
In this subsection we consider the same problem and the same hypotheses as in Subsection
1.2.6. We assume that XiE (XiC) is normally distributed with mean θE (θC) and a common
and unknown variance σ2.
The common variance σ2 can be estimated as follows;
S2 =
(n− 1)s2E + (n− 1)s2C
2n− 2 (1.21)
where
s2E(C) =
1
n− 1
n∑
i=1
(xiE(C) − xE(C))2 (1.22)
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and xE (xC) denote the sample mean of XiE(XiC) .
The t-test is then given by
T =
X¯E − X¯C
S
√
2/n
. (1.23)
Under the hypothesis of no treatment difference, T follows a t-distribution with 2n-
2 degrees of freedom. Hence we reject the null hypothesis when T > t1−α,2n−2; where
t1−α,2n−2 is define as quintile of a t-distribution.
Under the alternative hypothesis that there is a clinical difference δ > 0, T follows a t-
distribution with 2n-2 degrees of freedom and non-centrality parameter µ∗ defined in the
previous subsection as follows: µ∗ = δ√
2S2/n
> 0.
The corresponding power can be written as
1− β = P (t1−α,2n−2 − µ∗) (1.24)
where P is the cumulative distribution. Practically one could use Eq. (1.17) for the initial
sample size calculation and then calculate the power for this sample size using Eq. (1.23),
iterating the sample size up as necessary until the required power is reached.
1.2.8 Significant tests and P-value
In Subsection 1.2.5 and Subsection 1.2.6, we explained that to carry out the test of signif-
icance, we supposed that in the population, there is no difference between the two treat-
ments. The hypothesis of no difference in the population was called the null hypothesis H0.
We then explained that if this is not true, then the alternative hypothesis H1 must be true,
that there is a difference between the treatments in one direction (or the other).
The general procedure for a significant test, presented in Bland (2000), is as follows.
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(i) Set up the null hypothesis and its alternative.
(ii) Find the value of the test statistic.
(iii) Refer the test to a known distribution (in our case a normal distribution) which it
would follow if the null hypothesis were true.
(iv) Find the probability of a value of the test statistic arising which is as or more extreme
than the one observed, if the null hypothesis were true.
(v) Conclude that the data are consistent or inconsistent with the null hypothesis.
The probability of such an extreme value of the test statistic occurring if the null
hypothesis were true is often called the p-value. It (p-value) is well illustrated in Figure
(1.1) and is used as an alternative to rejection points to provide the smallest level of sig-
nificance at which the null hypothesis would be rejected. Its one sided form is defined
mathematically as
p = 1− Φ(Z) (1.25)
where Z represents the standardized test statistic defined in Eq. (1.12) and Φ(.) the
cumulative standard normal distribution function defined in Eq. (1.5).
The p-value can also be computed using t-test defined in Eq. (1.23), that is
p = 1− P (T, df) (1.26)
where P(.) denotes cumulative distribution and df degree of freedom defined as
df = 2n− 2. (1.27)
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Figure 1.1: Example of a p-value computation - licensed under the Creative Commons
Attribution-ShareAlike 3.0
One often rejects the null hypothesis when the p-value is less than the predetermined
one sided significance level 0.025, indicating that the observed result would be highly un-
likely under the null hypothesis (i.e., the observation is highly unlikely to be the result of
random chance).
The p-value should not be confused with the type I error rate defined in Eq. (1.10).
Even though α is also called a significance level, these two significance levels have different
meanings. Their parent approaches are incompatible, and the numbers p and α cannot
meaningfully be compared. The p-value is not the probability that the null hypothesis is
true. The null hypothesis is either true or it is not; it is not random and has no probability.
It is simply a measure of how likely the data is to have occurred by chance, assuming the
null hypothesis is true (Bland (2000)).
1.2.9 Motivation of sequential analysis
The motivation for conducting interim assessments on accumulated data in a clinical trial
has been classified as follows by several authors (e.g. Jennison and Turnbull (2000a) and
Dmitrienko et al. (2005)):
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Ethical. There is an ethical need to monitor the safety of patients in all treatment
arms when conducting clinical trials. For example, this can be done through sequential
monitoring. Less patients are exposed to an inferior treatment than for the corresponding
fixed sample design when a sequential trial is stopped early for a positive effect. Patients in
the trial do not have to be exposed to potential side-effects of the drugs under investigation
if a group sequential trial is stopped early for futility. Likewise, the resources that would
have been necessary to complete the trial can instead be used to study a different treatment
in the same or another area of medical necessity.
Administrative. Some of the administrative reasons given by Jennison and Turnbull
(2000a) for conducting interim analysis include the need to ensure that the experiment is
conducted and executed as planned, that the subjects or experimental units are from the
correct population and satisfy eligibility criteria, and that the test procedures or treatments
are as prescribed in the protocol. A further administrative reason for early examination of
study results is to check on assumptions made when designing the trial. For example, in an
experiment where the primary response variable is quantitative, the sample size is often set
assuming this variable to be normally distributed with a certain fixed variance. An early
interim analysis can reveal inaccurate assumptions in time for adjustments to be made to
the design. For example, Dmitrienko et al. (2005) explained that early evidence of efficacy
may generate a decision to increase manufacturing spending in order to support continuing
development of the experimental drug. However, to better help describe the efficacy and
safety profiles of the drug, the trial may still be continued.
Economic. Sequential statistical procedures can also lead to economic benefits. For
example, a trial that has a positive result may be stopped early. This is an indication that
a new product can be exploited more quickly. Although, if a negative result is observed,
stopping a trial early would ensure that resources are not mis-used. Jennison and Turn-
bull (2000a) explain that sequential procedures lead to savings in cost, time and sample
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size when compared with standard fixed sample methods. The authors also added that in-
terim analyses allow informed management choices to be made concerning the continuing
allocation of limited research and development funds.
Ethics is the most important and persuasive reason for sequential clinical trials. This
is why most major trials now have a data monitoring committee (DMC), whose primary
responsibility is to protect the safety of patients. For example, the ICH guideline E9 Statis-
tical Principles for Clinical Trials encourages the use of interim monitoring through group
sequential methods (ICH, 1998).
Three types of data monitoring may be considered in a blinded randomisation trial
(Stallard and Todd (2010)): first, administrative monitoring of clinical trial conduct and
monitoring of safety data without monitoring of efficacy data; second, monitoring of ef-
ficacy data with no unblinding of treatment allocation. Stallard and Todd (2010) give an
example of the estimation of nuisance parameters. Third, monitoring of efficacy data with
treatment allocation unblinded to allow the estimation of the difference in efficacy between
the treatments being compared. This (the third) type of monitoring presents the most ethical
and statistical challenge. Stallard and Todd (2010) explain that in the second and the third
type of data monitoring, administrative and safety monitoring will most likely be conducted
in addition. This thesis focuses on the second and the third types of data monitoring.
When conducting sequential clinical trials, there are many aspects to consider that
may differ from fixed sample trials. The books by Wald (1947), Siegmund (1985), Proschan
et al. (2006), Whitehead (1997) and Jennison and Turnbull (2000a) all focus on practical
and statistical aspects of interim monitoring. These books cover all the sequential design
methods that will be described in this thesis and in particularly in Chapter 4.
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1.3 Multiple endpoints
This section provides background on multiple endpoints in a clinical trial. It introduces
various methods used to adjust for multiplicity. Subsection 1.3.1 is an introduction; Sub-
section 1.3.2 defines and discusses the Family-wise type I error rate; Subsection 1.3.3 de-
scribes methods for controlling family-wise type I error rate and Subsection 1.3.4 defines
disjunctive power.
1.3.1 Introduction
A number of factors can influence the analysis, interpretation and conclusions drawn from
a clinical trial. Among them are the disease under study, the patient population, multiple
endpoints, the study design and the conduct of the study. One of the key factors that make
interpretation difficult, and sometimes impossible, is the presence of multiple endpoints.
Running a clinical trial with multiple endpoints may be justified by the nature of the disease
and the type of questions that a clinical trial aims to investigate. For example, in patients
with coronary heart disease, we may be interested in both resting and exercise ejection
fractions. In blood-pressure-lowering trials, we might be interested in diastolic and systolic
blood pressure or mean arterial pressure and pulse pressure. In stroke treatment, there are
a number of scales used to measure recovery and no one scale is believed to assess all
dimensions. In lung diseases, we may be interested in several lung function tests, such
as FEV1, FVC, PI (Pocock et al. (1987)). In behavioral studies, we may be interested in
several scales for the quality of life. In patients with severe arthritis of the hip, we may be
interested in the main outcome measures, hip function at 12 months after surgery, assessed
using the Oxford hip score and Harris hip score (Costa et al. (2012)). These examples show
that it is often inappropriate to restrict ourselves to one primary endpoint when designing
or analysing a clinical trial.
21
Conventionally, in testing a single hypothesis, the probability of a type one error
(i.e. the probability of rejecting the null hypothesis when it is true) is usually controlled at
some chosen level α. For the setting considered here, this concept needs to be extended to
the multiple testing situation to take account of the number of hypotheses tested.
1.3.2 Family-wise type I error rate ( FWER )
1.3.2.1 Definition of family of hypotheses
Throughout this thesis, a family of hypotheses is defined as a set of hypotheses for which
significance statements are considered and errors jointly controlled ( Shaffer (1995)). Hochberg
and Tamhane (1987) describes a family as any collection of inferences for which it is mean-
ingful to take into account some combined measure of error.
Suppose we are considering testing a family of hypotheses, H0k against a family of
alternative hypotheses H1k, k = 1,..,K. Suppose we do this using a series of test statistics
Tk, k = 1,...,K. Suppose we also define the event that H0k is rejected in preference of H1k
to be Sk. To adjust for multiplicity, we need to control probabilities of disjunctive events
of the form D =
⋃K
k=1 Sk (Senn and Bretz (2007)). Note that the event D corresponds to
rejecting at least one null hypothesis.
In this thesis we suppose that we are running a study for one purpose and the results are
considered under one family of hypotheses. But if a study is used for different purposes,
the results have to be considered under several different family configurations.
1.3.2.2 Preliminaries
Suppose K null hypotheses are of interest: H0k, k =1,...,K. Suppose, as shown in Table
1.1, that U is the number of true declared null hypotheses (number of true negatives) and S
denotes the number of true declared alternative hypotheses (number of true positives). V is
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Table 1.1: Number of errors when testing K hypotheses
Null Hypotheses Not Reject H0 Reject H0 Total
True null U V K0
True alternative T S K −K0
Total W R K
the number of false declared null hypotheses (number of false positives or Type I error) and
T denotes the number of false declared alternative hypotheses (number of false negatives
or Type II error). R is the total number of null hypotheses rejections and W denotes the
total number of non-rejections. K0 is the number of true null hypotheses, an unknown
parameters whereas K - K0 is the number of true alternative hypotheses. U, V, S, T are not
observable, whereas R and W are observable.
1.3.2.3 Individual and familywise error rate
In the context of a single hypothesis, type I error rate is the probability of rejecting the null
hypothesis when it is true. It is usually controlled at some chosen level α, where α is chosen
by considering the costs of rejecting a true hypothesis as compared with those of accepting
a false hypothesis. It is usually set to a conventional value of 0.025 (one sided). In the
context of a family of hypotheses, type I error rate is the probability of falsely rejecting at
least one null hypothesis in the family or the probability of at least one error in the family. It
(type I error rate) is called the family-wise error rate (FWER) in this setting and is defined
mathematically as below:
Suppose we have K null hypotheses, denoted by H01, ..., H0K . If we use test statistics,
each hypothesis may be confirmed as significant or non-significant. Table 1.1 presents a
summary the test results
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FWER = Pr(V > 0) (1.28)
meaning the probability of making at least one type I error in the family,
or equivalently,
FWER = 1− Pr(V = 0). (1.29)
In connection to the event D (defined in Subsection 1.3.2.1), we may consider Pr(D)
as the disjunctive type I error rate or FWER, that is:
Disjunctive type I error rate = Pr(reject at least one false H0k | θk = 0). (1.30)
So, by assuming FWER ≤ α, the probability of making at least one type I error in the
family is controlled at level α.
1.3.2.4 Control of FWER
In this thesis, we are going to test a family of hypotheses and will claim that the treatment in
group E works against the one in group C if any H0k is rejected, which means the FWER or
disjunctive type I error rate. That is why we need to control the FWER. Some tests control
the FWER only when all null hypotheses in the family are true, others control this error rate
for any combination of true and false hypotheses. Hochberg and Tamhane (2001) refer to
these as weak control and strong control, respectively. These concepts are discussed below.
The weak type controls the type I error only when all null hypotheses in the family are true:
H0 = ∩k∈KH0k, K0 = K, where K0 is the number of true null hypothesis defined in Table
1.1.
For FWER : Pr(V > 0)
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whereas the strong type controls the type I error for any partial configuration S (defined in
Table 1.1) of the null hypotheses, K0 ≤ K.
For FWER : maxS⊆KP (V > 0| ∩k∈S H0k), k = 1, . . . , K.
1.3.3 Methods for controlling FWER
In Subsection 1.3.2, the FWER has been defined and type of controls of the FWER have
been described. In this section, we review two methods for controlling the FWER. This
includes single-step and stepwise methods. In the single-step procedure, the rejection or
non-rejection of a single hypothesis does not depend on the decision on any other hypoth-
esis. Bonferroni and Sˇida`k methods are cited as examples. Whereas in the stepwise sce-
nario, the rejection or non-rejection of a particular hypothesis may depend on the decision
on other hypotheses. As examples, we have the Holm procedure and Hochberg method.
Although both methods are described below, only the Bonferroni method will be
considered as a method for adjusting the FWER in this thesis.
1.3.3.1 Single-step procedures
Single-step procedures use the same boundary for the rejection of hypotheses. Two single-
step methods are described below.
1.3.3.1.1 Bonferroni procedure
Bonferroni (1936) developed the Bonferroni procedure. It is one of the best-known and
most widely used multiple-hypotheses testing procedures. It satisfactorily controls the
FWER at a specified level α in the strong sense.
25
Let us consider a set of p-values, p1, ..., pK , to test hypotheses H1, ...., HK . The
Bonferroni procedure states that if any p-value is less than α/K, H0 = {H01, .., H0K} is
rejected, where H0 is the intersection of all H0k. This means that each hypothesis H0k (k
= 1,. . . ,K) will be individually rejected if pk ≤ α/K, where α here is the overall level of
significance. The Bonferroni inequality,
Pr{
K⋃
k=1
(pk ≤ α/K)} ≤ α (1.31)
ensures that the probability of rejecting at least one hypothesis when all are true is
no greater than α (Simes (1988)).
If the K endpoints are independent,
Pr(smallest p-value ≤ α/K) = Pr(rejecting at least one H0k)
= 1− Pr(not rejecting any H0k)
= 1− (1− α/K)K
= < 1− (1− (α/K)K)
= α
If the K endpoints are dependent,
Pr(rejecting at least one H0k) ≤
K∑
k=1
Pr(reject one H0k|θk = 0)
= Kα/K (1.32)
= α
If alternative hypotheses are considered in which several endpoints are affected in the same
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direction, Bonferroni’s procedure may lack power because the rejection of the overall hy-
pothesis is based on the smallest p-value of the K test statistics.
In practice, endpoints are usually correlated. Pocock et al. (1987) show that Bon-
ferroni’s correction practically works well for moderately correlated normally distributed
endpoints with known variance and identical correlation ρ for all possible pairs within the
two compared groups. The conservatism of Bonferroni’s method increases as ρ increases,
but Bonferroni’s correction still performs well as the number of correlated endpoints in-
creases.
1.3.3.1.2 S˘ida`k procedure
Bonferroni’s inequality was modified by Sidak (1967). Instead of testing each hypothesis
at αk = α/K, S˘ida`k suggested using a level of significance αk = 1− (1− α)1/K . Similar
to Bonferroni’s approach, Sˇida`k indicated that, for K independent endpoints:
Pr(smallest p-value ≤ 1− (1− α)1/K) = 1− {1− [1− (1− α)1/K ]}K
= 1− ((1− α)1/K)K
= α
1.3.3.2 Stepwise procedures
Single step procedures use the same boundary for the rejection of hypotheses. Nevertheless,
if different boundaries are assigned to different tests, testing methods may have a higher
ability to preserve the FWER and to identify true alternative hypotheses. The following
briefly describes three of them.
Let H01, . . . , H0K be a family of null hypotheses and p1, . . . , pK the corresponding
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p-values. Consider ordering the p-values p(1), . . . , P(K) and let the associated null hypothe-
ses be H0(1), . . . , H0(K).
1.3.3.2.1 Holm procedure
Holm (1979) proposed a method that applies in the same cases as the Bonferroni
procedure but is uniformly more powerful. His step-down method proceeds as follows.
Step 1. If p(1) < α/K, reject H0(k) and go to Step 2; otherwise stop.
Step 2. If p(2) < α/K − 1, reject H0(2) and go to Step 3; otherwise stop.
· · ·
Step K. If p(K) < α, reject H0(K) and stop.
The benefit of using Holm’s procedure is that the tests are made more powerful
(smaller adjusted p-values) while, in most cases, maintaining strong control of the FWER.
The method is based on the Bonferroni inequality and is valid regardless of the joint distri-
bution of the test statistics. However, the downside of the procedure is that the stochastic
(or random) dependencies between test statistics are not taken into account.
1.3.3.2.2 Hochberg procedure
Hochberg (1988) suggested a step-up method described as follows.
Step 1. If p(K) < α, reject H0(k), k = 1,. . . ,K, and stop otherwise go to Step 2.
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Step 2. If p(K−1) < α/2, reject H0(k), k = 1,. . . ,K - 1, and stop, otherwise go to Step
3.
· · ·
Step K. If p(1) < α/K, reject H0(k), k = 1, and stop.
The procedure is valid under independent or positively dependent p-values. Under
independence, Hochberg’s method is more powerful than Holm’s, it maintains strong con-
trol of the FWER. However, the problems with this procedure are that the stochastic (or
random) dependencies between test statistics are not taken into account and it is only valid
for positively correlated test statistics.
1.3.3.2.3 Hommel procedure
Hommel (1983) suggested a method that combines both step-up and step-down pro-
cedures. The method is somewhat more powerful than Hochberg’s but is more difficult
to understand and carry out. The method is as follows: reject all hypotheses that have a
p-value α/k∗ where k∗ is defined as
k∗ = max(kǫ{1, . . . , K}: p(K−k+k⋆) > k⋆αk for k⋆ = 1, . . . , k).
If no maximum exists, all hypotheses are rejected (the largest p-value is then smaller
than α). To illustrate this method, we consider the example given by Ekenstierna (2004)
that shows that Hommel’s procedure rejects more than Hochberg’s:
Suppose that we have three hypotheses H01, H02, H03 and the corresponding p-
values p1 = 0.012, p2 = 0.015, p3 = 0.0363. Let α be 0.025. With Hommel’s procedure
we first calculate k∗:
For k = 1 : p3 = 0.0363 > α = 0.025.
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For k = 2 : p3 = 0.0363 > α = 0.025, p2 = 0.015 > α/2 = 0.0125.
For k = 3 : p3 = 0.0363 > α = 0.025, p2 = 0.015 < 2α/3 = 0.0167, p1 = 0.012 >
α/3 = 0.000835.
Thus in this example k∗ = max{1, 2} = 2 and all hypotheses with a p-value ≤
α/2 = 0.0125 are rejected. The hypothesis with p-value p1 = 0.012 is then rejected
by Hommel’s procedure. If Hochberg’s procedure would be used instead, no hypotheses
would be rejected: p3 = 0.0363 is larger than α = 0.025, p2 = 0.015 is larger than
α/2 = 0.0125 and p1 = 0.012 is larger than α/3 = 0.00835.
As for Holm’s and Hochberg’s procedures, Hommel’s method maintains strong con-
trol of the FWER. It is valid under independent or positively dependent p-values.
1.3.4 Disjunctive Power
Suppose we are considering testing a family of hypotheses, H0k, against a family of alter-
native hypotheses, H1k, k = 1,..,K. Suppose we do this using a series of test statistics Tk,
k = 1,...,K. In connection to the event D (defined in Subsection 1.3.2.1), we may consider
Pr(D) as disjunctive power, that is:
Disjunctive power = Pr(reject at least one false H0k | θk = δk). (1.33)
This thesis focuses mostly on the disjunctive. However, sometimes we may be inter-
ested in the probabilities of conjunctive events of the form of C = ⋂kk=1 Sk. In connection
to the event C, we may consider Pr(C) as conjunctive power, that is:
Conjunctive power = Pr(reject all false H0k | θk = δk). (1.34)
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1.4 Multiple co-primary endpoints: General framework
of analysis
In this thesis, we consider methodology for situations where there are multiple continuous
co-primary correlated endpoints in a clinical trial. This means that we are interested in
obtaining significance in one of the endpoints. We also consider two different methods of
analysing interim data: First, the sample size re-estimation method, in which data are used
at one or more interim analyses to estimate nuisance parameters with this information used
to determine the sample size for the remainder of the trial. Second, the group sequential
designs approach, that includes a series of interim analyses with the possibility of stopping
the trial at each analysis. Such a trial must be designed in advance, so as to maintain the
FWER. The group sequential design method considered in this thesis is the combination of
the concepts of early stopping and sample-size recalculation.
Based on concepts described previously in this chapter, the general framework for
each of the two methods are defined in the following setting: There are two treatments,
experimental E and control C.
1.4.1 General framework of analysis for the sample size re-estimation
approach
(i) To reiterate, let XikE be the random variable of the kth endpoint for the ith subject in
group E (k = 1, . . . , K, i = 1, . . . , nE) and XikC be the random variable of the kth
endpoint for the ith subject in group C (k = 1, . . . , K, i = 1, . . . , nC).
(ii) We consider one-sided tests as described in Subsection 1.2.5.
(iii) We are interested in testing a null hypothesis that two K-dimensional mean vectors of
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K co-primary endpoints are equal against an alternative hypothesis that the difference
in mean vectors is a vector of positive constants:
H0k : θk = 0
H1k : θk = δk, (δk > 0)
where θk is the k’th element of θ (a K x 1 column vector of true means) and we are
testing a family of k hypotheses.
(iv) Suppose Tk represents test statistics for endpoint k and c the corresponding critical
value observed at the end of the trial.
(v) To reiterate, we assume that XikE (XikC) has a multivariate normal distribution lead-
ing to a multivariate normal distribution for the test statistics Tk with a mean vector
θk and a variance vector σ2k.
(vi) We consider the following decision rules: if Tk ≥ c, reject H0k.
(vii) We want to control the FWER in the strong sense, that is, to have
FWER = Pr(reject any true H0k) ≤ α, under any θk, which may combine true and
false hypotheses, with at least one true hypothesis.
(viii) We want also to maintain the power, i.e Power = Pr(reject any true H0k; θk = δk) =
1 − β. Somehow we want to use interim data to modify the sample size to fix the
power.
We generalize this framework of analysis in the following sub-section.
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1.4.2 General framework of analysis for the group sequential designs
method
(i) To reiterate, let XijkE be the random variable of the kth endpoint for the ith subject in
group E at stage j (k = 1, ..., K, i = 1, ..., nEj, j = 1, ..., J) and XijkC be the random
variable of the kth endpoint for the ith subject in group C at stage j (k = 1, ..., K, i =
1, ..., nCj, j = 1, ..., J).
(ii) We consider one-sided tests as described in Subsection 1.2.5.
(iii) At each stage, we are interested in testing a null hypothesis that two K-dimensional
mean vectors of K endpoints are equal against an alternative hypothesis that the dif-
ference in mean vectors is a vector of positive constants:
H0k : θk = 0
H1k : θk = δk, (δk > 0)
where θk is the k’th element of θ (a K x 1 column vector of true means) and we are
testing a family of k hypotheses.
(iv) Suppose Tkj represents test statistics for endpoint k at stage j and cj the corresponding
critical value.
(v) To reiterate, we assume that XijkE (XijkC) has a multivariate normal distribution
leading to a multivariate normal distribution for the test statistics Tkj with a mean
vector θk and a variance vector σ2k.
(vi) At each stage j we consider the following stopping rules: if Tk1 ≥ c1or, . . . , orTkj ≥
cj , stop at stage j and reject H0k, otherwise continue to stage j + 1; where cj repre-
sents a critical value at stage j.
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(vii) We want to control the FWER in the strong sense, that is, to have
FWER = Pr(reject any true H0k) ≤ α, under any θk, which may combine true and
false hypotheses, with at least one true hypothesis.
(viii) We want also to maintain the power, i.e Power = Pr(reject any true H0k; θk = δk) =
1 − β. Somehow we want to use interim data to stop or not at stage j and to modify
the sample size to fix the power.
1.5 Summary
This chapter provides background information on key concepts needed throughout this
thesis. It gives a brief introduction in Section 1.1, describes various statistical concepts in
Section 1.2, introduces the concept of multiple endpoints in Section 1.3 and Section 1.4
defines the general framework of analyses. The next chapter presents a literature review on
the methods needed for this thesis.
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Chapter 2
Literature review
This Chapter presents a literature review of following designs in the context of a single
endpoint: sample size re-estimation, inverse normal combination test procedure and group
sequential designs. Sample size re-estimation is described in Section 2.1, the inverse nor-
mal combination test in the sample size re-estimation setting in Section 2.2, group sequen-
tial designs in Section 2.3, following by inverse normal combination tests in the group
sequential designs setting in Section 2.4.
2.1 Sample Size Re-estimation (SSR) with a single end-
point
This section revises characteristics of the sample size re-estimation (SSR) method. In this
context, the data of the interim analyses are used to estimate one or more nuisance parame-
ters, and this information is used to determine the sample size for the remainder of the trial.
Subsection 2.1.1 introduces the section, followed by a general framework of analysis for
sample size re-estimation in Subsection 2.1.2. Subsection 2.1.3 presents a formulation of
the problem. Next, Subsection 2.1.4 describes unblinded methods for conducting sample
size re-estimation and Subsection 2.1.5 discusses blinded methods. The final Subsection
(2.1.6) describes SSR methodology for a single endpoint.
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2.1.1 Introduction
The purpose of a Sample Size Re-estimation (SSR) is to obtain an adequate sample size.
This is useful because of power testing and precision for estimation of parameters. Uncer-
tainty during the planning stage of a clinical trial (e.g variability of a continuous endpoint)
could lead to inaccurate sample size calculation due to the use of incorrect parameters. So it
is necessary to use SSR method to change the sample size and to maintain power. It (SSR)
is also useful for ethical, administrative and economic reasons as described in Subsection
1.2.9.
This thesis describes SSR that estimate parameters in the context of a clinical trial.
In this setting, Wittes and Brittain (1990) advise that the designer of such a clinical trial
should have reliable prior estimates of three classes of parameters related to the adminis-
tration of the study [e.g. (i) the number of patients that the participating clinic can expect
to identify; (ii) the willingness of patients and their physician to join the trial; and (iii) the
recruitment rate in the clinic], the process of the disease [the variance of the outcome vari-
able, or, for binary outcomes, the event rate in the control group; the rate of the progression
of the disease in the control group during the course of the study, the rate of competing risks,
etc.] and the effect of the treatment. They also comment that the sample size required to
detect a given effect is sensitive to all the above parameters, but their values are extremely
difficult to specify accurately before the trial begins; hence they recommend performing
a pilot study prior to the trial and using information obtained to adjust the parameters in
order to ensure the precision of the parameters used for the design.
A sample size may be adjusted based on unblinded or blinded data from a pilot
study. When performing such adjustments on unblinded data, an Independent Data Moni-
toring Committee (IDMC) is needed in order to preserve blindness of everybody involved
in the conduct of the trial. A literature review on unblinded and blinded sample size re-
estimation is given in Subsections (2.1.4) and (2.1.5) respectively, but in the next subsec-
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tion we present a framework for the analysis of a SSR, followed by a description of the
problem we are going to resolve in the setting of a single endpoint in Subsection 2.1.3.
2.1.2 A framework for the analysis of a SSR
In this section, we introduce an analysis framework for SSR in the context of a single end-
point. More details regarding the framework are given throughout the chapter, but this sec-
tion provides a summary. Designs with sample size re-estimations are also called designs
with Internal Pilot Study (IPS). This term was introduced by Wittes and Brittain (1990) to
refer to the class of designs that used early observations in a trial to recalculate sample size.
The sample size re-estimation method can be described as a three step procedure (Wittes
and Brittain (1990)):
(i) The initial sample size calculation, leading to a provisional sample size N0, is carried
out on the basis of initial estimates of the nuisance parameters.
(ii) After recruiting n1 = πN0 patients (e.g., π = 0.5), the nuisance parameters are re-
estimated from these observations and the sample size re-calculated to give N . This
can be done using either:
– upwards adjustment, i.e. n2 = max(n0, N)− n1 or
– unrestricted design, i.e. n2 = max(n1, N)− n1,
and using either:
– unblinded method, i.e. a pooled estimate of the variance σ2 or
– blinded method, i.e. use whole variance or assume difference between groups
of δ.
(iii) The final analysis, including all N = n1 + n2 observations with a hypothesis test
conducted using a standard t-test.
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2.1.3 Formulation of the problem
Suppose that two treatment groups (E = experiment and C = control) with a normal dis-
tributed outcome are compared. Suppose also we are considering a situation of unknown
and common variance σ2. Let H0 : θE−θC = 0 be tested against H1 : θE−θC = δ, δ > 0.
Let N0 be the initially planned sample size per group, n1 is the sample size per group in
stage 1, n2 is the sample size per group in stage 2 and N = n1 + n2 is the size of the entire
trial per group. N0 and n1 are fixed numbers, while n2 and N are chosen based on data.
Also let 1 − β be a target power to detect a treatment effect θ = θE − θC = δ for a given
type I error α. If the variance σ2 is known, the required sample size per group is obtained
as follows
N0 =
2(Φ−1(1− α) + Φ−1(1− β))2σ2
θ2
. (2.1)
A sample size re-estimation design might be useful in the case of high uncertainty in the
planning phase of a trial about the size of the variance σ2. This can be done in an unblinded
or blinded way; a number of methods have been proposed in the literature to do this, and
in the following subsections we present their characteristics in more detail.
2.1.4 Unblinded methods
Initially, publications on two-stage sampling, using data of the first stage to re-estimate
the sample size, were not necessarily motivated by clinical trials, therefore maintaining the
treatment blind was not a primary consideration.
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2.1.4.1 Stein’s Method
Stein (1945) was the first to propose a two-stage procedure for determining the required
sample size of the second stage.
Let nE1 and nC1, denote the number of observations in group E and C at the stage
1; and nE and nC indicate the total number of observations at the end of the trial in group
E and C respectively.
After nE1 and nC1 patients have been evaluated, the sample size per group is esti-
mated based on the stage 1 estimate of variance σ2:
N =
2(z1−α + z1−β)2S21
θ2
(2.2)
where
S21 =
1
2n1 − 2[(nE1 − 1)s
2
E1 + (nC1 − 1)s2C1] (2.3)
The normal quantiles z1−α and z1−β could be replaced by quantiles from the t-
distribution with (nE1 + nC1 - 2) degrees of freedom.
One continues recruiting n2 = N − n1 patients so that the required per-arm sample
size N is reached and a t-statistic is computed at the end using the first-stage pooled variance
S21 , defined in Eq. (2.3), at the denominator:
T =
XE −XC√
2S21/n
(2.4)
where XE and XC are the sample means of all n patients. The statistic T has a
t-distribution with 2(n1− 1) degrees of freedom as the variance estimate uses only the first
stage data.
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Proschan (2009a) explained that the use of the first-stage variance is both a strength
and a weakness of Stein’s method. It is a strength because the denominator of Eq. (2.4) is
completely determined after the first stage. Proschan argued that this would not be true if
we used the usual t-statistic because the pooled variance at the end of the trial might differ
considerably from the first stage variance. Using the first-stage variance in the denominator
also guarantees that power is at least 1- β, irrespective of the true variance σ2. It is a
weakness because the first-stage estimate variance S21 is less efficient than the estimate
variance S2 using all of the data.
Also Proschan (2009a) shows that the properties of Stein’s procedure depend on
whether S21 is close to σ2. If it is much smaller than σ2, then the conditional type I error
rate might be inflated even though the type I error rate averaged over all possible values of
S21 is α.
2.1.4.2 Wittes and Brittain Method (the naive t-test)
Wittes and Brittain (1990) modify Stein’s procedure by using in the denominator the pooled
variance estimate of all nE + nC observations at the end of the trial and referring this
standard t-statistic to a t-distribution with nE + nC - 2 degrees of freedom. They call this
the naive method, because it ignores the fact that the sample size was adapted.
S22 =
1
nE + nC − 2[(nE − 1)s
2
E2 + (nC − 1)s2C2] (2.5)
and
T =
XE −XC√
2S22/n
(2.6)
Wittes and Brittain (1990) introduced the concept of the SSR in clinical trial setting
for the two-sample t-test with a continuous outcome (Stein (1945) uses one-sample t-test).
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For them, the SSR design can be described as a three-step procedure consisting of initial
sample size calculation, sample size review and final analysis. The initial sample size
calculation leading to a provisional sample size N̂0 is carried out on the basis of initial
estimates of the nuisance parameters. Friede and Kieser (2006) give an example to illustrate
this by saying that earlier phases of the drug development process might inform the choice
of initial estimates.
When the data of the first n1 = πN0 patients (e.g., π=0.5) are available, then the
nuisance parameters are re-estimated from these observations, which constitute the inter-
nal pilot study. These estimates are then used for sample size recalculation with N the
recalculated sample size. The sample size can then be adjusted following a predefined re-
calculation rule. For instance, Wittes and Brittain (1990) proposed the restricted design
allowing only upwards adjustments of the initially planned sample size N0, i.e. the sample
size of the second stage n2 is given by:
n2 = max(N0, N)− n1. (2.7)
Restricted designs require a final sample size at least as large as the originally calculated
size.
Birkett and Day (1994) suggested an ”unrestricted design” allowing downwards
adjustments, i.e.
n2 = max(n1, N)− n1. (2.8)
Unrestricted designs permit smaller final sample sizes than originally calculated.
The final analysis includes all N = n1 + n2 observations. These observations are not
analysed separately for each stage; rather all observations are pooled as in a fixed sample
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size design.
To estimate S21 defined in Eq. (2.3), in the unblinded fashion when n1 patients have been
recruited, the variances in the two treatment groups need to be estimated separately, then
pooled, because we know that the two groups have the same variance. An Independent Data
Monitoring Committee (IDMC) is needed in order to preserve blinding of all involved in
the conduct of the trial.
2.1.4.3 Birkett and Day procedure
Birkett and Day (1994) extend the work of Wittes and Brittain (1990). Rather than using
half of the originally planned sample size, as suggested by Wittes and Brittain (1990), Bir-
kett and Day (1994) propose using different numbers of patients for the SSR and allowing
an unrestricted design. One of their examples assumed that only the size of the internal
pilot was pre-specified, not the original total sample size. They concluded that the type I
error rate and power were close to target levels as long as there were at least 20 degrees of
freedom to estimate the variance.
2.1.4.4 Denne and Jennison procedure
To modify the final sample size and σ2, Denne and Jennison (1999) use a t-test for a two-
treatment comparison based on Stein’s two-stage test which involves the use of an internal
pilot study. They explain that even if the estimated S2 is less than the true variance σ2,
both Stein’s procedure and Wittes and Britain’s approach still use the true variance σ2 for
estimating the initial sample size N0. To correct this, they propose a procedure that makes
explicit adjustment for the random variation in the estimate of S2. Their method controls
the type I rates more closely than previously existing methods.
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2.1.4.5 Wittes et al. and Coffey and Muller procedure
Wittes et al. (1999) and Coffey and Muller (1999) use a general linear model to show that
the naive method is precise when restricted or unrestricted designs are considered, as it
controls the type I error rate and maintains the power. They examine the impact of (i) small
samples; (ii) allowing the planned sample size to decrease; (iii) the choice of internal pilot
sample size; and (iv) the maximum allowable size of the second sample. Their results show
that the increase in the type I error rate is often negligible, especially in restricted designs.
2.1.4.6 Kieser and Friede procedure
Kieser and Friede (2000) suggest an alternative variance estimator at the end of the trial:
S2∗ =
1
n1 + n2 − 4((n1 − 1)S
2
1 + (n2 − 1)S22). (2.9)
where S21 denotes the pooled variance before the interim analysis and S22 the pooled
variance after the interim analysis.
This procedure consists of replacing the pooled variance of all the data in the de-
nominator in Eq. (2.4) and refers the test statistics to a t-distribution with 2(n-1) degrees of
freedom. The procedure is called the naive method by Wittes and Brittain (1990).
2.1.4.7 Miller procedure
Miller (2005) adjusted the final unblinded variance estimate using an additive correction.
The reason for this is that the sample size is determined in such a flexible way that the usual
variance estimator at the end of the trial is biased. Miller derived sharp bounds for this bias.
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These bounds have a quite simple form and can help in deciding if this bias is negligible
for the actual study or if a correction should be done.
2.1.5 Blinded methods
In the previous subsection, sample size re-estimation methods that require unblinding of
the data were discussed. In Section 4.4 of the ICH (1999) E9 guideline it states clearly that
unblinding of the allocation to treatment groups for trial participants during the ongoing
study is a serious concern because it could cause a bias. In this subsection, procedures that
do not breach the treatment rules during the ongoing trial are reviewed. The advantage of
preserving blinding is that there is no need to put in place an Independent Data Monitoring
Committee (IDMC) to guarantee secrecy of interim results.
2.1.5.1 Gould and Shih procedure
The methods described above require a trial statistician to be unblinded in order to pool
the separate variances from the treatment and control arms. However, the lumped variance
of all observations can be computed, irrespective of treatment assignment, even without
knowledge of the treatment assignments. This is why Gould and Shih (1992b) proposed
variance estimators that do not require breaking the treatment blind. For them, the replace-
ment of the combined variance in Eq. (2.2) would be the basis of sample size calculation.
The logic of this approach is to take no notice of the treatment group measure and to use the
estimator of the total variance as an estimator for the within-group variance. This quantity
was later called the ”lumped variance” by Zucker et al. (1999):
S21,total =
1
n1 − 1
2∑
g=1
n1g∑
i=1
(X1ig −X1)2. (2.10)
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where g represents experiment E and control group C; and X1 is the mean of all
observations in stage 1, i.e. the mean of 2n1 observations.
Eq. (2.10) can also be expressed as
S21,lumped =
1
2n1 − 1
2n1∑
i=1
(Xi −X1)2. (2.11)
The idea behind the lumped (total) variance is that, at the first stage, all patients are put in
one group ignoring their group of origin; then the variance is estimated as in Eq. (1.6).
Suppose that we have:
S2B =
SSB
dfB
denotes sample variance between group. This statistic is a measure of the
variability of group means around the grand mean X . It represents the mean difference or
treatment difference θ where:
SSB =
∑g
i=1 ni(xii − x)2, denotes the sum of square between groups, where xii
represents the sample mean, g describes two groups E and C and dfB = g − 1 denotes the
degree of freedom between groups.
S2W =
SSW
dfw
denotes the sample variance within groups and quantifies the spread
of values within groups where SSW =
∑g
i=1(ni − 1)2 denotes the sum of square within
groups and dfW = n− g denotes the degree of freedom within groups.
The total variance is the sum of within-group variance and between-group variance
i.e.
S2T = S
2
W + S
2
B
Eq. (2.10) shows that the total variance is an estimate of within group variance as
long as the between group variance is zero or very small. For example, in a typical clinical
trial setting, the between-group variance (S2B) is smaller than the within-group variance
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(S2W ). This is why the total variance is often a good estimate of the within-group variance,
i.e. the treatment effect θ is between 0.2 to 0.7 in a clinical trial setting.
2.1.5.2 Zucker et al. procedure
Zucker et al. (1999) developed the adjusted total variance similar to that of Wittes and
Brittain (1990), see Eq. (2.12).
They let
S21,adj = S
2
1,total −
n1
4(n1 − 1)θ
∗2. (2.12)
The basis of their development was to adjust the total variance for the treatment
difference equal to the alternative the trial is planned for, i.e. θ = θ∗. Friede and Kieser
(2001) examined the consequences of the inflation of the total variance on sample size and
found this was marginal.
2.1.5.3 Gould and Shih procedure
Gould and Shih (1992b) suggested an EM algorithm-based procedure for sample size re-
calculation. However, Friede and Kieser (2002) have shown that this method has some
severe errors, so they recommended not to use it.
2.1.6 SSR: Methodology for a single endpoint
In this subsection, the framework of analysis described in Subsection 2.1.2 and the problem
defined in Subsection 2.1.3 are used to construct a test in such a way as to control the type I
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error rate and maintain the power. This will be done using a blinded method and restricted
design, or upwards adjustment.
2.1.6.1 Hypotheses, test procedures and sample size calculation
We consider a two-sample situation comparing E and C. Let NE and NC denotes the num-
ber of randomised patients in group E and C. To simplify the notation, we assume that each
group has equal sample size and denote this byN . Suppose that XiE andXiC (i = 1, ..., N)
are a series of independent normal observations with means θE and θC , respectively, and
common unknown variance σ2. If the difference of means is defined as θ = θE − θC , the
corresponding test problem can be formulated as follows:
H0 : θ = 0 versus H1 : θ > 0.
The null hypotheses H0 can be rejected at level α if T ≥ c, where
T =
XE −XC√
2S2/N
(2.13)
and
c = t1−α,2N−2 (2.14)
c is the quintile of a t-distribution, S2 the pooled variance estimate,XE (XC) denote
the sample mean of XiE(XiC).
The total required sample size per group for the rejection of H0, with power 1 − β
at a specified alternative θ = δ (δ > 0) is approximate by
N =
2(Φ−1(1− α)− Φ−1(1− β))2σ2
δ2
. (2.15)
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2.1.6.2 Sample size re-estimation and test procedures
2.1.6.2.1 Sample size re-estimation
We consider the sample size re-estimation procedure described in Subsection 2.1.2.
Prior to the study, a preliminary total sample size per group N0 is calculated using an initial
guess of the variance.
The first n1 < N0 observations, which constitute the internal pilot study, are used
for re-estimation of the variance. The new variance estimate σ21 is replaced in the sample
size formula Eq. (2.15) to compute the updated total number of observations N needed to
achieve the desired power. The resulting final sample sizeN depends on the applied sample
size adjustment method as described in more details in Subsection 2.1.2. For example, if
the final sample size is lower than initially planned as explained by Wittes and Brittain
(1990), we have the rule N = max(N0,N). If the final sample size is uniquely determined
by the re-estimated value of the variance as suggested by Birkett and Day (1994), the rule
N = max(n1, N) applies.
After inclusion of further n2 = N − n1 patients in the second stage of the trial, the
hypothesis test is performed using all N observations.
2.1.6.2.2 Type I error rate
The type I error rate is
Pr(T ≥ c|θ = 0) = α (2.16)
meaning that the null hypotheses H0 can be rejected at level α if T ≥ c, where
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T =
XE −XC√
2S2/Nf
and
c = t1−α,2N−2 = t{(1− α), df} (2.17)
c is the quintile of a t-distribution, df is the degree of freedom and S2 the pooled
variance estimate, XE (XC) denote the sample mean of XiE(XiC), i = 1, . . . N .
2.1.6.2.3 Power
The power of the test at θ = δ is
Pr(T ≥ c|θ = δ) = 1− β (2.18)
where N is the total required sample size for the rejection of H0, with power 1− β
at a specified alternative θ = δ (δ > 0).
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2.2 SSR Inverse Normal Combination test method with a
single endpoint
Section 2.1 described sample size re-estimation methods. This section presents a method
integrating the concept of the inverse normal combination test into sample size re-estimation.
The method uses the inverse normal p-value combination function to combine interim data
or pilot data and final data at the final analysis. After an introduction in Subsection 2.2.1,
Subsection 2.2.2 discusses the two-stage combination test approach. Subsection 2.2.3 de-
scribes the inverse normal method, followed by the methodology for a single endpoint in
Subsection 2.2.4.
2.2.1 Introduction
Bauer (1989) develops the combination tests that control the significance level even if no
specific adjustment rule is pre-specified. These tests are based on the following principle:
the test statistics are calculated separately from different stage data. The test decision is
derived from a predefined function that combines the test statistics into a single criterion
after each stage. Since the original statement of this principle, numerous multi-stage
sequential procedures with interim analyses, has been proposed to allow one to modify the
design of the rest of the study without compromising the overall significance level of the
test decision (Brannath et al. (2002)).
This thesis will only consider the combination test method proposed by Lehmacher
and Wassmer (1999). The following section describes the approach in more detail.
2.2.2 Two-stage combination test
This subsection introduces the idea of a combination test with a general combination func-
tion with a known null distribution. Suppose a null hypothesis, H0, is tested using a two-
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stage sequential design at level α against a one-sided alternative. At the design stage, we
fix the design of the first phase and the test statistic to calculate a p-value, as defined in Eq.
(1.25), for the test of H0, p1, from the sample drawn at the first stage. We also calculate
p2 from the second stage sample and consider a function C(p1,p2), which is used in the
case where a second stage is performed to combine p1 and p2. We also fix in advance early
decision boundaries α1 and β1 for 0 ≤ α1 < α < β1 ≤ 1, with the following stopping
rules.
If at the first stage:
p1 ≤ α1, then we reject H0
if p1 > β1, then we accept H0.
In both cases, we stop the trial. Furthermore,
if α1 < p1 < β1,
then we proceed to the second stage. In this case, all of the information collected at
the first stage can be used to design the second stage.
At the second stage, if C(p1, p2) < c, H0 is rejected,
c is determined by α, α1, β1, and the form of C(p1, p2) is selected before the study
begins to control the α level so that
α1 +
∫ β1
α1
∫ 1
0
1{C(X,Y )≤c} dxdy = α, where 1{C(x,y)≤c} = 1 if C(X, Y ) ≤ c and 0
otherwise.
The assumptions underlining the two-stage combination test are that the function
C(p1, p2) is increasing in both arguments, strictly increasing in at least one argument and
left continuous in p2 (Brannath et al. (2002)). These properties must hold for all p1 ∈
]α1, β1] and p2 ∈ [0, 1].
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The distribution of the p1 and p2 under H0 satisfies PrH0(p1 ≤ α) ≤ α and
PrH0(p2 ≤ α|p1) ≤ α, for all 0 ≤ α ≤ 1.
These assumptions tell us that the distribution of p1, and the conditional distribution
of p2 given p1, are stochastically larger than or equal to the uniform distribution on [0,1]
(Brannath et al. (2002)). This applies whenever any independent sample units are recruited
at different stages and tests are applied that control the type I error probability for any
significance level α chosen in advance.
Several combination functions exist in the literature, but this thesis covers only the
weighted inverse normal method proposed by Mosteller and Bush (1954), and Lehmacher
and Wassmer (1999). Their combination function is defined by:
C(p1, p2) = 1− Φ[w1Φ−1(1− p1) + w2Φ−1(1− p2)] (2.19)
where 0 < wj < 1 (j = 1,2) and:
w21 + w
2
2 = 1. (2.20)
The following section provides the characteristics of the two-stage combination test
as proposed by Lehmacher and Wassmer (1999) in more detail.
2.2.3 Two stage Inverse Normal method
Lehmacher and Wassmer (1999) proposed an adaptive version of the group-sequential test
which is sometime called the inverse normal method. Group-sequential tests are defined in
more detail in the next section, however this subsection presents a method integrating the
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concept of the inverse normal combination test into the sample size re-estimation methods
described in Section 2.1. The framework of analysis is presented as follows.
2.2.3.1 Framework of analysis
2.2.3.1.1 Step 1
In step 1, we consider the sample size re-estimation procedure described in Sub-
section 2.1.2. Prior to the study, a preliminary total sample size N0 is calculated using an
initial guess of the variance.
2.2.3.1.2 Step 2
In step 2, the first n1 < N0 observations, which constitute the internal pilot study,
are used for re-estimation of the variance. The new variance estimate σ21 is used to calculate
the t-test at stage 1, that is
T1 =
XE1 −XC1√
2σ21/n1
where XE1 and XC1 denote sample mean for XiE1 and XiC1 , i = 1, . . . , n1 re-
spectively. T1 is then used to calculate the p-value at stage 1 as defined in Eq. (1.26), that
is
p1 = 1− P (T1, df1) (2.21)
where P(.) represents the cumulative distribution and df1 the degrees of freedom at
stage 1 as defined in Eq. (1.27)
df1 = 2n1 − 2. (2.22)
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The new variance estimate σ21 is then replaced in the sample size formula Eq. (2.15)
to compute the updated total number of observations N . The resulting final sample size N
depends on the sample size adjustment method as described in more details in Subsection
2.1.2.
Furthermore, in step 2, an additional n2 = N − n1 observations are used for re-
estimation of the variance. The new variance estimate σ22 is used to calculate the t-test at
stage 2, that is
T2 =
XE2 −XC2√
2σ22/n2
T2 is then used to calculate the p-value at stage 2, that is
p2 = 1− P (T2, df2) (2.23)
where P(.) represents the cumulative distribution and df2 is defined as
df2 = 2n2 − 2. (2.24)
2.2.3.1.3 Step 3
In step 3, which constitutes the final analysis, the evidence from stage 1 and stage
2 are combined via the weighted inverse normal functions of the observed p1 and p2. The
resulting test statistic
B = w1Φ
−1(1− p1) + w2Φ−1(1− p2) (2.25)
is used to perform a hypothesis test, where w1 and w2 represent the weights chosen
independently of the observed data. More details on when the null hypothesisH0 is rejected
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based on the value of the test statistic B are addressed below.
2.2.3.2 Characteristics of the Inverse normal combination test
Under the null hypothesis, pj , j = 1,2 in Eq. (2.25) is uniformly distributed on (0, 1), that is
pj ∼ U [0, 1]. (2.26)
If this is so, then
Φ−1(1− pj) (2.27)
follows the standard normal distribution, and for any constant pre-defined weight
wj , wjΦ
−1(1− pj) is normally distributed with mean 0 and variance w2j , that is
wjΦ
−1(1− pj) ∼ N(0, w2j ), j = 1, 2. (2.28)
If the weights, wj , j = 1,2, are determined in advance, the wjΦ−1(1 − pj) term are
independent, so under the null hypothesis,B = w1Φ−1(1−p1)+w2Φ−1(1−p2) is normally
distributed with mean 0 and variance (w1)2 + (w2)2, that is,
B ∼ N(0, (w1)2 + (w2)2). (2.29)
An other way of presenting the test statistics proposed by Lehmacher and Wassmer
(1999) is:
B =
1√
J
J∑
j=1
Φ−1(1− pj), J = 2 (2.30)
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where 1√
J
represents the weight wj , j = 1,2 as in Eq. (2.25).
Whitehead (2010) explains that the choice of weights wj has to be made in advance.
These can all be set to 1 such as (w1)2 + (w2)2 = 1, or they can be chosen to reflect the
information contained in each new batch of data. The author explains that the difficulty in
implementing the later strategy is that many adaptive designs are used precisely to allow
flexibility in the choice of sample size for each stage of the trial, and so the amount of
information to be collected will not be known in advance.
If the weights are set to 1 i.e,
∑2
j=1w
2
j = 1, as suggested by Whitehead (2010), the
test statistics B defined in Eq. (2.25) and Z defined in Eq. (1.12) have the same distribution
under the null hypothesis i.e. N(0,1), consequently B can use the same critical value as Z
at the final analysis, that is
c = Φ−1(1− α).
In the following section, we present methodology of this method.
2.2.4 SSR Inverse Normal Combination test method: Methodology
for a single endpoint
In this subsection, the framework of analysis described in Subsection 2.2.3.1 is used to con-
struct a test in such a way as to control the type I error rate. However, power considerations
are covered here as the specification and interpretation of alternative hypotheses is more
difficult to define in general (Whitehead (2010)).
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2.2.4.1 Hypotheses and Test procedures
We consider the same problem as in Subsection 2.1.6.1. Suppose a two-sample situation
comparing E and C. Let NE and NC denotes the number of randomised patients in group
E and C. To simplify the notation, we assume that each group has equal sample size and
denote this by N . Suppose that XiE and XiC (i = 1, ..., N) are a series of independent
normal observations with means θE and θC , respectively, and common unknown variance
σ2. If the difference of means is defined as θ = θE − θC , the corresponding test problem
can be formulated as follows:
H0 : θ = 0 versus H1 : θ > 0.
In Subsection 2.2.3.1, we have shown that at the final analysis, the test statistic is
obtained by combining the observations at stage 1 and the new observations at stage 2 via
the weighted inverse normal functions of the observed p-values at stage 1 and 2, that is
B = w1Φ
−1(1− p1) + w2Φ−1(1− p2)
where w1 and w2 are chosen independently of the observed data. In the same sub-
section, we also show that if the weights, wj , j = 1,2, are determined in advance, the terms
w1Φ
−1(1− p2) and w2Φ−1(1− p2) are independent, so under the null hypothesis,
B ∼ N(0, (w1)2 + (w2)2) = N(0, 1).
The null hypotheses H0 can be rejected at level α if B ≥ c, where c represents the
quintile of a normal distribution as defined in Eq. (1.15).
A type I error probability is:
Pr(B ≥ c|θ = 0) = α. (2.31)
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So to control the type I error rate, one must use the critical value c to satisfy Eq.
(2.31).
The specification and interpretation of alternative hypotheses is more difficult to
define in general, although in special cases it will be possible to make some form of power
requirement (Whitehead (2010)). However, in this thesis, we consider using the sample
size of the SSR method and the inverse normal combination test statistics to maintain the
power. This will be checked by simulations in the setting of multiple co-primary endpoints.
2.2.4.2 SSR Inverse Normal Combination test: Motivation
The main reason for choosing inverse normal combination test method in SSR setting is that
analytically, it has been proven that the combination test method maintains the type I error
rate for any possibly data-driven choice of sample sizes. To illustrate this, consider first a
fixed sample size setting with an interim look halfway through as suggested by Proschan
(2009b).
If the data are independent and identically distributed (iid) normal with known vari-
ance σ2, the most appropriate way to combine the two independent halves is to com-
bine the Z-scores Zstage1 and Zstage2 using Z = 1√2(Zstage1) +
1√
2
(Zstage2), which is
the usual Z-statistic on the full sample. A more general method that works for other
types of data with or without the assumption of known variance is to combine p-values
using the inverse normal method proposed by Lehmacher and Wassmer (1999): B =
w1Φ
−1(1− p1) + w2Φ−1(1− p2).
Now suppose that after looking at results from the first half, we decide to change
the second stage sample size. How does this affect the joint distribution of the Z-scores
or p-values? The following result, proposed by Proschan (2009b), underlying adaptive
two-stage procedures shows that it does not.
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Result 1: If p1 and p2 are uniformly distributed on (0,1) in a fixed sample setting
with iid data, the same is true if the second stage sample size depends on first stage data.
Therefore, any α-level rejection region in a fixed sample setting remains level α in the
adaptive sample size setting.
Proschan (2009b) gives some immediate applications of Result 1 as follows.
(i) Result 1 shows that p1 and p2 are uniformly distributed on (0,1) and B is normal dis-
tributed with mean 0 and variance 1 even when the second stage sample size depends
on stage 1 data.
(ii) Result 1 shows that the first and second stage Z-scores remain iid N(0,1) under H0
even though the second stage sample size depends on results from the first stage
i.e, Z = 1√
2
(Zstage1)+
1√
2
(Zstage2) has a standard normal distribution, so regardless
of whether the second stage sample size is changed, we may refer Z to a standard
normal distribution at the end.
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2.3 Group Sequential Designs with a single endpoint
In Section 2.1, the SSR method was described as one type of clinical trial design in which
the data of the interim analyses are used to estimate one or more nuisance parameters,
and this information is used to determine the sample size for the remainder of the trial.
Another type of clinical trial design is the group sequential design (GSD). In this context,
the accumulating data are analysed at a series of interim analyses. They allow a trial to
be stopped or continued at interim analyses. Further details of the methods described here
are given by Wald (1947), Siegmund (1985), Whitehead (1997), Proschan et al. (2006)
and Jennison and Turnbull (2000a). After an introduction in Subsection 2.3.1, Subsection
2.3.2 describes elements of sequential methodology. Subsection 2.3.3 presents stopping
boundary calculations, followed by a brief description of post trial analysis in Section 2.3.4.
2.3.1 Introduction
A sequential clinical trial is one in which accumulating data are analyzed at a series of
interim analyses. One potential type of a sequential trial is called a Group Sequential
Design (GSD). It allows a trial to be stopped at an interim time point during a planned
sequence of analyses. In this setting, the trial might be stopped with the conclusion that
the experimental treatment is effective, to abandon the trial, or otherwise be continued to
the next interim analysis (Jennison and Turnbull (2000a)). Such trials must be designed in
advance, with the specified design adhered to, so as to maintain the overall type I error rate.
Sequential monitoring on accumulated data was initially focused on applications in quality
control, which gained importance during World War II when it was essential to make sure
that ammunition was of appropriate quality. Wald (1945) and Wald (1947) proposed the
sequential probability ratio test (SPRT) for testing the simple null hypothesis H0 : θ = θ0
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against the alternative H1 : θ = θ1 . In Wald’s SPRT, the only decision to be made is
whether to terminate or continue the trial. This classical sequential design is called an open
plan because there is no maximum sample size. Wald and Wolfowitz (1948) showed that
under certain assumptions, the SPRT is optimal in the sense that it minimises the expected
sample size. However, the SPRT leads to an issue, which is that there is no maximal sample
size at which sampling is guaranteed to stop. Consequently, the distribution of the sample
size can be quite skewed with a large variance. Armitage (1957) introduced the closed
sequential design to impose a limit on the sample size. Later, McPherson and Armitage
(1971) proposed a theory of repeated significance tests on accumulating data that is similar
to the closed sequential design. Despite the savings in sample size, the need for constant
data monitoring and rapid response measures was not interesting. Group sequential designs
were later developed to avoid some of the problems of classical sequential designs.
2.3.2 Elements of a sequential method
Whitehead (1999) proposes four fundamental elements of any sequential method, allow-
ing the significance of the treatment difference to be evaluated and its magnitude to be
estimated. In the case of a single endpoint, two treatments, and considering a frequentist
approach of analysis, the key elements are as follows:
(i) A parameter θ, which is an unknown population characteristic and expresses the
benefit of E over C in terms of efficacy.
(ii) A statistic that provides information on the size of this benefit based on the sample
of data available at an interim analysis, and a second statistic that gives the amount
of information about θ contained in the sample.
(iii) A stopping rule, which determines, on the basis of the observed test statistics, values
at the interim analysis whether to continue or to stop a trial.
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(iv) A final analysis procedure, valid for the stopping rule used, which enables one to
conclude whether or not E is superior to C and provides a p-value and point estimate
and confidence interval for the treatment difference at the end of the trial.
Diverse suggestions have been provided by various authors for each of these four elements.
In the following subsection they are presented in more detail. The specification of the
treatment difference θ and test statistics is required when either fixed sample or sequential
methods are considered. A solution to the problem of the control of the type I error rate is
the main reason for the specification of the third element, which is the stopping boundary,
and several approaches are seen in existing literature on how to calculate it. Some of these
methods are presented below. With regards to the fourth element, Stallard and Todd (2010)
clarify that the final analysis is very important in the interpretation of the results from the
sequential trial. Statistical methodology in this area has generally fallen behind that for the
construction of stopping rules. In practice, the use of an appropriate final analysis has often
been neglected, in part due to the lack of availability of suitable software. Methods for
the validity of analysis have been developed, and the analysis can now be conducted using
commercially available software for some settings, but not all.
2.3.2.1 Parametrisation of treatment difference
When designing a sequential clinical trial, one must first select an appropriate primary
outcome measure of the treatment efficacy. This is because the importance of any clinical
trial will be significantly enhanced if a single primary analysis is specified in the protocol,
and is later found to show significant benefit from the experimental treatment (Whitehead
(1999)). This is true even in the case of a trial with a fixed sample size. This measure
should be chosen on the basis of clinical relevance, ease and accuracy of measurement, and
familiarity to clinicians, as explained by Stallard and Todd (2010).
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After defining the primary endpoint, one must then choose an associated parameter that
measures the difference between the experimental and control treatments. This will be
influenced by the type of data collected on the primary endpoint, the ability to interpret the
parameter (eg. ratio or difference) and the accuracy of the resulting analysis. In this thesis,
only parallel group studies are considered. The parameter θ represents a measure of the
difference between the experimental and the control treatment groups. A value of zero for
θ corresponds to equivalence of the treatments, positive values correspond to an advantage
for the experimental treatment and the negative values correspond to an advantage for the
control.
In this thesis, only continuous outcomes are considered; for example, blood pressure. It
(blood pressure outcome) represents a difference in true unknown mean blood pressure be-
tween the two groups of interest. Other classes of response exist but they are not considered
here. For example, if the primary response is the time to some event, such as time from
HIV infection to AIDS, the difference between treatment groups might be measured by the
ratio of the hazards in the two groups or the logarithm of this ratio. If the primary response
is a dichotomous variables such as success or failure, the chance of success in each group
can be measured by the odds of success, and the difference between the treatment groups
can be measured by the ratio of the odds in the two groups.
2.3.2.2 Test statistics and distribution theory
Suppose that we are interested in repeated looks at the accumulating data on the primary
endpoint with repeated hypothesis testing. At each interim analysis we will base inference
on some calculated test statistics. We need to think about the distribution for the data and
the test statistics. In the following, an example of a single normal sample with known
variance is given followed by a more general case of two normal samples with nuisance
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parameters. Throughout this chapter, the notation introduced in Section 2.1 is still valid,
but the index k is omitted because we are in the scenario of a single endpoint.
2.3.2.2.1 Single normal sample with known variance
Assume we have a sequence of independent identically distributed observations
Xi ∼ N(θ, 1), (i = 1, ..., nj , j = 1,..,J) and we want to draw inference regarding θ and
test H0 : θ = 0. At look j, we have x1...xnj observations (including those from previous
looks so, that nj ≥ nj−1).
The likelihood for θ at look j is:
L(θ; x1...xnj) =
nj∏
i=1
Lij(θ)
=
nj∏
i=1
1√
2π
exp{−1
2
(xi − θ)2}
= (
1√
(2π)
)njexp{
nj∑
i=1
(−x2i /2 + θxi − θ2/2)} (2.32)
where θ is the population parameter and Lij(θ) is the probability or probability density of
xi. Using the likelihood function, two statistics can be derived that are useful for inference:
the likelihood estimator and the test statistics.
Hence, the log-likelihood is:
l(θ) = −njlog(2π)/2−
nj∑
i=1
x2i /2 + θ
nj∑
i=1
xi − θ2nj/2
= constant + (
nj∑
i=1
xi)θ − (nj
2
)θ (2.33)
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where
∑nj
i=1 xi represents a sufficient statistic for θ. Also, l(θ) is a quadratic with linear
and quadratic coefficients
∑nj
i=1 xi,−nj/2.
Assume Sj =
∑nj
i=1 xi. Sj will be the basis of our inference, i.e Sj is normally distributed
with mean θnj and variance nj .
Sj ∼ N(θnj , nj)
if j1 ≤ j2, cov(Sj1, Sj2) = nj1 .
Thus S1,...SJ have a joint multivariate normal distribution:

S1
.
.
.
SJ

∼ N


θn1
.
.
.
θnJ

,

n1 n1 . . . n1
n1 n2 n2
. . .
. . .
. . .
n1 n2 . . . nJ


(2.34)
The standardised test statistic at stage j is:
Zj = Sj/
√
var(Sj) = Sj/
√
nj
Zj ∼ N(θ√nj , 1)
Under H0, Zj is normal distributed with mean 0 and variance 1, i.e. Zj ∼ N(0, 1)
cov(Zk1, Zk2) = cov(
Sj1√
nj1
,
Sj2√
nj2
) =
nj1√
nj1nj2
=
√
nj1
nj2
, j1 ≤ j2
Z1, ..., ZJ have a joint multivariate normal distribution:
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
Z1
.
.
.
ZJ

∼ N


θ
√
n1
.
.
.
θ
√
nJ

,

1
√
n1
n2
. . .
√
n1
nJ√
n1
n2
1
√
n2
nJ
. . .
. . .
. . .√
n1
nJ
√
n2
nJ
. . . 1


(2.35)
An alternative test statistic at stage j is:
θ̂j = Sj/var(Sj) = Sj/
√
nj
θ̂j ∼ N(θ, 1/√nj)
cov(θ̂j1 , θ̂j2) = cov(
Sj1
nk1
,
Sj2
nj2
) =
nj1
nj1nj2
=
1
nj2
, j1 ≤ j2
θ̂1, ..., θ̂J have a joint multivariate normal distribution:

θ̂1
.
.
.
θ̂J

∼ N


θ
.
.
.
θ

,

1
n1
1
n2
. . . 1
nJ
1
n2
1
n2
1
nJ
. . .
. . .
. . .
1
nJ
1
nJ
. . . 1
nJ


(2.36)
The above results show that if we want to test H0, test statistics Sj , Zj , θ̂j can effectively
be used interchangeably using the appropriate distribution.
Note that in the Eq. (2.34), defining the distribution of the Sj statistics,
S1 ∼ N(θn1, n1)
Sj − Sj−1 ∼ N((nj − nj−1)θ, (nj − nj−1)), independent of Sj−1
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That is, the increments S1, S2 − S1, Sj − Sj−1 are independently distributed.
2.3.2.2.2 A more general distribution
The results from the previous subsection can be made more general. For instance, for non-
normal data, unknown nuisance parameters or the comparison of two samples. If we wish
to draw inference regarding θ and test H0 : θ = 0, we need to specify a model in terms of
the parameter of interest θ, and obtain the (profile) log-likelihood for θ.
Consider a Taylor series expansion for l(θ) at θ = 0 :
l(θ) = l(0) + dl
dθ
|θ=0 θ − 12 d
2l
dθ2
|θ=0 θ2 + ...
dl
dθ
|θ=0 is the efficient score statistic, i.e. the first derivative of the log-likelihood
-
d2l
dθ2
|θ=0 is the Fisher’s information statistic, i.e. minus the second derivative of the
log-likelihood.
Denoting these by S and I , we can write
l(θ) ≈ l(0) + Sθ − I
2
θ2 , where I = − d2l
dθ2
|θ=0
This is the same as the single-sample normal log-likelihood, with S replacing the sample
sum at stage j and I replacing nj .
If we denote the score statistic at look j by Sj and use this as our test statistic, we have
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
S1
.
.
.
SJ

∼ N


θI1
.
.
.
θIK

,

I1 I1 . . . I1
I1 I2 I2
. . .
. . .
. . .
I1 I2 . . . IK


(2.37)
at least for large samples and small θ. Jennison and Turnbull (2000a) describe this as
the canonical form, and almost all group-sequential methods are based on this assumption.
Sj and Ij are the same as defined in Eq. (1.18) and Eq. (1.13), respectively.
S1, ..., SJ are like points on a continuous Brownian motion process. Wald (1947) and
Siegmund (1985) described other methods based on this model. Jennison and Turnbull
(2000a) provided a comprehensive account of how to construct group sequential tests for a
wide range of response distributions.
The standardised test statistic version for Eq. (2.37) is given by

Z1
.
.
.
ZJ

∼ N


θ
√
I1
.
.
.
θ
√
IJ

,

1
√
I1
I2
. . .
√
I1
IJ√
I1
I2
1
√
I2
IJ
. . .
. . .
. . .√
I1
IJ
√
I2
IJ
. . . 1


(2.38)
2.3.2.3 Stopping rules
The distribution of the test statistics introduced in Eq. (2.38) are used at each interim stage
of a GSD and have this form of the stopping rule:
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After stage j = 1, ..., J-1
if Zj ≥ cj stop, reject H0
otherwise continue to stage j +1
after stage J
if ZJ ≥ cJ stop, reject H0
otherwise stop, accept H0
(2.39)
where cj represents a critical value or boundary for Zj . Subsection 2.3.3 provides
details on how to compute cj numerically.
A type I error probability is:
∑
Pr(Z1 < c1, ..., Zj−1 < cj−1, Zj ≥ cj |θ = 0) = α (2.40)
for some j = 1,...,J, estimated when {Z1, ..., Zj} follow the null distribution of Eq.
(2.38).
The power of the test at θ > 0 is
∑
Pr(Z1 < c1, ..., Zj−1 < cj−1, Zj ≥ cj|θ = δ) = 1− β (2.41)
for specified δ > 0, estimated when {Z1, ..., Zj} follow the distribution in Eq.
(2.38). The probability in Eq. (2.41) results entirely from outcomes that terminate at an
analysis j with Zj ≥ cj when θ > 0. For given J, α, β and {c1, ..., cJ}, the maximum
sample size can be found that satisfies Eq. (2.41) when {Z1, ..., Zj} follow the distribution
in Eq. (2.38).
A variety of tests (e.g. Pocock, O’Brien & Fleming, etc...) use different sequences
of boundaries {c1, ..., cj}, but all are chosen to ensure the type I error probability is equal
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to a specified value α, or the power is equivalent to a specific value 1− β, when Eq. (2.38)
holds. In the following section we review some of these.
2.3.2.3.1 Pocock’s Test
Pocock (1977) proposes group sequential tests, where nEj = nCj = nj , j = 1,...,J.
The test satisfies Eq. (2.39) with cj = Cp(J, α), whereCp(J, α) represents Pocock’s bound-
ary. It is constant throughout interim stages and is computed numerically using the joint
distribution of the sequence of statistics Z1, ..., Zj; see Subsection 2.3.3 below for more
details. The boundary Cp(J, α) is chosen to give overall type I error α, i.e.,
Pr(θ=0)(Reject H0 at analysis j = 1, j = 2, ..., or j = J) = α (2.42)
The power is then given by
Pr(θ=δ)(Reject H0 at analysis j = 1, j = 2, ..., or j = J) = 1− β (2.43)
The maximum sample size of the group sequential design depends on J, α, β, and is
proportional to σ2
θ2
.
2.3.2.3.2 O’Brien and Fleming’s Test
O’Brien and Fleming (1979) proposed a sequential method that boundary values
decrease over the stages on the standardised normal Z scale, as defined in Eq. (1.12), to
make the early stop less likely. The procedure has conservative stopping boundary values
at very early stages, and boundary values at the final stage are close to the fixed-sample
design.
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Formally, the test follows Eq. (2.39) with cj = CB(J, α)
√
(J/j).
The power is given by:
P(θ=δ)(Reject H0 at analysis j = 1, j = 2, ..., or j = J) = 1− β (2.44)
The maximum sample size that the group sequential design may need depends on J,
α, β, and is proportional to σ2
θ2
.
In general, O’Brien & Fleming’s test requires a smaller group size than Pocock’s
test to satisfy the same power requirement, but is less likely to stop early.
2.3.2.3.3 Spending function approach
Pocock, and O’Brien and Fleming’s approaches ensure that the overall type I error is equal
to the pre-specified value if test statistics have the canonical form. But all these designs
require a fixed number and spacing of interim looks specified at the design stage. An alter-
native approach was introduced by Lan and DeMets (1983). It is based on an error spending
approach and allows the data monitoring committee to change the timing and frequency of
interim evaluations. Within the error spending context, interim monitoring enables the logi-
cal basis of the design thinking while allowing significant flexibility (Jennison and Turnbull
(2000a)).
The tests defined in the previous section assume information sequences to be fixed. If
the observed information sequence is different from the one used to derive the critical
values prior to the start of the trial, the type I error will no longer be equal to α. Lan
and DeMets (1983) proposed error spending designs as a way of dealing with random
information sequences. In error spending designs, the cumulative type I error, partitioned
into probabilities π1, ..., πj (j = 1,...,J) is specified as a function of the observed information.
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The boundary at a decision time is determined by πj (j = 1,...,J), and by past and current
decision times, but does not depend on the future decision times or the total number of
decision times.
As noted by Jennison and Turnbull (2000a), if the information levels I1, ..., Ij are
observed, the critical value cj , for the standardised statistics Zj , conditionally on I1, ..., Ij
are calculated such that:
Pr(θ=0)(Z1 < c1, ..., Zj−1 < cj−1, Zj ≥ cj) = πj (2.45)
where πj represents the probability of stopping at stage j to reject H0 when this
hypothesis is true. It is also called the error spent at stage j.
In the context of a maximum information trial, Jennison and Turnbull (2000a) explain that
the type I error rate can be divided according to an error spending function, f(t), which is
non-decreasing and satisfies f(0) = 0 and f(t) = α for t ≥ 1. The quantity t represents the
information time. It is supposed that the maximum information Imax will be reached if the
trial does not stop with an early decision. Imax and f(t) must be selected before the study
begins. So the type I error probabilities for each stage are
π1 = f(I1/Imax)
πj = f(Ij/Imax)− f(Ij−1/Imax). (2.46)
The critical values cj are computed to satisfy Eq. (2.45). They do not depend on
unobserved information Ij+1,Ij+2,...,IJ . The stopping rule defined in Eq. (2.39) is still
valid here, but the only difference is the critical values cj depend on the observed values I1,
I2,....Ij .
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Flexible spending function families exists which can also approximate group sequential
boundaries. Two of them have been proposed by Lan and DeMets (1983):
The Pocock type is defined as
f(tj) = αlog{1 + (e− 1)tj}, (2.47)
O’Brien and Fleming’s type is:
f(tj) = 2{1− Φ(Z1−α/2/
√
tj)}, (2.48)
Hwang et al. (1990) describe flexible spending function as
f(t) = α
(1− exp(−γtj))
(1− exp(−γ)) , (2.49)
for tj = Ij/Imax, representing the proportion of the total information accumulated.
The boundaries created with γ = 1 are similar to the boundaries from the Pocock
method, and the boundaries created with γ = -4 or γ = -5 are similar to the boundaries from
the O’Brien-Fleming method. The last two scenarios can be visualised in Figure 2.1.
To achieve a specified power, Jennison and Turnbull (2000a) explain that under
θ = δ, the distribution {z1, ..., zj} depends on the absolute information levels {I1, ..., Ij}.
Furthermore, the authors explain that for design purposes, it is necessary to set a maximum
number of stage, J, and to assume that the information levels I1, ..., IJ are specified in
advance.
Under the assumption in Eq. (2.45), the value of IJ can be chosen to meet a given
power requirement.
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Figure 2.1: Hwang-Shih-DeCani family of type I probability spending functions for vari-
ous values of γ
2.3.3 Stopping boundary calculation
The critical values c1, ...cJ satisfying Eq. (2.45) can be found using the method proposed
by Armitage et al. (1969) and also described by Jennison and Turnbull (2000a), known as
recursive numerical integration. This methodology is used to find the joint distribution of
Z1, ...ZJ when θ = 0 allowing for stopping.
Under H0, and considering the distribution of the test statistics in Eq. (2.38), at the first
interim analysis, we have Z1 ∼ N(0, 1). The density of this distribution is denoted by:
f1(Z1) = φ(Z1) (2.50)
where φ denotes the standard normal density function. To satisfy Eq. (2.45) for j=1, critical
value c1 are set to the upper π1 points for the above normal distribution.
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For the second interim analysis, the subdensity of Z2 for those trials that continue to the
second stage is given by
f2(Z2) =
∫ c1
−∞
f1(Z1)φ(Z2 − Z1)dZ1. (2.51)
knowing that increment Z2 − Z1 is normally distributed and independent of Z1.
This subdensity can be calculated by evaluating the integral numerically given the value of
c1 found previously. The critical value c2 to satisfy Eq. (2.39) is then given by the upper π2
point for this subdensity.
If we continue in this way, the subdensity fj(Zj) forZj , for those trials that continue
to stage j, is given recursively
fj(Zj) =
∫ cj−1
−∞
fj−1(Zj−1)φ(Zj − Zj−1)dZj−1 (2.52)
allowing calculation of cj for all j=1,2...,J to satisfy Eq. (2.39) as required.
2.3.4 Post-trial analysis
At the end of a sequential trial, an analysis must be performed. The interim analyses serve
only to determine whether stopping should take place, but they do not provide complete
interpretations of the data. The final analysis of the data expresses the degree of evidence
that a difference between the experiment and the control group exists using a P-value, and
to estimate its magnitude using point estimate and confidence interval (Whitehead (1999)).
In this thesis, it will be assumed that the trial has stopped according to a formal stopping
procedure.
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2.4 Group Sequential Inverse Normal combination tests
with a single endpoint
This section describes in more details a method integrating the Inverse Normal combina-
tion test approach described in Section 2.2 into the classical Group Sequential Designs
illustrated in Section 2.3. This implies using the sample size estimated with the GSD
method and the inverse normal combination test statistics to control the type I error rate.
Chapter 5 will present the group sequential inverse normal combination tests in the con-
text of multiple co-primary endpoints based on the methodology and notation used in this
section. Subsection 2.4.1 presents an introduction, Subsection 2.4.2 describes elements of
inverse normal combination test methodology in GSD setting, following by an illustration
of stopping rules in subsection 2.4.3.
2.4.1 Introduction
In Subsection 2.2.1, we explained that combination test approaches, as initially developed
by Bauer (1989), are based on the principle that the test statistics are calculated separately
from different stages data. The test decision is derived from a predefined function that
combines the test statistics into a single criterion after each stage. The advantage of the
combination test methods is their flexibility that allows the adaptation of certain experi-
mental conditions, such the sample size, the test statistic, or even the outcome variable
used to measure the treatment effect, to the data observed in the previous stages of the
trial. The advantage of group sequential tests is that there is a range of possible choices for
the critical boundaries (Muller and Schafer (2001)). For example, in the planning phase,
the group sequential test may optimally be fitted to the clinical situation and the special
research problem. One may choose a design out of a number of different plans published
in the literature, such as Pocock (1977), O’Brien and Fleming (1979), or Lan and DeMets
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(1983), or may construct boundaries that meet the requirements of the individual trial, using
fairly simple methods of numerical integration.
However, combination test approaches are based on special combination rules for
p-values such as Fisher’s rule or inverse normal combination test rule and do not offer such
a large variety of possible plans as group sequential designs do. On the other hand, group
sequential designs do not offer the flexibility to make data adaptive changes to the trial
design during the course of the trial based on the results of interim analyses (Muller and
Schafer (2001)). That is why, several authors, such as Cui et al. (1999), Lehmacher and
Wassmer (1999) and Muller and Schafer (2001), proposed a method that uses the classical
stopping boundaries while enabling an adaptive planning of the ongoing trial. The first
authors implemented a valid inference procedure that allows flexibility for adjusting sample
size based on the updated estimate of treatment effect during the course of the trial. The
proposed approach is a group sequential test procedure with pre-specified weights used in
the traditional repeated significance two-sample mean test. The second authors proposed a
method for group sequential trials based on the inverse normal method for combining the
results of the separate stages and the last authors suggested a method for integrating the
concept of adaptive interim analysis into classical group sequential testing.
In the following subsection we focus on the method proposed by Lehmacher and
Wassmer (1999) which implies that if, at some stage j, one always uses the unweighted
mean of the test statistics and the critical values designed for the case of equal sample
sizes between the stages, then the resulting group sequential test procedure is independent
of these sample sizes as long as the test statistics are independent and standard normally
distributed. These normal scores are obtained by the inverse normal method, which is a
common method in combining test results.
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2.4.2 Representing GSD tests as a Combination rule of j independent
p-values
The idea behind the method in this subsection is that we describe a group sequential design
defined implicitly as a combination of inverse normal tests of p-values, that is, at the time of
the first interim analysis, the decision rule of a group sequential test can be represented as a
combination rule for j p-values, one of the j p-values being derived from the data collected
in the first stage of the trial and the other p-value being derived from the independent data
collected in the further course of the trial, i.e., in stages 2 to j. At each time point of the
interim analysis, the further stage of the trial can be understood as an independent new trial.
To define GSD inverse normal tests, let B defined in Eq. (2.25) now be Bj , express-
ing the inverse normal test statistic at stage j, that is
Bj = w1Φ
−1(1− p1) + . . .+ wjΦ−1(1− pj)
satisfying
J∑
j=1
w2j = 1.
If the weight wj , j = 1, . . . , J are determined in advance, the terms wjΦ−1(1− pj),
j = 1, . . . , J , are independent, so under the null hypothesis, Bj is normal distributed with
mean 0 and variance w21 + . . .+ w2j , that is
Bj ∼ N(0, w21 + . . .+ w2j ).
If the pj are independent and uniform, the covariance between the inverse normal
test statistics at stages j and j + 1 is:
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Cov(Bj, Bj+1) = wj. (2.53)
Under H0, B1, B2, . . . , BJ , have a multivariate normal distribution:

B1
.
.
.
BJ

∼MVN


0
.
.
.
0

,

w1 w1 . . . w1
w1 w2 w2
. . .
. . .
. . .
w1 w2 . . . wJ


. (2.54)
Because each p-value is computed from a separate dataset, Bj and (Bj+1 − Bj)
are independently distributed and under the joint null distribution, the process Bj is of the
form defined Eq. (2.54); consequently when monitored according to the GSD, type I error
specifications will be maintained.
2.4.3 Stopping rules
The distribution of the test statistics introduced in Eq. (2.54) are used at each interim stage
of a GSD and have this form of the stopping rule:
After stage j = 1, ..., J-1
if Bj ≥ cj stop, reject H0
otherwise continue to stage j +1
after stage J
if BJ ≥ cJ stop, reject H0
otherwise stop, accept H0.
(2.55)
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where cj represents a critical value or boundary for Zj defined in Eq. (2.38). As in
the GSD, the boundary cj is computed exactly as in Subsection 2.3.3.
A type I error probability is:
J∑
j=1
Pr(B1 < c1, . . . , Bj−1 < cj−1, Bj ≥ cj|θ = 0) = α (2.56)
for some j = 1,. . . ,J, estimated when {B1, . . . , Bj} follow the null distribution of
Eq. (2.54).
The type I error probability can also be expressed in term of spending function as
defined in Eq. (2.45), that is:
Pr(B1 < c1, . . . , Bj−1 < cj−1, Bj ≥ cj |θ = 0) = πj (2.57)
where πj represents the probability of stopping at stage j to reject H0 when this
hypothesis is true. It is also called the error spent at stage j. It is obtained by specifying cj
calculated using Eq. (2.45).
As explained by Whitehead (2010), the specification and interpretation of alterna-
tive hypotheses is more difficult to define in general. However, this thesis considers using
the sample size of the GSD method and the GSD inverse normal combination test statis-
tics to maintain the power. This will be checked by simulations in the setting of multiple
endpoints.
2.4.4 GSD Inverse Normal combination test: Motivation
This subsection is an extension of Subsection 2.2.4.2 in the setting of J stages. It shows
analytically that combination test method in GSD setting maintains the type I error rate for
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any possibly data-driven choice of sample sizes. To illustrate this, we begin by extending
Result 1 described in Subsection 2.2.4.2 in J-stage setting .
Result 2 (J-stage combination functions): Result 1 (given by Proschan (2009b)) is
true with J stages provided that for each j = 1,. . . ,J, the sample size for stage j depends
only on data from stages 1,. . . ,j-1. If this holds, and if p1, . . . , pj are uniformly distributed
on (0,1) in a fixed sample setting, then they remain uniformly distributed on (0,1) in the
adaptive sample size setting. Therefore, any level α rejection region in a fixed sample
setting remains level α in an adaptive setting.
The following example given by Proschan (2009b) explains that Result 2 can be used
to combine monitoring with sample size re-estimation: without sample size modification,
we might plan to monitor the data j times over the course of the trial. The stage-specific
B-scores B1, . . . , Bj are iid N(0, 1) under the null hypothesis, and the B-score for the
cumulative data up to look j is
Bj =
1√
J
(B1 + . . .+Bj). (2.58)
Suppose that c1, . . . , cj is any boundary for B1, . . . , Bj in a fixed sample size set-
ting. Then even if we modify sample sizes of subsequent stages on the basis of past data,
Proschan (2009b) explains that the stage-specific B-scores remain iid N(0,1) under the null
hypothesis, and therefore B1, . . . , Bj has the same joint distribution in the adaptive sample
size setting. Therefore, as long as we apply the boundaries cj to the cumulative B-scores
defined in Eq. (2.58) the type I error rate will be α. This is the idea underlying a method
proposed independently by Cui et al. (1999) and Lehmacher and Wassmer (1999).
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2.5 Summary
This chapter provides a literature review of the methods in the context of a single endpoint.
Section 2.1 provides a background on the sample size re-estimation procedure with a single
endpoint, Section 2.2 describes the inverse normal combination test method in the context
of a single endpoint, Section 2.3 describes the group sequential design method, again in the
setting of analysis of a single endpoint and Section 2.4 presents the group sequential design
inverse normal combination test method with a single endpoint. The next chapter describes
how the SSR approach with a single endpoint, developed in Section 2.1 and Section 2.2,
can be extended to the setting of multiple co-primary endpoints.
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Chapter 3
Methods for sample size re-estimation
with multiple co-primary endpoints
without early stopping
This chapter describes how the SSR approach with a single endpoint, developed in Sec-
tion 2.1 and Section 2.2, can be extended to the setting of multiple co-primary endpoints.
Section 3.1 presents SSR method in the context of multiple co-primary endpoints and Sec-
tion 3.2 illustrates SSR inverse normal combination test approach with multiple co-primary
endpoints.
3.1 Sample Size Re-estimation with Multiple Co-primary
Endpoints
In the introduction, we explained that the aim of this thesis is to answer two questions.
First, how to adjust a sample size in a clinical trial with multiple continuous co-primary
endpoints using adaptive and group sequential designs. Second, how to construct a test in
such a way to control the FWER and maintain the power, even if the correlation ρ between
endpoints is not known. To answer these questions, the following method is proposed:
K different tests are conducted, each for one endpoint and each at level α/K, and SSR is
performed in which the results of the interim analysis are used to estimate one or more
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nuisance parameters. This information is used to determine the sample size for the rest of
the trial.
In this section, we start by defining an analysis framework in Subsection 3.1.1, fol-
lowed by a formulation of the problem for K co-primary endpoints in Subsection 3.1.2.
Subsection 3.1.3 presents the construction of K tests that satisfy FWER conditions and
power requirements, Subsection 3.1.4 illustrates how to calculate sample size in the mul-
tiple co-primary endpoints setting, Subsection 3.1.5 describes the implementation of the
method, Subsection 3.1.6 presents a worked example and Subsection 3.1.7 presents simu-
lation results.
3.1.1 Framework for the analysis of a SSR with multiple
co-primary endpoints
The framework of the analysis developed in Subsection 2.1.2 is extended as follows in the
context of multiple co-primary endpoints:
(Step 1) The initial sample size calculation leading to a provisional sample size N0 is carried
out on the basis of an initial estimate of the nuisance parameters ρkk′0 (k
′
> k) and
σ2k0 . Further details on how to compute the sample size are given in Subsection 3.1.4.
(Step 2) When the data for the first n1 = πN0 patients (e.g., π = 0.5) are available, then the
nuisance parameters ρkk′1 , k
′
> k and σ2k1 are re-estimated from these observations,
which constitute the internal pilot study. These estimates are then used to calculate
the sample size N . The sample size can then be adjusted following a predefined
recalculation rule:
– restricted design, i.e. n2 = max(N0, N)− n1 or
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Figure 3.1: SSR with multiple co-primary endpoints: Implementation of the method
– unrestricted design, i.e. n2 = max(n1, N) - n1
This also can be done using:
– unblind method, i.e. use pooled estimate of ρkk′ and σ2k
– blind method, i.e. use whole variance or assume difference between groups of
δ
(Step 3) The final analysis includes all N = n1 + n2 observations. The hypothesis test is
conducted using a standard t-test.
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This framework can also be visualised in Figure 3.1, and the program in Appendix
A follows steps of the framework to stimulate the data, calculate the critical value, estimate
the sample size and perform the test of hypotheses. More details about the values of each
variable in Figure 3.1 are given in Table 3.1. The same values have been used in the worked
example described in Subsection 3.1.6.
3.1.2 Formulation of the problem
In this section, we consider methodology for situations where there are K co-primary con-
tinuous correlated endpoints in a clinical trial. The general setting for this problem is
defined in Subsection 1.4.1. Suppose that E and C are two treatments to be compared in
a randomised (phase III) parallel group clinical trial. After each group of N subjects has
been randomised in equal numbers to the two therapies and the response obtained, ρkk′
and σ2k are re-estimated and the accumulated data tested. The primary trial’s objective is
to determine whether E is more efficacious than C in terms of K continuous co-primary
responses. This procedure is conducted at the final step of SSR analysis framework de-
scribed in Subsection 3.1.1, this includes all N = n1 + n2 observations, which involves a
comparison of the evidence of efficacy of E and C, with the rejection occurring as soon as
one of the K-hypotheses is in some sense sufficiently convincing.
3.1.3 Test statistics
In this Subsection, we are interested in constructing test statistics in the setting of K co-
primary endpoints and deriving their distribution.
Suppose we use the standardised statistic defined in Eq. (1.12) and the information
for θ defined in Eq. (1.13) to construct test statistics, and we assume σ2k is known. Let Zk,
k = 1,..,K now denote the standardised statistic for θk and endpoint k, which we write as:
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Zk =
1√
(2Nσ2k)
(
N∑
i=1
XikE −
N∑
i=1
XikC)
∼ N((θkE − θkC)
√
{N/(2σ2k)}, 1) (3.1)
and the information is now defined as
Ik =
N
2σ2k
. (3.2)
Under H0k, Zk is normal distributed with mean 0 and variance 1, i.e. Zk ∼ N(0, 1).
Suppose ρkk′ is the correlation between endpoints:
Cov(Zk, Zk′ ) = ρkk′ , k
′
> k. (3.3)
Zk (k = 1,. . ., K) has a multivariate normal distribution:

Z1
.
.
.
ZK
 ∼MVN


θ1
√
I1
.
.
.
θK
√
IK
 ,

1 ρ12 · · · ρ1K
1 · · · ρ2K
.
.
.
.
.
.
1

 (3.4)
Replacing Ik by its value in Eq. (3.4), we have

Z1
.
.
.
ZK
 ∼ MVN


θ1
√
N/2σ21
.
.
.
θK
√
N/2σ2K
 ,

1 ρ12 · · · ρ1K
1 · · · ρ2K
.
.
.
.
.
.
1

 (3.5)
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3.1.3.1 Implications for the FWER
We now need to show that using the critical value c defined in Eq. (1.15), the distribution
of the tests constructed in Eq. (3.5) controls the FWER in the strong sense.
So, for one endpoint, in place of Eq. (1.14), we now define
Pr(reject H0 | θ = 0) =
Pr(Z ≥ c)|θ = 0) = α/K (3.6)
where α/K now describes the error rate adjusted using the Bonferonni correction.
In the setting of K endpoints and using the decision rule defined in Subsection 1.4.1
(vi), in place of Eq. (3.6), we now have:
Pr(reject at least one H0k | θk = 0) =
Pr(Z1 > c or,...,or ZK > c | θk=0) ≤ α. (3.7)
So, to control the FWER, one must use c to satisfy Eq. (3.7).
3.1.3.2 Implications for the power
The power is described as in Eq. (1.16), but here we use K multiple co-primary endpoints.
So, in place of Eq. (1.16) the power is now given by:
Pr(reject at least one H0k | θk = δk) =
Pr(Z1 > c or,...,or ZK > c | θk = δk) = 1− β. (3.8)
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For given the values of α, β and c, the sample size can be found that satisfies Eq.
(3.8) when Zk follows the distribution of Eq. (3.5). We use mvtnorm package in R to com-
pute multivariate normal probabilities as described in more details in the next subsection.
3.1.4 Sample size calculation
The aim of this subsection is to show how to calculate the sample size of a design with
multiple co-primary endpoints. As stated in the previous subsection, given the values of
α/K, β and c, a sample size can be found that satisfies Eq. (3.8) when Zk, k = 1, . . . , K
follows the distribution of Eq. (3.5). This is done by using the mvtnorm package in R to
compute the multivariate normal probability of the following equation:
Φ(c,Σ) =
1√|Σ|(2π)K
∫ c
−∞
∫ c
−∞
...
∫ c
−∞
e−
1
2
xtΣ−1xdX (3.9)
where X = (x1, x2, ..., xK)t, −∞ < c < +∞ and Σ is a KxK semi-definite sym-
metric covariance matrix.
Within the mvtnorm package, the pmvnorm(lower, upper, mean, corr) function is
used to compute such probability. The lower argument of the pmvnorm function represents
the vector of lower limits of length K. In the one sided setting, it is
Lower limits =

−∞1
.
.
.
−∞K
 . (3.10)
The upper argument indicates the vector of upper limits of length K, that is
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Upper limits =

c
.
.
.
c
 . (3.11)
The mean argument represents the mean vector of length K, that is
Mean vector =

θ1
√
N
2σ21
.
.
.
θK
√
N
2σ2
K
 . (3.12)
The correlation argument indicates the variance-covariance matrix of dimension K,
that is:

1 ρ12 · · · ρ1K
1 · · · ρ2K
.
.
.
.
.
.
1
 . (3.13)
The sample size N is then found iteratively using the function uniroot in R, which
searches the interval from lower to upper for a root (i.e., zero) of the pmvnorm(lower, upper,
mean, corr) function with respect to its first arguments. The lower and upper arguments of
the uniroot function are the end points of the interval to be searched.
3.1.5 Implementation of the method
This section illustrates how the framework of analysis described in subsection 3.1.1 could
be implemented in practice. It is based on the extension of a three step procedure developed
by Wittes and Brittain (1990). The following is an illustration of such a method:
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3.1.5.1 Step 1 - Initial sample size calculation
In step 1, the initial sample size calculation leading to a provisional sample size N0 is
carried out on the basis of an initial estimate of the nuisance parameters.
A1.1. Guess ρkk′0 (k
′
> k) and σ2k0 ; or consider initial estimates of studies in earlier phases
of the drug development process.
A1.2. Determine α and target power = 1 - β.
A1.3. Calculate the critical value c as in Eq. (1.15).
A1.4. Calculate the initial sample size N0 as illustrated in more detail in Subsection 3.1.4.
A1.5. Fix the fraction of the initial sample size π to be used at interim step.
3.1.5.2 Step 2 - Sample size re-estimation
In step 2, the nuisance parameters are re-estimated based the interim data collected, which
constitute the internal pilot study. These estimates are then used to calculate the sample
size N for the remainder of the trial.
A2.1. Simulate n1 = πN0 observations.
A2.2. Estimate σ2k1 using blinded method (as in Eq. (2.10)) based on n1 observations.
A2.3. Use n1 observation to estimate ρkk′1 as in Eq. (1.9).
A2.4. Use α and power defined in step (A1.2.), c defined in step (A1.3.), σ2k1 and ρkk′1
estimated in steps (A2.2.) and (A2.3.) respectively to re-calculate the initial sample
size N as illustrated in Subsection 3.1.4.
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A2.5. Collect n2 using the restricted design which requires a final sample size at least as
large as the original calculated as in Eq. (2.7) .i.e. n2 = N − n1, where N =
max(N0, N).
3.1.5.3 Step 3 - Final analysis
In step 3 which includes all N = n1 + n2 observations, the hypothesis test is conducted
using a standard t-test.
A3.1. Estimate σ2k2 using blinded method (as in Eq. (2.10)), based on all N = n1 + n2
observations.
A3.2. Use σ2k2 estimate in step (A3.1.) and N = n1 + n2 to calculate T-statistic as in Eq.
(2.6).
A3.3. Calculate the critical value c as in Eq. (2.14).
A3.4. Reject at least one H0k at level α if Tk ≥ c. Note that Tk is defined in Eq. (1.23) in a
single endpoint context but in this setting, it is a t-statistic for endpoint k calculated
with N observations.
3.1.6 Example: SSR with Multiple Co-primary Endpoints
Suppose that E and C are two treatments to be compared in a randomised (phase III) parallel
group clinical trial. Two co-primary endpoints are considered, i.e. K = 2. Patients are
randomised in equal numbers between E and C, and a normally distributed response is
observed for each of the endpoints. Suppose the parameters of interest representing the
mean differences are θ1 = θ2 = 0.5.
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Table 3.1: SSR: Implementation of the method
Steps Values
Step 1
Significance level α 0.025 (one sided)
Power 1− β 0.8
Endpoints K = 2
Assume ρ120 0.5
Assume σ210 1.5
Assume σ220 1
Assume π 0.5
Calculate N0 54
Step 2 Interim step
Simulate n1 = πN0 data 27
Estimate ρ121 0.53
Estimate σ211 1.30
Estimate σ221 0.94
Estimate N 67
Use restric. design: n2 40
Simulate n2 data 40
Step 3 Final analysis
Calculate critical value c with N data 1.98
Calculate T1 and T2 with N data 0.84 and 2.42
Conclusion T1 < c and T2 > c Stop, reject H0k
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In step 1 (see Subsection 3.1.5.1 and Figure 3.1), the values considered are summa-
rized in Table 3.1. We assume (or guess) that the variance for endpoint 1 is σ210 = 1.5, the
variance for endpoint 2 is σ220 = 1 and the correlation between endpoints is ρ120 = 0.5.
A SSR with multiple co-primary endpoints is required to test H0k : θk = 0, k = 1,2, with
a one-sided test type I error rate of α = 0.025 and a power of 1 - β = 0.80 for θ = 0.5.
We use step (A1.3.) to calculate the critical value, that is c = Φ−1(1 − α/K) which can
be evaluated in R using qnorm(1-0.025/2) = 2.241403. We then use step (A1.4.) to esti-
mate the initial sample size N0 by defining the mean vector, variance-covariance matrix,
the lower and upper limit vectors respectively as followθ1
√
N
2σ210
θ2
√
N
2σ220
,
 1 ρ120
ρ120 1
,
−∞1
−∞2
 and
c
c

.
This gives an initial sample size of N0 = 54. We finally fix the fraction of the initial
sample size to be used at interim step by π = 0.5.
In step 2, the values simulated and estimated are summarized in Table 3.1. We
simulate n1 = πN0 = 0.5 ∗ 54 = 27 observations; then the nuisance parameters σ2k1 and
ρ121 are re-estimated from these observations as in steps (A2.2) and (A2.3) respectively.
The initial sample size N0 is re-calculate by replacing the values of σ2k1 and ρ121 in the the
mean vector and the variance-covariance matrix as in step 2. Suppose this gives N = 67.
We carry on by simulating n2 data as in step (A3.1) i.e. n2 = N − n1 = 67− 27 = 40.
In step 3, the values calculated and the conclusions of hypothesis testing are sum-
marized in Table 3.1. We estimate σ2k2 as in step (A3.2.). We then calculate T-statistic and
critical value c = 1.98 as in step (A3.3.) and (A3.4.) respectively. We finally perform
hypothesis testing by rejecting H01 or H02 at level α if T1 ≥ c or T2 ≥ c.
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Table 3.2: Initial values considered in the simulation study.
Fixed parameters SSR
Significance level α 0.025 (one sided)
Standard error of estimate FWER 0.001
Target power 1− β 0.8
Standard error of estimate power 0.0025
Number of endpoints K = 2
Number of simulations 100,000
Null hypothesis H0k θ1 = θ2 = 0
Guessed nuisance parameters
ρ120 0.5
σ210 1.5
σ220 1
3.1.7 Simulation results
As we said in the introduction of this section, the procedure for sample size re-estimation
with continuous data aims to maintain the desired power of the study without inflating the
FWER above the nominal level, even if the nuisance parameters ρkk′ and σ2k are not known
at the planning stage. In this section, we evaluate these characteristics by simulations. We
focused on situations that are typical for phase III trials with two co-primary endpoints.
Table 3.2 presents the fixed values considered in the simulation study. In all the scenarios
to be described in Table 3.3 below, we conduct 100,000 simulated trials (standard error of
estimate FWER α = 0.025 is 0.001 and 0.0025 for the power 1-β = 0.80). We consider the
initial guess correlation ρ120 to be 0.5, the initial guess variance for endpoint 1 σ210 to be 1.5
and for endpoint 2 σ220 to be 1. We aim to randomise patients in equal numbers between E
and C.
The scenarios considered in Table 3.3 have the following variable values:
In scenario 1, we consider the parameters of interest representing the mean differ-
ence to be (θ1 = θ2 = 0.5). We also consider the proportion of interim data π to be 0.50 and
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Table 3.3: Scenarios considered in the simulation study.
Variable values SSR
Scenario 1
Alternative hypothesis θk = δk δ1 = δ2 = 0.5
Proportion pi in SSR 0.50
True nuisance parameters
ρ12 0,0.1,...,1
σ21 1.5
σ22 1
Scenario 2 Common values for all settings
Alternative hypothesis θk = δk δ1 = δ2 = 0.5
Proportion pi in SSR 0.50
True nuisance parameters
ρ12 0,0.1,...,1
σ21 1,1.1,1.2,...,2
Setting 1
σ22 1
Setting 2
σ22 1.2
Setting 3
σ22 1.5
Setting 4
σ22 1.8
Setting 5
σ22 2
Scenario 3 Constant ρ12
Alternative hypothesis θk = δk δ1 = δ2 = 0.5
Proportion pi in SSR 0.50
True nuisance parameters
ρ12 0.5
σ21 1,1.1,1.2,...,2
σ22 1,1.1,1.2,...,2
Scenario 4 Different size effects
Alternative hypothesis δ1 = 0.5, δ2 = 0.7
Alternative hypothesis δ1 = 0.7, δ2 = 0.5
Same true nuisance parameters as in Setting 3
Scenario 5 Different proportion pi in SSR
Proportion pi in SSR 0.10, 0.80
Same alternative hypothesis as in Setting 3 δ1 = δ2 = 0.5
Same true nuisance parameters as in Setting 3
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simulate data with the following true characteristics: ρ12 ranged from 0 to 1 .i.e. (0, 0.1,. . . ,
1), true pooled variance for endpoint 1 σ21 = 1.5 and true pooled variance for endpoint
σ22 = 1.
In scenario 2, we consider five settings with the same parameters of interest repre-
senting the mean difference to be (θ1 = θ2 = 0.5) and the same proportion of interim data
to be 0.50. The five settings have the same values of ρ12 ranging from 0 to 1 .i.e. (0, 0.1,. . . ,
1) and the same values of true pooled variances for endpoint 1 σ21 ranging from 1 to 2 .i.e,
(1, 1.2, . . . , 2). However, each setting has the following true pooled variance for endpoint
2: In setting 1, σ22 = 1; setting 2, σ22 = 1.2; setting 3, σ22 = 1.5; setting 4, σ22 = 1.8; and setting
5, σ22 = 2.
In scenario 3, we consider ρ12 to be 0.5, pooled variance for endpoint 1 σ21 ranging
from 1 to 2 .i.e, (1, 1.2, . . . , 2) and pooled variance for endpoint 2 σ22 ranging from 1 to 2
.i.e, (1, 1.2, . . . , 2).
In scenario 4, we consider the same true nuisance parameters as in Setting 3 with
different parameters of interest representing the mean difference to be (θ1 = 0.5, θ2 = 0.7)
and (θ1 = 0.5, θ2 = 0.7).
In scenario 5, we consider different proportion of interim data to 0.10 and 0.8 re-
spectively, with the same true nuisance parameters and the same parameters of interest
representing the mean difference as in Setting 3.
3.1.7.1 Power in the fixed sample size design for the guess values of the nuisance
parameters
Figure 3.2 presents the power in the fixed sample size design for two correlated endpoints.
We consider the fixed values defined in Table 3.2 and the variable values defined in Table
3.3, scenario 1. We want to estimate the sample size for the guess values of the nuisance
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Figure 3.2: Power in the fixed sample size design for two correlated endpoints
parameters without knowing their true values.
The solid line of the left panel in Figure 3.2 indicates the sample size for various
values of true correlation (ρ12 = 0, 0.1, . . . , 1), while the dashed line corresponds to the
sample size for the guess ρ120 = 0.5. The figure in left panel shows that the sample sizes
of the true ρ12 = 0, 0.1, . . . , 0.4 are below the one of the guess ρ120 = 0.5. It also shows
that the sample size of the true ρ12 = 0.5 is equal to the one of the guess ρ120 = 0.5, while
the sample size of the true ρ12 = 0.6, 0.7, . . . , 1 are above the one of the guess ρ120 = 0.5.
In the right panel, the light dashed line shows the power at various points of the true
ρ12, while the bold dashed line indicates the target power for the guess ρ120 = 0.5. The
figure in the right panel shows that if the guess ρ120 is above the true ρ12 in the left panel,
its sample size is above the one of the true ρ12, consequently the power in the left panel is
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above the target power, and vice versa; and if the guess ρ120 is equal to the true ρ12, they
generate the same sample size, consequently give the same power.
The results in Figure 3.2 have a number of consequences. At the planning stage of
a clinical trial, it is often quite uncertain to know the size of parameters needed for sample
size calculation. Figure 3.2 illustrates this. For example, if a clinical trial investigator
decide to run a trial with a sample size of 54 above the true sample size of 48 as shown
on the left panel of Figure 3.2, this would lead to a more powerful trial than originally
planned, with the power of 0.8613 above the target power of 0.80. However, the trial would
be unethical as more patients would be exposed to an inferior treatment, and the trial would
also cost more money and require more time to be completed. A solution to this problem
is to perform a SSR in which the results of the interim analysis are used to re-estimate ρ12
and this information is used to determine the sample size for the rest of the trial to make
sure it (the trial) is not unnecessarily large for ethical reasons, budget restrictions and time
pressure. We present how this could be done in the following subsections.
3.1.7.2 FWER, power and sample size in SSR design
The aim of this subsection is to check the effect of the mis-specification of the nuisance
parameters on the FWER, power and sample size using SSR design; in other word, we
need to check if the FWER would be controlled and the power maintained if the nuisance
parameters change as in the following settings:
3.1.7.2.1 Scenario 2 : FWER in Settings 1 - 5
Figure 3.3 presents SSR FWER’s simulation results with the fixed and variable val-
ues defined in Table 3.2 and Table 3.3 respectively. It shows that the method effectively
controls the overall FWER at the nominal 0.025 level despite variation of ρ12, σ21 and σ22
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in all five settings. In setting 1, the FWER has a minimum value of 0.01101 for perfectly
correlated data i.e. ρ12 = 1 and a maximum value of 0.02264 for uncorrelated data, i.e.
ρ12 = 0. In setting 2, a minimum value of 0.01012 for ρ12 = 1 and a maximum value of
0.02315 for ρ12 = 0 have been observed. In setting 3, the FWER has a minimum value of
0.01176 for ρ12 = 1 and a maximum value of 0.02345 for ρ12 = 0. In setting 4, a minimum
value of 0.01012 for ρ12 = 1 and a maximum value of 0.02420 for ρ12 = 0 have been
observed. Finally, in setting 5, the FWER has a minimum value of 0.01105 for ρ12 = 1 and
a maximum value of 0.02451 for ρ12 = 0.
3.1.7.2.2 Scenario 2 : Sample size in Settings 1 - 5
Figure 3.4 presents SSR sample size simulation results with the fixed and variable
values defined in Table 3.2 and Table 3.3 respectively. The results are presented in all five
settings of scenario 2. The figure shows that the sample size increases as ρ12, σ21 and σ22
increase. This is known as the sample size is proportional to the variance. The results in
Figure 3.4 also show that the method is working as expected.
3.1.7.2.3 Scenario 2 : Power in Settings 1 - 5
Figure 3.5 presents simulation results for the SSR power with the fixed and variable
values defined in Table 3.2 and Table 3.3 respectively. The results are presented in all five
settings of scenario 2. For example in setting 1, the power has a minimum value of 0.7808
for uncorrelated data i.e. ρ12 = 0 and a maximum value of 0.7895 for perfectly correlated
data i.e. ρ12 = 1. In setting 2, a minimum value of 0.7801 for ρ12 = 0 and a maximum
value of 0.7994 for ρ12 = 1 have been observed. In setting 3, the power has a minimum
value of 0.7800 for ρ12 = 0 and a maximum value of 0.7901 for ρ12 = 1. In setting 4,
a minimum value of 0.7810 for ρ12 = 0 and a maximum value of 0.7900 for ρ12 = 1
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Figure 3.3: SSR FWER in Scenario 2; Settings 1 - 5
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Figure 3.4: SSR Sample size in Scenario 2; Settings 1 - 5
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have been observed. Finally, in setting 5, the power has a minimum value of 0.7801 for
ρ12 = 0 and a maximum value of 0.7991 for ρ12 = 1. Figure 3.5 illustrates that SSR
method effectively maintains the power and this is constant despite variation of ρ12, σ21 and
σ22 . By observing the sample size increasing in the same direction as the variances in Figure
3.4, we would expect the constant power at the nominal level of 0.80. This is an indication
that the method is working as expected.
3.1.7.2.4 Scenario 3: Constant ρ12
The results in scenario 3 are presented in Figure 3.6. It (figure) illustrates that de-
spite variation of σ21 and σ22 , the FWER is controlled and fairly constant with the minimum
value of 0.02079 and the maximum value of 0.02284. The same figure illustrates that the
sample size increases in the same direction as σ21 and σ22 with the minimum value 58 and the
maximum value 220. Finally the same figure illustrates that the power is maintained and
fairly constant despite variation of σ21 and σ22 with 0.7820 the minimum value and 0.7940
the maximum value.
3.1.7.2.5 Scenarios 2 and 3: Summary and comments on the results
The results in scenario 2 show that the FWER is controlled but becomes increasingly
conservative as ρ12 increases (Settings 1 - 5). The results in scenario 2 also show that the
FWER increases as σ22 increases, however, this is true only when the data are not correlated
.i.e, ρ12 = 0 and is assigned to simulation error. The results obtained in this scenario are
in line with what we would expect to have because we have used the Bonferroni correction
and more details about its characteristics are described in Subsection 1.3.3.1.1. The results
in scenario 3 show that the FWER is controlled and fairly constant when ρ12 is constant
(Scenario 3). Again this is known and this shows that the method is working as expected.
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Figure 3.5: SSR Power in Scenario 2; Settings 1 - 5
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Figure 3.6: SSR FWER, Sample size and Power in Scenario 3
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The results in scenario 2 also show that the sample size is increasing in the same
direction as ρ12, σ21 and σ22 , and the power is fairly constant despite variations of these
nuisance parameters. This is an indication that this method is adjusting for the sample size
needed to maintain the power as defined at the design stage. This is also true for the results
in scenario 3.
The results in scenario 2 finally show that all settings control the FWER and main-
tain the power therefore we only consider Setting 3 to check the characteristics of the
FWER, power and sample size when different effect sizes and different timings of the in-
terim analysis are considered.
3.1.7.3 Different effect sizes
3.1.7.3.1 Scenario 4: δ1 = 0.5, δ2 = 0.7
In this subsection, simulations are conducted to check the effect of the variations
of the effect size on the FWER, sample size and power. The fixed and variable values
considered are described in Table 3.2 and Table 3.3 respectively. Figure 3.7 illustrates a
situation where δ1 = 0.5 and δ2 = 0.7. It shows that the FWER in this setting is controlled
with a minimum value of 0.01123 for ρ12 = 1 and a maximum value of 0.02324 for ρ12 = 0.
The same figure shows that the sample size is increasing in the same direction as ρ12 and
σ21 with a minimum value of 51 and a maximum value of 98. Finally, Figure 3.7 shows that
the power in this setting is not maintained for the combination of ρ12 = (0-0.6) and σ21 =
(1-1.2), but maintained for any other combination of ρ12 and σ21 .
3.1.7.3.2 Scenario 4: δ1 = 0.7, δ2 = 0.5
Figure 3.8 presents a situation where δ1 = 0.7 and δ2 = 0.5. It shows that the FWER
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Figure 3.7: SSR FWER, Sample size and Power in Scenario 4 (δ1 = 0.5, δ2 = 0.7)
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Figure 3.8: SSR FWER, Sample size and Power in Scenario 4 (δ1 = 0.7, δ2 = 0.5)
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in this setting is controlled with a minimum value of 0.01011 for ρ12 = 1 and a maximum
value of 0.0222 for ρ12 = 0. The same figure shows that the sample size is increasing in
the same direction as ρ12 and σ21 with a minimum value of 39 and a maximum value of 92.
However, the power in Figure 3.7 is not maintained for the combination of ρ12 = (0-0.6)
and σ21 = (1-2), but maintained for any other combination of ρ12 and σ21 .
3.1.7.3.3 Scenario 4: Summary and comments on the results
The results in Scenario 3 show that the FWER is controlled but becomes increas-
ingly conservative as ρ12 increases. The results in setting (δ1 = 0.7 and δ2 = 0.5) show
that the FWER is even more conservative compared to the findings in setting (δ1 = 0.5 and
δ2 = 0.7), however, this is assigned to simulation error.
The results in Scenario 4 also show that sample sizes are increasing in the same
direction as ρ12, σ21 , however they (sample sizes) are not large enough to detect different
effect sizes at the same time, hence reduction in power. The comment about this scenario is
that if different effect sizes are considered in a trial ( e.g. δ1 = 0.7 and δ2 = 0.5), it is rec-
ommended to use the small effect size for sample size calculation. This is a guarantee that
the sample size obtained is large enough to detect even the large effect size and maintain
the power.
3.1.7.4 SSR: Different timings
3.1.7.4.1 Scenario 5: π = 0.10
Figure 3.9 presents simulation results with the fixed variable values defined in Table
3.2 and the variable values of Scenario 5 defined in Table 3.3. The situation of π = 0.10 is
illustrated. The figure shows that SSR design controls the FWER with the minimum value
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Figure 3.9: SSR FWER, Sample size and Power in Scenario 5 (π = 0.10)
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0.01164 for perfectly correlated data i.e. ρ12 = 1 and 0.02413 for uncorrelated data, i.e.
ρ12 = 0. The same figure also shows that the sample size increases as ρ12 and σ22 increase
with a minimum value of 61 and maximum value of 176. However, Figure 3.9 shows that,
in this setting, the method does not maintain the power when ρ12 and σ22 vary. This is due to
bias in estimation of ρ12 and σ22 from small samples. The minimum and maximum values
observed are 0.7240 and 0.7500 respectively.
3.1.7.4.2 Scenario 5: π = 0.8
Similar to Figure 3.9, Figure 3.10 presents the situation of π = 0.80. It shows that
SSR method effectively maintains the overall FWER at the nominal 0.025 level despite
variation of ρ12 and σ21 with the minimum value 0.01140 for perfectly correlated data i.e.
ρ12 = 1 and 0.02376 for uncorrelated data, i.e. ρ12 = 0. The figure shows that the method
become increasingly conservative as ρ12 increases. The same figure also shows that the
sample size increases as ρ12 and σ21 increase with a minimum value of 64 and maximum
value of 176. Finally the same figure shows that the method maintains the power and this
is constant despite variation of ρ12 and σ21 with a minimum value of 0.7810 and maximum
value of 0.7980.
3.1.7.4.3 Scenario 5: Summary and comments on the results
As noted by Friede and Schmidli (2010), the timing of the interim evaluation in
clinical trials is not only important for logistic motivations but also affects the operational
characteristics of the recalculation procedure. An early interim review cannot give a good
estimate of the nuisance parameters, while a very late sample size review may lead to a
larger sample size than needed. These scenarios are illustrated in scenario 5.
The results in scenario 5 show that the FWER is controlled but becomes increasingly
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Figure 3.10: SSR FWER, Sample size and Power in Scenario 5 (π = 0.8)
112
conservative as ρ12 increases. The timings of the interim evaluation has no impact on the
FWER. This has not been shown analytically although we have shown this by simulations
in this scenario.
The results in Scenario 5 also show that sample sizes are increasing in the same
direction as ρ12, σ21 and σ22 , and this is similar on both settings. However Figure 3.9 shows
that the power is not maintained, while Figure 3.10 indicates that it is maintained. One
of the explanations is given by Gould (1992), who stipulates that as the sample size at
the interim review is decreasing, the likelihood of inadequate or unnecessarily large final
samples sizes is increased. As can be seen in this scenario, although a similar sample size,
Figure 3.9 gives a variable sample size, which depends on variable and unprecise nuisance
parameters, so it is less powerful than the one in Figure 3.10 which gives a precise sample
size based on precise nuisance parameters, hence powerful.
113
3.2 SSR Inverse Normal Combination test for multiple co-
primary endpoints
This Section describes how the SSR inverse normal combination test method, described
in Section 2.2, can be extended to the setting of K co-primary endpoints. It shows in
more detail how to construct test statistics in such a way as to control the FWER if the
variance σ2k for endpoint k and the correlation ρkk′ between inverse normal tests is not
known. Subsection 3.2.1 presents a framework of the analysis, Subsection 3.2.2 describes
the formulation of problem considered, Subsection 3.2.3 presents test statistics, Subsection
3.2.4 illustrates the implementation of the method, Subsection 3.2.5 presents a worked
example and Subsection 3.2.6 presents simulations results.
3.2.1 Framework for the analysis of the method
The framework of analysis developed in Subsection 2.2.3.1 is extended as follows in the
context of multiple co-primary endpoints:
3.2.1.1 Step 1 - Initial sample size calculation
The initial sample size N0 is calculated on the basis of an initial estimate of the nuisance
parameters ρkk′0 (k
′
> k) and σ2k0 guessed before the trial begins. N0 is computed as in
Subsection 3.1.4.
3.2.1.2 Step 2 - Sample size re-estimation
When the data for the first n1 = πN0 patients (e.g., π = 0.5) are available, then the nuisance
parameters ρkk′1 , k
′
> k and σ2k1 are re-estimated from these observations, which constitute
the internal pilot study. These estimates are then used to calculate the sample size N . The
new variance estimate σ2k1 is used to calculate t-statistics Tk1 for endpoint k calculate with
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n1 observations. Tk1 is then used to calculate the p-value pk1 for endpoint k. A further
n2 = N − n1 observations are collected and used to estimate the variance σk22 , which is
used to calculate t-statistics Tk2 for endpoint k. Tk2 is then used to calculate p-value pk2 for
endpoint k.
3.2.1.3 Step 3 - Final analysis
At the final analysis, the evidence from stage 1 and stage 2 are combined via the weighted
inverse normal function Bk of the observed pk1 and pk2. The hypothesis test is conducted
using Bk; more details about this are given in the Subsection below.
3.2.2 Formulation of the problem
In this section, we take into account the same problem as in Subsection 3.1.2. We consider
methodology for situations where there are K co-primary continuous correlated endpoints
in a clinical trial. Suppose that E and C are two treatments to be compared in a ran-
domised (phase III) parallel group clinical trial. After each group of N subjects has been
randomised in equal numbers to the two therapies and the response obtained, ρkk′ and σ2k
are re-estimated and the accumulated data is tested. However, in contrast to the problem
defined in Subsection 3.1.2, the accumulated data are now tested using a combination of in-
verse normal tests of pkj-values, one of the pkj-values being derived from the data collected
at interim stage and the other pk(j+1) being derived from the independent new data collected
after sample re-estimation. The primary trial’s objective is to determine whether E is more
efficacious than C in terms of K continuous co-primary responses. This procedure is con-
ducted at the final step of SSR analysis framework described in Subsection 3.2.1.3, which
involves a comparison of the evidence of efficacy of E and C, with the rejection occurring
as soon as one of the K-hypotheses is in some sense sufficiently convincing.
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3.2.3 Test statistics
In this Subsection, we are interested in constructing test statistics in the setting of K co-
primary endpoints and deriving their distribution.
Suppose we use the test statistic Bk defined in Eq. (2.25), where wj is a predefined
weight and the p-value pj is defined in Eq. (2.26). Let Bk, k = 1,..,K now denote the test
statistic for θk and endpoint k and pkj (j = 1,2) the p-value for endpoints k and stage j,
which we write as:
pkj = 1− Φ(Zkj) (3.14)
and
Bk = w1Φ
−1(1− pk1) + w2Φ−1(1− pk2) (3.15)
where Zkj defined in Eq. (3.1) is now the standardised test statistics for endpoint k
based on new data at stage j.
Under H0k, Bk is normal distributed with mean 0 and variance (w1)2 + (w2)2, i.e.
Bk ∼ N(0, (w1)2 + (w2)2).
Suppose ρkk′ is the correlation between endpoints :
Cov(Bk, Bk′ ) = ρkk′ , k
′
> k. (3.16)
Bk (k = 1,. . ., K) has a multivariate normal distribution:
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3.2.3.1 Implication for the FWER
We now need to show that using the critical value c defined in Eq. (1.15), the distribution
of the inverse normal test statistics constructed under the null hypothesis in Eq. (3.17)
controls the FWER in the strong sense.
So for one endpoint, in place of Eq. (2.31) we now define the type I error rate to be:
Pr(reject H0 | θ = 0) =
Pr(Bk ≥ c) = α/K. (3.18)
Here, the Bonferonni correction is applied as illustrated in Section 3.3.1.
In the setting of K endpoints, in place of Eq. (3.18), we now have:
Pr(reject at least one H0k | θk = 0) =
Pr(B1 > c or,. . . ,or BK > c | θk = 0) ≤ α. (3.19)
So, to control the FWER, one must use c to satisfy Eq. (3.19).
As explained previously, Whitehead (2010) stated that the specification and interpre-
tation of alternative hypotheses is more difficult to define in general. However, this thesis
consider using the sample size of the SSR method with multiple co-primary endpoints and
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the SSR inverse normal combination test statistics with multiple co-primary endpoints to
maintain the power. This is checked by simulations in Subsection 3.2.6.
3.2.4 Implementation of the method
This section illustrates how the framework of analysis described in Subsection 3.2.1 could
be implemented in practice. It is a adaptation of the three-steps procedure developed in
Subsection 3.1.1. The following is an illustration of such a method:
3.2.4.1 Step 1 - Initial sample size calculation
As in SSR with multiple co-primary endpoints setting, in this step, the initial sample size
calculation leading to a provisional sample size N0 is carried out on the basis of an initial
estimate of the nuisance parameters.
B1.1. Guess ρkk′0 (k
′
> k) and σ2k0 .
B1.2. Determine α and target power = 1 - β.
B1.3. Calculate the boundary c as in Eq. (1.15).
B1.4. Calculate the initial sample size N0 as illustrated in more details in Subsection 3.1.4.
B1.5. Fix the fraction of the initial sample size π to be used in step 2.
B1.6. Pre-define the weight wj (j= 1,2) in advance satisfying Eq. (2.20).
3.2.4.2 Step 2 - Sample size re-estimation
In this step, the interim data are used to re-estimated the nuisance parameters guessed at
the design stage and determine the sample size for the remainder of the study. In this step,
we also compute p-values, pk1 and pk2, from the t-distribution.
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B2.1. Simulate n1 = πN0 observations.
B2.2. Estimate σ2k1 using blinded method as in Eq. (2.10), based on n1 observations.
B2.3. Use σ2k1 to calculate t-test Tk1 for endpoint k.
B2.4. Calculate degrees of freedom df1 as in Eq. (1.27), based on n1 observations.
B2.5. Use Tk1 and df1 to calculate p-value pk1 as defined in Eq. (1.26).
B2.6. Estimate ρkk′1 as in Eq. (1.9), based on n1 observations.
B2.7. Use α and power defined in step (B1.2), c defined in step (B1.3), σ2k1 and ρkk′1 defined
in steps (B2.2) and (B2.6) respectively to re-calculate sample size N as illustrated in
Subsection 3.1.4.
B2.8. Collect a further n2 = N − n1 observations using a restricted design as described in
Eq. (2.7).
B2.9. Estimate σ2k2 using blinded method as in Eq. (2.10), based on n2 observations.
B2.10. Use σ2k2 to calculate t-test Tk2 for endpoint k.
B2.11. Calculate degrees of freedom df2 as in Eq. (1.27), based on new n2 observations.
B2.12. Use Tk2 and df2 to calculate p-value pk2 as defined in Eq. (1.26).
3.2.4.3 Step 3 - Final analysis
At the final analysis, the evidence from stage 1 and stage 2 are combined via the weighted
inverse normal function Bk of the observed pk1 and pk2. The hypothesis test is conducted
using test statistic Bk.
B2.1. Combine pk1 and pk2 by the weighted inverse normal function Bk
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B2.2. Reject at lest one H0k at level α if Bk ≥ c.
3.2.5 Worked example of the method
In this subsection, the same example as in Subsection 3.1.6 is considered. Suppose that E
and C are two treatments to be compared in a randomised (phase III) parallel group clinical
trial. Two co-primary endpoints are considered, i.e. K = 2. Patients are randomised in
equal numbers between E and C, and a normal distributed response is observed for each
of the endpoints. Suppose the parameters of interest representing the mean differences are
θ1 = θ2 = 0.5.
In step 1 (see Subsection 3.2.4.1 and Figure 3.1), we suppose (or guess) that the
variance for endpoint 1 is σ10 = 1.5, the variance for endpoint 2 is σ20 = 1 and the
correlation between endpoints is ρ120 = 0.5. A SSR inverse normal combination test with
multiple co-primary endpoints is required to test H0k : θk = 0, k = 1,2, with a one-sided
test type I error rate of α = 0.025 and a power of 1 - β = 0.80 for θ = 0.5. We use step
(B1.3) to calculate the critical value or boundary at level α/K. We then use step (B1.4) to
estimate the initial sample size N0. We finally fix the fraction of the initial sample size π =
0.5 as in step (B1.5) and the weight wj (j= 1,2) =
√
0.5 as in step (B1.6).
In step 2, we simulate the interim data n1 = πN0 as illustrated in step (B2.1).
Based on n1 observations, the nuisance parameter σ2k1 is re-estimated as in steps (B2.2),
the t-statistic Tk1 for endpoint k is calculated as in step (B2.3), the degrees of freedom
df1 is calculated as in step (B2.4) and p-value pk1 is calculated as in step (B2.5). The
correlation ρkk′1 is also re-estimated based on n1 observations as in step (B1.6). The initial
sample size N0 is re-calculated by replacing the values of σ2k1 , ρ121 and c in the mean
vector, the variance-covariance matrix and the upper limit matrix as illustrated in more
detail in Subsection 3.1.6 and step (B2.7). This gives N . We continue by collecting a
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Table 3.4: Scenarios considered in the simulation study.
Variable values SSR inverse normal combination test
Scenario 6 Different weights
Alternative hypothesis θk = δk δ1 = δ2 = 0.5
Proportion pi in SSR 0.50
True nuisance parameters
ρ12 0,0.1,...,1
σ21 1,1.1,1.2,...,2
Setting 3
σ22 1.5
Weight for stage 1 0.1
Weight for stage 2 0.9
further n2 = N − n1 observations as in step (B2.8). Based on n2 observations, σ2k2 is
estimated as in step (B2.9), t-statistic Tk1 is calculated as in step (B2.10), the degrees of
freedom df2 is calculated as in step (B2.11) and p-value pk2 is calculated as in step (B2.12).
In step 3, we combine pk1 and pk2 by the weighted normal function Bk as in step
(B3.1) and perform hypothesis testing by rejecting H01 or H02 at level α if B1 ≥ c or
B2 ≥ c as in step (B2.2).
3.2.6 Simulation results
This subsection presents simulation results of the SSR inverse normal combination test
method. On top of the scenarios considered in the Table 3.2, scenario 6 have been added to
check the impact of different weights on FWER, sample size and power. This can be seen
in Table 3.4.
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3.2.6.1 FWER, power and sample size in the SSR inverse normal combination test
design
The aim of this subsection is to check whether the FWER would be maintained and the
power controlled if the nuisance parameters change as in the following settings:
3.2.6.1.1 Scenario 2 : FWER in Settings 1 - 5
Figure 3.11 presents FWER’s simulation results with the fixed and variable values
defined in Table 3.2 and Table 3.3 respectively. On top of that, an equal weight of 0.5 has
been considered for stage 1 and stage 2 data. The figure shows that this method effectively
controls the overall FWER at the nominal 0.025 level despite variation of ρ12 and σ21 in
all five settings. In setting 1, the FWER has a minimum value of 0.01036 for perfectly
correlated data i.e. ρ12 = 1 and a maximum value of 0.02194 for uncorrelated data, i.e.
ρ12 = 0. In setting 2, a minimum value of 0.01079 for ρ12 = 1 and a maximum value of
0.02292 for ρ12 = 0 have been observed. In setting 3, the FWER has a minimum value of
0.01046 for ρ12 = 1 and a maximum value of 0.02416 for ρ12 = 0. In setting 4, a minimum
value of 0.01091 for ρ12 = 1 and a maximum value of 0.02378 for ρ12 = 0 have been
observed. Finally, in setting 5, the FWER has a minimum value of 0.01066 for ρ12 = 1 and
a maximum value of 0.02388 for ρ12 = 0.
3.2.6.1.2 Scenario 2 : Sample size in Settings 1 - 5
Figure 3.12 presents sample size simulation results with the fixed and variable val-
ues defined in Table 3.2 and Table 3.3 respectively. The results are presented in all five
settings of scenario 2. The figure shows that the sample size increases as ρ12, σ21 and σ22
increase. This is what we would expect. This also shows that the method is working.
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Figure 3.11: SSR Combination test FWER in Scenario 2; Settings 1 - 5
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Figure 3.12: SSR Combination test Sample size in Scenario 2; Settings 1 - 5
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3.2.6.1.3 Scenario 2 : Power in Settings 1 - 5
Figure 3.13 presents simulation results for the power with the fixed and variable
values defined in Table 3.2 and Table 3.3 respectively. The results are presented in all
five settings of scenario 2. The figure illustrates that the method does not maintain the
power. The figure shows that the power starts by increasing in setting 1, becomes constant
in setting 2, then starts decreasing in settings 3 - 5 when ρ12, σ21 and σ22 increase. This is
because of inefficient weighting if SSR occurs.
3.2.6.1.4 Scenario 3: Constant ρ12
The results in Scenario 3 are presented in Figure 3.14. It illustrates that despite
variation of σ21 and σ22 , the FWER is controlled and fairly constant with a minimum value
of 0.01918 and a maximum value of 0.02260. The same figure illustrates that the sample
size increases in the same direction as σ21 and σ22 with the minimum value 58 and the
maximum value 220. Finally the figure illustrates that the power decreases when σ21 and σ22
increase with a minimum value of 0.7230 and a maximum value of 0.7810.
3.2.6.1.5 Scenarios 2 and 3: Summary and comments on the results
The results in Scenario 2 show that the FWER is controlled, however they show
that the FWER becomes increasingly conservative as ρ12 increases. The results also show
that the FWER is controlled and fairly constant when ρ12 is constant (Scenario 3). This is
not surprising as it has been shown that the combination test method maintains the type I
error rate for any possibly data-driven choice of sample sizes as illustrated in more detail
in Subsection 2.2.4.2.
The results in Scenarios 2 and 3 also show that the sample size is increasing in the
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Figure 3.13: SSR Combination test Power in Scenario 2; Settings 1 - 5
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Figure 3.14: SSR Combination test FWER, Sample size and Power in Scenario 3
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same direction as ρ12, σ21 and σ22 , however, the power is not maintained despite the fact that
this method is adjusting for the sample size needed to maintain the power at least up to the
nominal level. The reason for this is that the method use pre-defined weights which are not
based on observed sample size but on weights fixed in advance. The paper by Bank et al.
(1996) has shown this.
3.2.6.2 Scenario 4: Difference effect sizes
3.2.6.2.1 Scenario 4: δ1 = 0.5, δ2 = 0.7
Figure 3.15 presents simulation results with the fixed and variable values defined in
Table 3.2 and Table 3.3 respectively; and a weight of 0.5 for stage 1 and stage 2 data. The
situation of δ1 = 0.5, δ2 = 0.7 is considered. The figure shows that the FWER is controlled
despite variation of ρ12 and σ21 with the minimum value 0.01024 for perfect correlated data
and 0.02151 for uncorrelated data. The same figure shows that the sample size increases
as ρ12 and σ21 increase with a minimum value of 51 and maximum value of 94. Finally the
figure shows that the power is not maintained but fairly constant when ρ12 and σ21 increase
with a minimum value of 0.7270 and a maximum value of 0.7490.
3.2.6.2.2 Scenario 4: δ1 = 0.7, δ2 = 0.5
Figure 3.16 presents the situation where δ1 = 0.7 and δ2 = 0.5 are considered. The
figure shows that the FWER is controlled despite variation of ρ12 and σ21 with the minimum
value 0.00788 for ρ12 = 1 and 0.02318 for ρ12 = 0 . The same figure shows that the sample
size increases as ρ12 and σ21 increase with a minimum value of 39 and maximum value of
160. Finally the figure shows that the power is not maintained. It starts by increasing up
to the peak for the value of σ21 = 1.2 then decreases afterwards with a minimum value of
0.6734 and a maximum value of 0.7784.
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Figure 3.15: SSR Combination test FWER, Sample size and Power in Scenario 4 (δ1 =
0.5, δ2 = 0.7)
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Figure 3.16: SSR Combination test FWER, Sample size and Power in Scenario 4 (δ1 =
0.7, δ2 = 0.5)
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3.2.6.2.3 Scenario 4: Summary and comments on the results
In scenario 4 the results show that the FWER is controlled but conservative as ρ12
increases.
The results in scenario 4 also show that sample sizes are increasing in the same
direction as ρ12 and σ21 , with setting (0.7,0.5) giving a larger sample size than the set-
ting (0.5,0.7). However, the power in both settings is not maintained due to the use of
pre-defined weights fixed before the trial begins and for the same reasons described in
Subsection 3.1.7.3.3.
3.2.6.3 Scenario 5: Different timings
3.2.6.3.1 Scenario 5: π = 0.10
Figure 3.17 presents the simulation results for a situation where the time of interim
evaluation happens when 10% of the data have been collected .i.e, π = 0.10. An equal
weight of 0.5 for the two stages is also considered. The figure shows that this method
effectively controls the overall FWER at the nominal 0.025 level despite variation of ρ12
and σ21 with the minimum value 0.00932 for perfectly correlated data and the maximum
value 0.01828 for uncorrelated data. The same figure also shows that the sample size
increases as ρ12 and σ21 increase with a minimum value of 61 and maximum value of 176.
Finally the figure shows that the method does not maintain the power although this is fairly
constant despite variation of ρ12 and σ21 with a minimum value of 0.5850 and maximum
value of 0.6406.
3.2.6.3.2 Scenario 5: π = 0.80
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Figure 3.17: SSR Combination test FWER, Sample size and Power in Scenario 5 (π = 0.1)
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Figure 3.18: SSR Combination test FWER, Sample size and Power in Scenario 5 (π = 0.8)
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In Figure 3.18, a situation where the time of interim evaluation happens is set to
π = 0.80 and an equal weight of 0.5 for the two stages is also considered. The figure
shows that this method effectively controls the overall FWER at the nominal 0.025 level
despite variation of ρ12 and σ21 with the minimum value 0.01021 for ρ12 = 1 and the
maximum value 0.02300 for ρ12 = 0. The same figure also shows that the sample size
increases as ρ12 and σ21 increase with a minimum value of 64 and maximum value of 177.
Finally the figure shows that the method does not maintain the power for the combination
of ρ12 = (0, 0.1, ..., 1) and σ21 = 1 but does maintain it for the remaining of the combination
of ρ12 and σ21 with a minimum value of 0.6063 and a maximum value of 0.7894.
3.2.6.3.3 Scenario 5: Summary and comments on the results
The results in Scenario 5 show that the FWER is controlled but becomes increas-
ingly conservative as ρ12 increases. The timing of the interim evaluation has no impact on
the FWER.
The same results show that sample sizes are increasing in the same direction as ρ12
and σ21 . However Figure 3.17 shows that the power is not maintained, while Figure 3.18
indicates that it is not maintained only for the value of σ21 = 1 and maintained for any
other values. Although we would expect this method not to maintain the power because it
uses pre-defined weights which are not based on observed sample size but on weights fixed
in advance, the results in Figure 3.18 shows that by changing the timing of the interim
intervention, this method maintains the power even if it uses pre-defined weights fixed in
advance.
3.2.6.4 Scenario 6: Different weights
We have further simulations to check the effect of unequal weights on FWER, sample
size and power. Figure 3.19 presents simulation results with the fixed and variable values
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Figure 3.19: SSR Combination test FWER, Sample size and Power in Scenario 6
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defined in Table 3.2 and Table 3.4 respectively; and a weight of 0.1 for stage 1 data and
0.9 for stage 2 data. The figure shows that despite variation of ρ12 and σ21; and unequal
weights allocation, the FWER is controlled with a minimum value of 0.01027 for ρ12 = 1
and a maximum value of 0.02408 for ρ12 = 0. The same figure shows that the sample size
increases in the same direction as ρ12 and σ21 with the minimum value 64 and the maximum
value 178. Finally the figure illustrates that the power is not maintained but increases when
ρ12 and σ21 increase with a minimum value of 0.639 and a maximum value of 0.779.
3.2.6.4.1 Scenario 6: Summary and comments on the results
The results in this scenario (see Figure 3.19) are compared to the ones in scenario
2, setting 3. The results in both settings show that the FWER is controlled but becomes
increasingly conservative as ρ12 increases. Equal or unequal allocation of the pre-defined
weights have no impact on the FWER.
The same results show that sample sizes are increasing in the same direction as
ρ12 and σ21 . However Figure 3.13, setting 3 shows that the power is not maintained and
this decreases when ρ12, σ21 and σ22 increase, while Figure 3.19 show that the power is
not maintained but increases when ρ12 and σ21 increase. The results in Figure 3.19 show
that changing the weights allocation has an impact on maintaining the power, however,
finding the optimal weights allocation is challenging because they are defined before the
trial begins.
3.3 Summary findings from the simulation results
This chapter presented the idea of sample size reestimation in the context of multiple co-
primary endpoints. In Section 3.1, we presented a sample size reestimation approach for
this setting and in Section 3.2 we described the inverse normal combination tests method
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with multiple co-primary endpoints with sample size reestimation. Simulation results have
been presented in Sections 3.1.7 and 3.2.6 respectively. This section summarize key find-
ings from these results.
In Section 3.1.7, we observed that the SSR with multiple co-primary endpoints
method controls the FWER; and this is true for all the scenarios considered. For exam-
ple, in Scenario 2 we noticed no evidence of an inflation of the FWER for all the settings
studied. We noticed similar results in Scenarios 3,4 and 5. These results are comparable
to the results obtained by Friede and Schmidli (2010). We also observed that, although the
FWER was controlled in Scenarios 2,4 and 5, it (FWER) became increasingly conserva-
tive as ρ12 increased. These results are similar to the findings obtained by Senn and Bretz
(2007). Therefore we concluded that for the settings considered here, the SSR procedure
controls the FWER.
In Section 3.1.7, we also observed that the sample size was increasing in the same
direction as ρ12, σ21 and σ22 .
In Section 3.1.7, we finally observed that in most scenarios, the method maintains
the power. However, we observed that if strange revision rules are used, the power could
not be maintained. For example, we noticed in Scenario 4 that the SSR method does not
maintain the power when different effect sizes are used simultaneously. The key findings
for this scenario were that the magnitude of the sample size for the SSR method was driven
by the big effect size; and this (sample size) was not large enough to detect two different
effect sizes at the same time, hence reduction in power. We recommended to use the small
effect size for sample size calculation which is a guarantee that the sample size obtained
would be large enough to detect even the large effect size and maintain the power. We also
noticed that in Scenario 5 - Figure 3.9, the interim evaluation of the nuisance parameters
was performed when 10% of the observations were in the internal pilot. This led to inac-
137
curate estimation of the nuisance parameters, with the consequence that the power was not
maintained. This finding was investigated by Friede and Schmidli (2010) who explained
that the timing of the interim evaluation in clinical trials is not only important for logistic
motivations but also affects the operational characteristics of the recalculation procedure.
An early interim review cannot give a good estimate of the nuisance parameters, while a
very late sample size review may lead to a larger sample size than needed. The finding
was also investigated by Gould (1992), who stipulated that as the sample size at the interim
review is decreasing, the likelihood of inadequate or unnecessarily large final samples sizes
is increased. As was seen in Scenario 5, although a similar sample size in both settings,
Figure 3.9 gave a variable sample size, which depends on variable and unprecise nuisance
parameters, so it was less powerful than the one in Figure 3.10 which gave a precise sample
size based on precise nuisance parameters, hence powerful.
In Section 3.2.6, we observed that the SSR inverse normal combination test method
controls the FWER; and this is true for all the scenarios considered. Although we have
shows this by simulations, the papers by Bauer (1989), Lehmacher and Wassmer (1999)
and Proschan (2009b) have proven analytically that the combination test method controls
the type I error rate for any possibly data-driven choice of sample sizes.
In Section 3.2.6, we also observed that the sample size was increasing in the same
direction as ρ12, σ21 and σ22 . In Section 3.2.6, we finally observed that the although the
method controls the FWER, there is a cost, which is a loss of power, because the weights
of the combination test are not based on the observed sample size but on weights fixed in
advance. The papers by Lehmacher and Wassmer (1999), Proschan (2009b) and Bank et al.
(1996) have shown this. We have noticed that although we would expect this method not
to maintain the power for the reasons explained earlier, simulation results in Figure 3.18
showed that by changing the timing of the interim intervention, this method maintained the
power even if it uses pre-defined weights fixed in advance. We finally noticed in Scenario
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6 that changing the weights allocation had an impact on maintaining the power, however,
finding the optimal weights allocation is challenging because they (weights) are defined
before the trial begins.
As a conclusion, we showed that the results presented in this chapter clearly indi-
cated that the FWER for both methods was controlled, regardless of the scenarios used.
However, the results showed that in most scenarios considered, the SSR method was more
powerful compared to the SSR inverse normal combination test method. In the next chapter,
we are going to present how the group sequential method with a single endpoint described
in Section 2.3 can be extended to the setting of multiple co-primary endpoints.
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Chapter 4
Group Sequential Designs with Multiple
Co-primary Endpoints
This chapter describes how the group sequential method with a single endpoint described
in Section 2.3 can be extended to the setting of multiple co-primary endpoints. In other
words, this chapter shows how a sequential clinical trial can be conducted in the presence
of multiple co-primary endpoints. In this thesis we propose one way of doing this, which
is to conduct K different group sequential tests, each for one endpoint and each adjusted
at level α/K, while monitoring the information. The information is adjusted to allow for
ρkk′ and σ2k to be estimated at each stage (i.e. we know that at the beginning of the trial
the endpoints are correlated with unknown ρkk′ and σ2k). After an introduction in Section
4.1, Section 4.2 describes GSD methodology for multiple endpoints, where the problem
defined in Subsection 1.4.2 is considered. Section 4.3 presents the implementation of the
method followed a summary in Section 4.4. Section 4.5 presents a worked example and
Section 4.6 simulation results.
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4.1 Introduction
In numerous phase III clinical trials, it is appropriate to distinctly assess the treatment
effect on two or more primary endpoints. Kosorok et al. (2004) quoted an example of
the MERIT-HF study, where two endpoints of primary interest were time to death and the
earliest of time to first hospitalisation or death (on Behalf of the MERIT-HF Study Group
(1997)). It is possible that treatment has no effect on death but a beneficial effect on first
hospitalisation time, or it has a detrimental effect on death but no effect on hospitalization.
A good clinical trial should permit early stopping as soon as the treatment effect on either
endpoint becomes clear.
Depending on the nature of the endpoints, there are two statistical methods for mul-
tiple outcomes in group sequential clinical trials: (i) global methods that attempt to combine
several endpoints into a single endpoint or statistical test; and (ii) multiple hypothesis meth-
ods that allow the assessment of differential treatment effects in two or more outcomes.
4.1.1 Global methods
If a similar aspect of treatment performance is measured by several endpoints, then demon-
strating efficacy in a collective way across the endpoints would be acceptable and global
method could be used. Examples and applications of this procedure include O’Brien
(1984), Wei and Lachin (1984), Pocock, Geller and Tsiatis (1987), Tang,Gnecco and Geller
(1989), Lin (1991), and Block, Lai, and Tubert-Bitter (2001). O’Brien (1984) describes a
randomised clinical trial of two therapies for the treatment of diabetes patients in which
improvements in nerve function were measured on 34 electromyographic variables com-
bined as a single variable. Pocock, Geller and Tsiatis (1987) consider a crossover trial of
chronic respiratory disease in which the active drug and placebo were compared with re-
spect to three lung function measurements: (peak expiratory flow rate, forced expiratory
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volume and forced vital capacity). This is a case where the outcome variables might be re-
garded as unordered since one does not take priority over another. Another example is the
standard approach to multivariate outcomes in clinical trials developed by Pocock (1997)
which includes the method of constructing a single composite endpoint from two or more
outcomes.
4.1.2 Multiple hypothesis methods
With some endpoints, it is not clinically meaningful to combine the endpoints into a single
measure; in this case, multiple hypothesis methods would be appropriate (Kosorok et al.
(2004)). Stallard and Todd (2010) give an example of Alzheimer’s disease where the need
to demonstrate efficacy for two outcomes to gain licensing requires the consideration of
both mental and physical aspects of a patient’s progress. They also give an example of
a simultaneous monitoring of efficacy and safety responses where the endpoints are kept
separate and the correlation between them are accounted for in the design and analysis of
any sequential trial.
Some other examples and applications include Jennison and Turnbull (1993), who
proposed group sequential tests for bivariate response. Their tests are defined in terms of
the two response components jointly, rather than through a single summary statistic. Such
methods are appropriate when the two responses concern different aspects of a treatment;
for example, one might wish to show that a new treatment is both as effective and safe as
the current standard. They present a formulation of the bivariate testing problem, introduce
group sequential tests that satisfy type I error conditions and show how to find the sample
size ensuring a specified power. Jennison and Turnbull’s (1993) approach is similar to what
we are proposing as they consider the case of two primary endpoints, which are efficacy
and safety outcomes. However, in terms of the types of analysis, Jennison and Turnbull’s
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(1993) method is different in the way that our method allows early stopping as soon as the
treatment effect on either endpoint becomes clear, while theirs permit early stopping as
soon as the treatment effect on both endpoints becomes obvious.
Cook and Farewell (1994) propose methodological guidelines for the sequential as-
sessment of experimental therapies formally based on both efficacy and toxicity responses.
It is based on a modified univariate sequential procedure (e.g., Lan and DeMets (1983)) ac-
counting for bivariate correlated responses. It differs from Jennison and Turnbull’s (1993)
approach in that it is a rejective test and does not involve specification of an indifference
region in the efficacy-toxicity parameter space. In terms of types of multiple endpoints,
both methods are similar to what we are proposing as they consider the case of two pri-
mary endpoints, which are efficacy and safety outcomes for Jennison and Turnbull (1993)
and efficacy and toxicity endpoints for Cook and Farewell (1994). However, in terms of the
types of analysis, both methods are different to what we are proposing in the way that our
method allows early stopping as soon as the treatment effect on either endpoint becomes
clear, while theirs permit early stopping as soon as the treatment effect on both endpoints
becomes obvious.
Glimm et al. (2010) propose a method of testing hierarchically a (key) secondary
endpoint in a group-sequential clinical trial that is mainly driven by a primary endpoint.
By mainly driven, they mean that the interim analyses are planned at points in time where
a certain number of patients or events have accrued on the primary endpoint, and the trial
will run either until statistical significance of the primary endpoint is achieved at one of the
interim analyses or to the final analysis. They also consider the situation where the trial is
stopped as soon as the primary endpoint is significant, as well as the situation where it is
continued beyond primary endpoint significance to further investigate the secondary end-
point. In addition, they investigate how to achieve strong control of the familywise error
rate (FWER) at a pre-specified significance level α for both primary and secondary hy-
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potheses. A similar problem is proposed by Tamhane et al. (2010), who suggest a method
of testing hierarchically a primary and secondary endpoint in clinical trial where the sec-
ondary endpoint is tested only if the primary endpoint is significant. The trial uses a group
sequential procedure with two stages. Glimm et al. (2010) address the same problem and
reach similar conclusions, but do not give explicit analytical results concerning the FWER
and the primary and secondary critical boundaries as the setting in Tamhane et al. (2010).
These two methods are completely independent and complementary to each other. In terms
of types of endpoint and types of analysis, both examples are different to what we are
proposing such that their outcome variables might be regarded as ordered as one does take
priority over the other, while our outcomes are considered as equal.
Other multiple hypothesis approaches include Todd (1987) and Conaway and Petroni
(1995). The application to survival data was developed by Cook (1994) and Williams
(1996). Tang and Geller (1999) proposed a closed testing procedure for multiple compar-
isons that allows the evaluation of significance of each endpoint individually. More recent
works are presented by Tamhane et al. (2012a) and Tamhane et al. (2012b).
4.2 Group Sequential Designs with multiple co-primary
endpoints
As explained in the introduction, the aim of this thesis is to answer two questions: First,
how to adjust a sample size in a clinical trial with multiple continuous primary endpoints
using adaptive and group sequential designs. Second, how to construct a test in such a way
to control the FWER and maintain the power, even if the correlation ρ between endpoints is
not known. The following method is proposed to resolve this: K different group sequential
tests are conducted, each for one endpoint and each at level α/K, and they are conducted to
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monitor the information and also where the information is adjusted to allow for estimation
of correlation ρ at each stage.
In the following section, we start by formulating a multivariate testing problem,
followed by the construction of group sequential tests that satisfy FWER conditions, then
show how to find the sample size that guarantees a specified power.
4.2.1 Definition of the problems
In this Section, we consider methodology for situations where there are K co-primary corre-
lated endpoints in a clinical trial. The general setting for this problem is defined in Section
3.5. Suppose that E and C are two treatments to be compared in a randomised (phase III)
clinical trial with parallel groups. After each group of 2n subjects has been randomised in
equal numbers to the two therapies and the response obtained, the nuisance parameters ρkk′
and σ2k are re-estimated, the sample size re-estimated, the boundaries adjusted based on
the re-estimated sample size and the accumulated data tested. The trial’s primary objective
is to determine whether E is more efficacious than C in terms of K continuous responses.
This procedure is conducted at a sequence of up to J interim analyses, each involving a
comparison of the evidence for efficacy of E and C, with stopping occurring as soon as one
of the interim analyses is in some sense sufficiently convincing.
4.2.2 Test statistics
Suppose that we are interested in repeated looks at the accumulating data on the co-primary
endpoints with repeated hypothesis testing. At each interim analysis we will base inference
on some calculated test statistics. We need to think about these test statistics and their
distributions.
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In Subsection 2.3.2.2, assumptions underlying many group sequential methods are pre-
sented in Eq. (2.38). In this subsection, we define test statistics for the setting of K end-
points and J stages, derive distributions and show how this relates to the canonical form.
We use the standardized statistic defined in Eq. (3.1) and the information for θ defined in
Eq. (3.2) to construct our test statistics, and we assume σ2k is known. Let Zkj , k = 1,..,K
and j = 1,...,J now denote the standardised statistic for θk and endpoint k based on the data
available at interim analysis j, which we write as:
Zkj =
1√
(2njσ2k)
(
nj∑
i
XijkE −
nj∑
i
XijkC)
∼ N((θkE − θkC)
√
{nj/(2σ2k)}, 1) (4.1)
under H0k, Zkj is normally distributed with mean 0 and variance 1, i.e., Zkj ∼
N(0, 1).
Let Ij now denote the information for θk based on the data available at interim
analysis j, that is:
Ij =
nj
2σ2k
(4.2)
Suppose the correlation between test statistics is:
Cov(Zkj, Zk′j) = ρkk′ , k
′
> k (4.3)
and:
Cov(Zkj, Zk′j′ ) = ρkk′
√
Ij
Ij′
, k
′
> k, j
′
> j. (4.4)
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As for Eq. (2.38), Z11, . . . , ZK1, . . . , Z1J , . . . , ZKJ has a multivariate normal distribution,
at least asymptotically:
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(4.5)
In the case of K = 2 and J = 3, Eq. (4.5) can be expressed as:
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(4.6)
Replacing Eq. (4.2) into equation Eq. (4.5) and Eq. (4.6) respectively, we have:
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4.2.3 Stopping boundaries
In the introduction we explained that the aim of this thesis was to construct a test in such
a way as to maintain the family-wise type I error rate and the power in the context of K
hypotheses. We have constructed the distribution of the tests in Eq. (4.5), now we need to
show that the test controls the FWER in the strong sense and maintains the power. First,
we consider the FWER. It is defined through the critical values {c1, ..cJ} described in Eq.
(2.45), calculated when {Z1, ..., ZJ} follow the null distribution of Eq. (2.38), but with this
setting we do that with K multiple co-primary endpoints using the stopping rules defined
in Subsection 1.4.2, step (vi). So for one endpoint, in place of Eq. (2.45), we now define:
Pr(stop and reject H0 at or before stage j | θ = 0) =
Pr(Z1 < c1, . . . , Zj−1 < cj−1, Zj ≥ cj) = πj/K (4.9)
where πj/K now describes the error rate spending function. Here, the Bonferonni
correction is applied as illustrated in Subsection 1.3.3.1.1.
In the setting of K endpoints, in place of Eq. (4.9) we now have:
Pr(stop and reject at least one H0k at or before stage 1 | θk = 0) =
Pr(Z11 > c1 or Z21 > c1 or . . . or ZK1 > c1 | θ=0) ≤ π1
Pr(stop and reject at least one H0k at or before stage 2 | θk = 0) =
Pr(Z11 > c1 or Z21 > c1 or . . . or ZK1 > c1 | θ=0) +
Pr(Z11 < c1, Z21 < c1,. . . , ZK1 < c1 , Z12 > c2 or
Z22 > c2or . . . orZK2 > c2|θ = 0) ≤ π2
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Pr(stop and reject at least one H0k at or before stage j | θk = 0) =
Pr(Z11 > c1 or Z21 > c1 or . . . or ZK1 > c1 | θ=0) +
Pr(Z11 < c1, Z21 < c1, . . . , ZK1 < c1, Z12 > c2 or
Z22 > c2or . . . orZK2 > c2|θ = 0) + ... + Pr(Z11 < c1, Z21 < c1, Z12
< c2, Z22 < c2, . . . , ZK2 < c2, ..., Z1(j−1) < cj−1, Z2(j−1) < cj−1, . . . ,
ZK(j−1) < cj−1, Z1j > cj or Z2j > cj or . . . or ZKj > cj | θK = 0)
≤ πj (4.10)
πj represents the error spending function at stage j, j = 1,...,J. So, to control the
FWER, one must choose cj to satisfy Eq. (4.9) ( i.e, calculate cj using (4.9) and workout
πj).
Second, we consider the power. It is described as in Eq. (2.41), estimated when
{Z1, ..., Zj} follow the distribution in Eq. (2.38), but here we use K multiple co-primary
endpoints. So, in place of Eq. (2.41) the power is now given by:
Pr(stop and reject at least one H0k at or before stage j | θk = δk) =
P (Z11 > c1 or Z21 > c1 or . . . or ZK1 > c1 | θk = δk) +
P (Z11 < c1, Z21 < c1 ,. . . , ZK1 < c1, Z12 > c2 or
Z22 > c2or . . . orZK2 > c2|θk = δk) + ...+ P (Z11 < c1, Z21 <
c1, Z12 < c2, Z22 < c2, . . . , ZK2 > c2, ..., Z1(j−1) < cj−1, Z2(j−1) <
cj−1, . . . , ZK(j−1) < cj−1, Z1j > cj or Z2j > cj or ZK(j) > cj | θk = δk)
= 1− β (4.11)
where j = 1, ..., J . For given values of J, α, β and {c1, ..., cJ}, the maximum sample
150
size can be found that satisfies Eq. (4.11) when {Z11, . . . , ZKJ} follow the distribution in
Eq. (4.5). We use mvtnorm package in R to compute multivariate normal probabilities as
described in more details in 3.1.4.
4.3 Implementation of the method
This section illustrates how the problem defined in Subsection 4.2.1 can be implemented in
practice. The general idea is that when the interim data are collected, the planned sample
size is re-calculated based on the estimate of the nuisance parameters and the test statistic,
and the timings of the test are adjusted accordingly. Details are given in the following
subsections.
4.3.1 Before stage 1
At the design stage, we need to:
S0.1. Fix the maximum number of interim analyses J before the study commences.
S0.2. Determine spacing of analyses and
S0.3. Fix times of the interim analyses i.e., Tj0 = (t10 , t20 , ..., tj0), j = 1,...,J.
S0.4. Choose the overall significance level α and the target power.
S0.5. Specify the type of spending function to apply and use Eq. (2.46) to calculate πj (j =
1,...,J), the type I error probabilities for each stage.
S0.6. Guess ρkk′0 (k
′
> k) and σ2k0 .
S0.7. Calculate boundaries (see also Subsection 2.3.3): the program at Appendix C finds
the univariate boundaries for each stage. It is the modified version of the program
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developed by Proschan et al. (2006). For given values of the previous boundaries
c10 , ..., c(j−1)0 and time points t10 , ..., t(j−1)0 , the program finds the current boundary
cj0 that satisfies Eq. (4.9).
S0.8. Use Eq. (4.11) to calculate the maximum sample size Nmax0: the program at Ap-
pendix D will compute the initial maximum sample size. For given values of J, α/K,
β and cj0 , j = 1,...,J, the maximum sample size can be found by computing the multi-
variate normal probabilities of Eq. (3.9), that satisfies Eq. (4.11) when Zkj (k=1,...,K
and j = 1,...,J) follow Eq. (4.5) as illustrated in more details in Subsection 3.1.4.
However, the only difference is that the critical value c is replaced by cj .
4.3.2 Stage 1
At this stage, interim data for stage 1 I1, which is a fraction of Nmax0, is used to estimate
the correlation ρkk′1 and the variance σ
2
k1
, which are then used to re-estimate the new maxi-
mum sample size Nmax1 or maximum information INmax1 . The new sample size Nmax1
is used to calculate the information fraction t1 at stage 1. t1 is used to calculate the type
I error π1 allocated to stage 1. π1 is used to find the boundary c1 at stage 1. c1 is then
compared to the standardised test statistic Zk1, calculated based on interim data at stage 1,
to stop the trial or not. In short, the main point about this step is that based on a fraction of
the data at the design stage (before stage 1), we can re-estimate nuisance parameters ρkk′0
and σ2k0 and modify the same size for stage 1 and, at the same time, we can stop the trial or
not. The steps for this stage are illustrated in more detail below:
S1.1. Simulate interim data for stage 1, i.e. I1 = t10Nmax0 observations.
S1.2. Use t10Nmax0 observations to estimate ρkk′1 as in Eq. (1.9).
S1.3. Estimate σ2k1 using the blinded method in Eq. (2.10).
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S1.4. Use boundaries calculated at the design stage (before stage 1) to estimate the maxi-
mum sample size Nmax1 as in step (S0.8).
S1.5. Calculate information fraction at stage 1 : t1 = I1INmax1 =
t10Nmax0
Nmax1
.
S1.6. Use Eq. (2.46) to calculate the type I error π1 allocated to stage 1, i.e. π1 = f(t1).
S1.7. Use Eq. (2.50) to find boundary c11 at stage 1.
S1.8. Use Eq. (4.1) to calculate standardised test statistic Zk1.
S1.9. Accept or reject H0k using the program at appendix E.
S1.10. if Z11 > c11 or...or Zk1 > c11 , reject H0k and stop the trial.
S1.11. Otherwise, go to stage 2
Before stage 2 begins, some adjustments need to be done to information fractions.
At stage 1, we realise that the maximum sample size calculated before stage 1 Nmax0
has changed to Nmax1. This is because we have used the estimated correlation ρ̂kk′1 and
the estimated variance σ̂2k1 instead of ρkk′0 and σ
2
k0
. That is why we need to modify the
information time to reflect this change, that is Tj1 = (
t10Nmax0
Nmax1
,
t20Nmax1
Nmax1
, ...,
tJ0Nmax1
Nmax1
).
4.3.3 Stage 2
For stage 2, we need to estimate nuisance parameters based on stage 2 data and, at the
same time, we need to re-estimate the maximum sample size. The new maximum sample
size Nmax2 will be different that Nmax1, because we now are going to use the estimated
correlation ρ̂kk′2 and the estimated variance σ̂
2
k2
instead of ρ̂kk′1 and σ̂
2
k1
. This change will
imply that the boundary at stage 1 c11 would need to be changed to reflect the change in
maximum sample size from Nmax1 to Nmax2. However, we cannot to go back to stage 1
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and change c11 based on the new maximum sample size Nmax2, because we have already
used it. We now need to construct stage 2 boundary c22 , allowing for the fact that we have
already used the first boundary c11 at a different time. That is why it is important to modify
the information time to reflect this change before stage 2 begins. The steps for stage 2 are
as follow:
S2.1. Simulate interim data for stage 2, i.e. I22 = t20Nmax1 observations.
S2.2. Use t20Nmax1 observations to estimate ρkk′2 as in Eq. (1.9).
S2.3. Estimate σ2k2 using the blinded method in Eq. (2.10) based on t20Nmax1 observa-
tions.
S2.4. Calculate boundaries based on the time of the interim analysis Tj1 as in step (S0.7).
S2.5. Estimate the maximum sample size Nmax2 as in step (S0.8).
S2.6. Calculate information fraction at stage 2: t2 = I2INmax2 =
t20Nmax1
Nmax2
.
S2.7. Use Eq. (2.46) to calculate the type I error π2 allocated to stage 2, i.e. π2 = f(t2).
S2.8. Use c11 calculated in step (S1.7) to find boundary c22 at stage 2 as illustrated in step
(S0.7) and Eq. (2.51).
S2.9. Use Eq. (4.1) to calculate standardised test statistic Zk2.
S2.10. Accept or reject H0 using the program at Appendix E.
S2.11. If Z12 > c22 or...or Zk2 > c22 , reject H0k and stop the trial.
S2.12. Otherwise, go to stage J.
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4.3.4 Stage J
Using the same rationale as in stage 2, we begin by making some adjustments on informa-
tion fractions T(j−1)j−1 = (
t10Nmax0
Nmaxj−1
,
t20Nmax1
Nmaxj−1
, ...,
tJ0Nmaxj−1
Nmaxj−1
). Now steps at stage J are:
SJ.1. Simulate interim data for stage J, i.e. IJ = tJ0Nmaxj−1 observations.
SJ.2. Use tJ0Nmaxj−1 observations to estimate ρkk′
J
as in Eq. (1.9).
SJ.3. Estimate σ2J using the blinded method in Eq. (2.10) based on tJ0Nmaxj−1 observa-
tions.
SJ.4. Calculate boundaries based on the time of the interim analysis T(j−1)j−1 as in step
(S0.7).
SJ.5. Estimate the maximum sample size NmaxJ as in step (S0.8).
SJ.6. Calculate information fraction at stage J: tJ = IJINmaxJ =
tJ0Nmaxj−1
NmaxJ
.
SJ.7. Use Eq. (2.46) to calculate the type I error πJ allocated to stage J, i.e. πJ = f(tJ).
SJ.8. Use c11 and c22 to find boundary cJJ at stage J as illustrated in step (S0.7) and Eq.
(2.51).
SJ.9. Use Eq. (4.1) to calculate standardised test statistic ZkJ .
Scenario 1: if tJ > 1:
SJ.10. Reject H0 and stop the trial if Z1J > cJJ or...or ZkJ > cJJ using the program at
Appendix E.
SJ.11. Otherwise, stop and accept H0.
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Scenario 2:
SJ.12. If tJ < 1, the type I error πJ is less than α, i.e. πJ < α. This implies that we still
have a proportion of α to spend, so we need to go to stage J + 1 if H0k is not rejected
at stage J, that is:
SJ.13. Reject H0 and stop the trial if Z1k > cJJ or . . . or ZkJ > cJJ using the program at
Appendix E.
SJ.14. Otherwise, go to stage J + 1.
4.3.5 Stage J + 1
This stage happens in Scenario 2 when H0k has not been rejected and tJ < 1. It gives us
the possibility to develop two options: either we proceed exactly as above by calculating
the information fraction tJ+1 and the type I error πJ+1 allocated to stage J + 1; or we force
the trial to stop by fixing the information fraction tJ+1 = 1 and πJ+1 = α. Steps at stage J
+ 1 follow the last option.
As in stage J, we begin by making some adjustments to information fractions T(J)J
= (
t10Nmax0
NmaxJ
,
t20Nmax1
NmaxJ
, ...,
tJ0Nmaxj−1
NmaxJ
).
S(J+1).1. Simulate data for stage J + 1, i.e. IJ+1 = tJ0NmaxJ observations.
S(J+1).2. Estimate ρkk′
J+1
as in Eq. (1.9) using tJ0NmaxJ observations.
S(J+1).3. Estimate σ2J+1 using the blinded method as in Eq. (2.10) and based on tJ0NmaxJ
observations.
S(J+1).4. Calculate boundaries based on T(J)J as in step (S0.7).
S(J+1).5. Estimate the maximum sample size NmaxJ+1 as in step (S0.8).
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S(J+1).6. The information fraction is set to tJ+1 = 1, which implies that the type I error πJ+1
allocated to stage J + 1 is equal to α i.e. πJ+1 = α/K.
S(J+1).7. Use Eq. (2.52) to find boundary c(J+1) at stage J + 1 as illustrated in step (S0.7).
S(J+1).8. Use Eq. (4.1) to calculate standardised test statistic Zk(J+1).
S(J+1).9. If Z1(J+1) > c(J+1) or . . . Zk(J+1) > c(J+1), reject H0 and stop the trial.
S(J+1).10. Otherwise, stop and accept H0.
4.4 Summary
We have illustrated how to implement a GSD with multiple co-primary endpoints. We
have shown that if the sample size calculated before the study begins is below or above the
actual estimated sample size, we can modify the actual information fraction and calculate
the actual boundary accordingly. If at the next stage we realise that the sample size has
changed again (is below or above the actual sample size), we can modify the next informa-
tion fraction and construct the next boundary allowing for the fact we have already used the
boundary at the previous stage. The proposed design allows the user to start with a GSD
with J stages and end up with a GSD with > J stages.
4.5 Example: Three-stage group sequential designs
Suppose that a clinical trial is to be designed to compare an experimental drug E with
a placebo control C. Two co-primary endpoints are considered, i.e. K = 2. Patients are
randomised in equal numbers between E and C, and a normal distributed response is ob-
served for each of the endpoints. Suppose the parameters of interest representing the mean
differences are θ1 = θ2 = 0.5.
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Table 4.1: GSD: Implementation of the method
Stages Values
Before stage 1
Significance level α 0.025 (one sided)
Power 1− β 0.8
Endpoints K = 2
Assume ρ120 0.5
Assume σ210 1.5
Assume σ220 1
Number of stages 3
Assume t10 , t20 , t30 13 ,
2
3
, 3
3
Calculate Nmax0 72
Stage 1
Simulate t10Nmax0 data 24
Estimate ρ121 0.53
Estimate σ211 1.30
Estimate σ221 0.94
Estimate Nmax1 240
Info. fraction. : t1 =
t10Nmax0
Nmax1
0.10
Calculate c1 with t1 3.78
Calculate Z11 and Z12 0.84 and 1.20
Conclude Z11 < c1 and Z12 < c1 Continue to stage 2
Stage 2
Simulate t20Nmax1 data 160
Estimate ρ122 0.49
Estimate σ212 1.46
Estimate σ222 0.89
Estimate Nmax2 220
Info. fraction : t2 =
t20Nmax1
Nmax2
0.72
Calculate c2 with t2 2.84
Calculate Z21 and Z22 0.85 and 1.60
Conclude Z21 < c2 and Z22 < c2 Continue to stage 3
Stage 3
Simulate t30Nmax2 data 220
Estimate ρ123 0.45
Estimate σ213 1.47
Estimate σ223 0.93
Estimate Nmax3 250
Info. fraction : t3 =
t30Nmax2
Nmax3
0.88
Calculate c3 with t3 2.40
Calculate Z31 and Z32 0.16 and 1.61
Conclude Z31 < c3 and Z32 < c3 Continue to stage 4
Stage 4
Simulate t30Nmax3 data 250
Estimate ρ124 0.48
Estimate σ214 1.48
Estimate σ224 0.95
Estimate Nmax4 230
Fix the info. fraction : t4 1
Calculate c4 with t4 2.33
Calculate Z41 and Z42 0.51 and 2.35
Conclude Z41 < c4 and Z42 > c4 Stop and accept H02
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At the design stage (see Subsection 4.3.1 and Figure 4.1), the values considered
are summarized in Table 4.1. We assume (or guess) that the variance for endpoint 1 is
σ210 = 1.5, the variance for endpoint 2 is σ
2
22
= 1 and the correlation between endpoints is
ρ120 = 0.5. A three-stage design (J = 3) is required to test H0k : θk = 0, k = 1,2, with a
one-sided test type I error rate of α = 0.025 and a power of 1 - β = 0.80 for θ = 0.5. We
consider the O’Brien and Fleming’s spending function as in Eq. (2.48), the time of interim
analyses at tj0 = (1/3, 2/3, 3/3), j = 1,2,3 and apply the Bonferroni correction. The first
boundary c10 is found by using the time t10 and its associated type I error rate π1, and also
the normal distribution function. For given c10 , t10 and the cumulative type I error rate to
spend at the current time t20 , the program in Appendix C finds c20 . For given c10 , t10 ,c20 ,
t20 and the cumulative type I error rate to spend by the current time t30 , the program in
appendix C finds c30 . The initial maximum sample size Nmax0 = 72 is then calculated as
described in more detail in step (S0.8).
At stage 1, the values simulated and estimated are summarized in Table 4.1. We
simulate stage 1 data as illustrated in step (S1.1). Based on the interim data at stage 1,
ρ̂121 , σ̂
2
k1
, k = 1,2 and Nmax1 are estimated following steps (S1.2) - (S1.4) as described
in Subsection 4.3.2. Suppose the maximum sample size is found to be Nmax1 = 240 as
in Figure 4.1. We then use step (S1.5) to calculate the information fraction t1 = 0.10 and
the corresponding type I error π1 as in step (S1.6) to find the boundary c11 at stage 1 as
described in step (S1.7). The boundary c11 = 3.78 is then compared to the standardised
test statistic Zk1 to accept or reject H0k as described in steps (S1.8) - (S1.11). Figure 4.1
and Table 4.1 show that H0k is not rejected, therefore we proceed to stage 2.
Before we start stage 2, we need to modify the information time to reflect the change
in the maximum sample size from Nmax0 = 72 to Nmax1 = 240 as explained at the end
of Subsection 4.3.2. This step gives T1 in Figure 4.1. The values simulated and estimated
at this stage are summarized in Table 4.1. We continue and simulate interim data at stage 2
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as in step (S2.1) and Figure 4.1. We then estimate ρ̂122 and σ̂2k2 , k = 1,2 as in steps (S2.2)
and (S2.3). We use step (S2.4) to calculate the boundaries based on the information time T1
as in Figure 4.1, we do it by using step (S0.7). The maximum sample size Nmax2 = 220 is
estimated as in step (S2.5). We calculate the information fraction t2 = 0.72 at stage 2 as in
step (S2.6), the type I error π2 allocated to stage 2 as in step (S2.7) and the corresponding
boundary c22 = 2.84 as in step (S2.8). We use steps (S2.9 - S2.11) to calculate standardised
test statistic Zk2 and do the test of the null hypotheses H0k. Figure 4.1 and Table 4.1 show
that H0k is not rejected, hence we go to stage J = 3, which is supposed to be the final stage.
At stage J = 3, we repeat the same process as in stage 2 to calculate the information
time to reflect the change in the maximum sample size from Nmax1 = 240 to Nmax2 =
220. This gives T2 in Figure 4.1. The values simulated and estimated at this stage are
summarized in Table 4.1. We continue and simulate interim data at stage 2 as in step (SJ.1)
and Figure 4.1. We then estimate ρ̂123 and σ̂2k3 , k = 1,2 using steps (SJ.2) and (SJ.3), and
calculate the boundaries and the corresponding maximum sample size Nmax3 = 250 as
described in steps (SJ.4), (SJ.5) and Figure 4.1. The information fraction t3 and the type I
error π3 allocated to stage J = 3 are then calculated using steps (SJ.6) and (SJ.7). We use
the same c11 , c22 calculated before to find c33 = 2.40 as in step (SJ.8) and use step (SJ.9) to
calculate the standardised test statistic Zk3. Figure 4.1 shows that H0k is not rejected. We
now need to proceed to the next stage, despite the fact that, at the design stage, the plan was
to conduct a three-stage group sequential design. The requirement to go to the next stage is
justified by the fact that the information fraction t3 = 0.88 is less than 1. This implies that
the type I error π3 allocated to stage 3 will be less than α/K. This situation is equivalent
to scenario 2 in Subsection 4.3.4.
At stage J + 1, i.e. J = 4, the values simulated and estimated are summarized in Table
4.1. We set the information fraction to 1 i.e. t4 = 1, so the type I error π4 allocated to stage
4 is equal to α, i.e. π4 = α. We repeat the same procedure as in stage 3 to calculate the
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information time to reflect the change in the maximum sample size from Nmax2 = 220
to Nmax3 = 250. This gives T3 in Figure 4.1. We then estimate ρ̂124 and σ̂2k4 , k = 1,2
using steps (S(J+1).2) and (S(J+1).3), and calculate the boundaries and the corresponding
maximum sample size Nmax4 = 230 as described in steps (S(J+1).4), (S(J+1).5), Figure
4.1 and Table 4.1. We use the same c11 , c22 and c33 calculated before to find c44 = 2.33
as in step (S(J+1).7) and use step (S(J+1).8) to calculate the standardised test statistic Zk4.
We then proceed as in step (S(J+1).9). If H0k is not rejected, we stop the trial as we do not
have any α to spend anymore; otherwise we stop and reject Hk0 as in Table 4.1.
The logic behind the implementation of the proposed group sequential method is
that we start by estimating σ̂21 using the usual variance estimate for endpoint 1. We do the
same for endpoint 2 and get σ̂22 and ρ̂. With all these estimates, we can estimate parameters
for stage 2 based on stage 1 data. However, the only thing we do not know is the maximum
sample size Nmax2 at stage 2. But now we can choose Nmax2 to give the required power
based on stage 1 estimates. That is why we assume constant variance throughout the stages.
For instance, if we want to go to stage 3, we now have two stages of data to use to estimate
σ2 and ρ, but actually we ignore the fact that they come from two stages. We then estimate
σ2 and ρ the same way using previous data. We then use Z test to assume that in large
sample t test can be accommodated to Z test.
Throughout this thesis, we assume that we are estimating the same θ as this may be
different for stage 1 and stage 2, but we assume they are the same. We also assume that σ2
is the same throughout the two stages. So the parameters we are estimating are the same,
but the estimate may be different, although we believe they are the same. That is why we
can use the Z test to compute the maximum sample size, because we believe they are the
same across stages.
The program in Appendix E is the group sequential method main program. It stim-
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Figure 4.1: Group Sequential Designs with multiple co-primary endpoints: Implementa-
tion of the method
ulates the data, calculates the boundary at each stage, estimates the maximum sample size
and performs test statistics to either stop the study or not. It uses the program at Appendix
D containing the power function defined in Eq. (3.9). It also uses the program at Appendix
C which calculates the boundary at each stage as defined in Eq. (2.52). The validation of
the main program was performed under different scenarios and the results indicated that
the program was working well. For example, we set up some simulations scenarios where
we knew in advance the expected results and obtained the anticipated outcomes. One typ-
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Table 4.2: Initial values considered in the simulation study.
Fixed parameters GSD
Significance level α 0.025 (one sided)
Standard error of estimate FWER 0.001
Target power 1− β 0.8
Standard error of estimate power 0.0025
Number of endpoints K = 2
Number of simulations 100,000
Number of looks = 3 1/3,2/3,3/3
Null hypothesis H0k θ1 = θ2 = 0
Guessed nuisance parameters
ρ120 0.5
σ210 1.5
σ220 1
ical trial took 26 to 36 hours to produce the results. The time depends on how the data are
correlated and the spending function used.
4.6 Simulation results
As for the two methods developed in Chapter 3, the GSD procedure with multiple endpoints
aims to maintain the desired power of the study without inflating the FWER above the
nominal level, even if the nuisance parameters ρkk′ and σ2k are not known at the planning
stage. In this section, we evaluate these characteristics by simulations. We also focused
on situations that are typical for phase III trials with two co-primary endpoints. Table
4.2 presents the fixed values considered in the simulation studies. In all the scenarios to
be described in Table 4.3 below, we conduct 100,000 simulated trials (standard error of
estimate FWER α = 0.025 is 0.001 and 0.0025 for the power 1-β = 0.80). We consider the
initial guess correlation ρ120 to be 0.5, the initial guess variance for endpoint 1 σ210 to be
1.5 and for endpoint 2 σ220 to be 1. We fix in advance the number of looks to 3 and equal
spaced i.e, 1/3,2/3,3/3. We aim to randomise patients in equal numbers between E and C.
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The scenarios considered in Table 4.3 have the following variable values: In sce-
nario 1, we consider five settings with the same parameters of interest representing the
mean difference to be (θ1 = θ2 = 0.5) and we use the O’Brien-Fleming spending function.
The five settings have the same values of ρ12 ranging from 0 to 1 .i.e. (0, 0.1,. . . , 1) and the
same values of true pooled variances for endpoint 1 σ21 ranging from 1 to 2 .i.e, (1, 1.2, . . . ,
2). However, each setting has the following true pooled variance for endpoint 2: setting 1,
σ22 = 1; setting 2, σ22 = 1.2; setting 3, σ22 = 1.5; setting 4, σ22 = 1.8; and setting 5, σ22 = 2.
In scenario 2, we consider ρ12 to be 0.5, pooled variance for endpoint 1 σ21 ranging
from 1 to 2 .i.e, (1, 1.2, . . . , 2), pooled variance for endpoint 2 σ22 ranging from 1 to 2 .i.e,
(1, 1.2, . . . , 2) and O’Brien-Fleming spending function.
In scenario 3, we consider the same true nuisance parameters as in Setting 3 with
different parameters of interest representing the mean difference to be (θ1 = 0.5, θ2 = 0.7)
and (θ1 = 0.5, θ2 = 0.7). We also consider the O’Brien-Fleming spending function.
In scenario 4, we consider the Hwang-Shi-DeCani spending function, with the same
true nuisance parameters and the same parameters of interest representing the mean differ-
ence as in Setting 3.
4.6.1 FWER, power and sample size in GSD with multiple co-primary
endpoints
This subsection aims to check the effect of the mis-specification of the nuisance parameters
on the FWER and power using the following settings:
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Table 4.3: Scenarios considered in the simulation study.
Variable values GSD
Scenario 1 Common values for all settings
Alternative hypothesis θk = δk δ1 = δ2 = 0.5
Type of spending function O’Brien - Fleming
True nuisance parameters
ρ12 0,0.1,...,1
σ21 1,1.1,1.2,...,2
Setting 1
σ22 1
Setting 2
σ22 1.2
Setting 3
σ22 1.5
Setting 4
σ22 1.8
Setting 5
σ22 2
Scenario 2 Constant ρ12
Alternative hypothesis θk = δk δ1 = δ2 = 0.5
Type of spending function O’Brien - Fleming
True nuisance parameters
ρ12 0.5
σ21 1,1.1,1.2,...,2
σ22 1,1.1,1.2,...,2
Scenario 3 Different effect sizes
Type of spending function O’Brien - Fleming
Alternative hypothesis δ1 = 0.5, δ2 = 0.7
Alternative hypothesis δ1 = 0.7, δ2 = 0.5
Same true nuisance parameters as in Setting 3
Scenario 4 Different type of spending function
Type of spending function Hwang-Shih-DeCani
Same alternative hypothesis as in Setting 3 δ1 = δ2 = 0.5
Same true nuisance parameters as in Setting 3
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4.6.1.1 Scenario 1 : Settings 1 - 5
4.6.1.1.1 Scenario 1 : FWER in Settings 1 - 5
Figure 4.2 presents GSD FWER simulation results with the fixed and variable values
defined in Table 4.2 and Table 4.3 respectively. It shows that the method effectively controls
the overall FWER at the nominal 0.025 level despite variation of ρ12, σ21 and σ22 . However,
we observe the inflation of the FWER in settings 1 2, 3, 4 and 5 for ρ12 = 0. In setting 1,
the FWER has a minimum value of 0.01267 for perfectly correlated data i.e. ρ12 = 1 and
a maximum value of 0.02687 for uncorrelated data, i.e. ρ12 = 0. In setting 2, a minimum
value of 0.01295 for ρ12 = 1 and a maximum value of 0.02699 for ρ12 = 0 have been
observed. In setting 3, the FWER has a minimum value of 0.01263 for ρ12 = 1 and a
maximum value of 0.02666 for ρ12 = 0. In setting 4, a minimum value of 0.01301 for
ρ12 = 1 and a maximum value of 0.02573 for ρ12 = 0 have been observed. Finally, in
setting 5, the FWER has a minimum value of 0.01317 for ρ12 = 1 and a maximum value
of 0.02630 for ρ12 = 0.
4.6.1.1.2 Scenario 1 : Sample size in Settings 1 - 5
Figure 4.3 presents GSD sample size simulation results with the fixed and variable
values defined in Table 4.2 and Table 4.3 respectively. The results are presented in all five
settings of scenario 1. The figure shows that the sample size increases as ρ12, σ21 and σ22
increase. This shows that the method is working as expected.
4.6.1.1.3 Scenario 1 : Power in Settings 1 - 5
Figure 4.4 presents simulation results for the GSD power with the fixed and variable
values defined in Table 4.2 and Table 4.3 respectively. The results are presented in all five
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Figure 4.2: GSD FWER in Scenario 1; Settings 1 - 5
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Figure 4.3: GSD Sample size in Scenario 1; Settings 1 - 5
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settings of scenario 2. The figure illustrates that the method effectively maintains the power
and this is fairly constant despite variation of ρ12, σ21 and σ21 . The figure also shows that the
power is above the nominal level of 0.80 in some settings.
4.6.1.2 Scenario 2: Constant ρ12
The results in scenario 2 are presented in Figure 4.5. It illustrates that despite variation of
σ21 and σ22 , the FWER is controlled and fairly constant with the minimum value 0.02223
for σ21 = 1 and σ22 = 1, and the maximum value 0.02504 for σ21 = 1 and σ22 = 2. The same
figure illustrates that the sample size increases in the same direction as σ21 and σ22 with the
minimum value 48 and the maximum value 158. Finally the figure illustrates that the power
is maintained and fairly constant and above the target value despite variation of σ21 and σ22
with 0.7998 the minimum value and 0.8113 the maximum value.
4.6.1.3 Scenarios 1 and 2: Summary and comments on the results
The results in scenario 1 show that the FWER is controlled but becomes increasingly con-
servative as ρ12 increases (Settings 1 - 5). The results in scenario 1 also show that the
FWER is above the nominal level of 0.025 for uncorrelated data, i.e. ρ12 = 0. Neverthe-
less, this slight increase in the FWER is less than 0.001, hence too small to be practically
relevant. Therefore we conclude that for the settings considered here, the GSD procedure
controls the FWER. The results in scenario 3 show that the FWER is controlled and fairly
constant when ρ12 is constant (scenario 3). Again this is know and this shows that the
method is working as expected.
The results in scenarios 1 and 2 show that the sample size is increasing in the same
direction as ρ12, σ21 or σ22 , and the power is fairly constant, and above the target power,
despite variations of these nuisance parameters. This is an indication that this method is
more powerful than the ones developed in Chapter 3.
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Figure 4.4: GSD Power in Scenario 1; Settings 1 - 5
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Figure 4.5: GSD FWER, Sample size and Power in Scenario 2
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The results in Scenario 1 finally show that all settings control the FWER and main-
tain the power therefore we only consider setting 3 to check the characteristics of the
FWER, power and sample size when different effect sizes and different timings of the
interim analysis are considered.
4.6.2 Scenario 3: Different effect sizes
4.6.2.1 Scenario 3: δ1 = 0.5, δ2 = 0.7
Figure 4.6 presents simulation results in scenario 3 with δ1 = 0.5 and δ2 = 0.7. It shows
that the FWER is controlled at the nominal 0.025 level despite variation of ρ12 and σ21 with
the minimum value 0.01100 for perfectly correlated data and 0.02376 for uncorrelated
data. The same figure shows that the sample size decreases as ρ12 and σ21 increases with a
minimum value of 14 and maximum value of 26. Finally the figure shows that the power
is not maintained and decreases when ρ12 and σ21 increase with a minimum value of 0.4009
and a maximum value of 0.6756.
4.6.2.2 Scenario 3: δ1 = 0.7, δ2 = 0.5
Figure 4.7 presents a situation where δ1 = 0.7 and δ2 = 0.5. It shows that the FWER in this
setting is controlled with a minimum value of 0.01100 for ρ12 = 1 and a maximum value
of 0.02429 for ρ12 = 0. The figure shows that the sample size is decreasing in the opposite
direction than ρ12 and σ21 with a minimum value of 20 and a maximum value of 46. Finally,
the figure shows that the power is not maintained and is decreasing in the opposite direction
with ρ12 and σ21 with a minimum value of 0.7560 and a maximum value of 0.7879.
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Figure 4.6: GSD FWER, Sample size and Power in Scenario 3 (δ1 = 0.5, δ2 = 0.7)
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Figure 4.7: FWER, Sample size and Power in Scenario 3 (δ1 = 0.7, δ2 = 0.5)
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4.6.2.3 Scenario 3: Summary and comments on the results
The results in Scenario 3 show that the FWER is controlled but is conservative as ρ12
increases.
The results in Scenario 3 also show that the sample sizes are decreasing in the oppo-
site direction than ρ12 and σ21 , with a large sample in setting (0.7,0.5) than setting (0.5,0.7).
However they (sample sizes) are not large enough to detect different effect sizes in both
settings at the same time, hence the reduction in power. This is illustrated in Figures 4.6
and 4.7 as the power decreases in the same direction as the sample size. It is also an illus-
tration that the sample size in this scenario is guided by the big effect size δ1 = 0.7 than
a small one (δ2 = 0.5), hence it is recommended to use a small effect size for sample size
calculation. This is a guarantee that the sample size obtained is large enough to detect even
a large effect size and maintain the power.
4.6.3 Scenario 4: Different spending function
4.6.3.1 Scenario 4: Hwang-Shih-DeCani spending function with γ = −10
Scenario 4 uses the Hwang-Shih-DeCani spending function with γ = −10. Figure 4.8
presents simulation results with the inputs of Setting 1. It shows that despite variation of
ρ12 and σ21 , the FWER is controlled with a minimum value of 0.01070 and a maximum
value of 0.02434. The figure shows that the sample size increases in the same direction
as ρ12 and σ22 with the minimum value 57 and the maximum value 125. Finally the figure
illustrates that the power is not maintained and tends to decease when ρ12 and σ21 increase
with a minimum value of 0.7627 and a maximum value of 0.7798.
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Figure 4.8: GSD FWER, Sample size and Power in Scenario 4 (γ = −10)
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Figure 4.9: GSD FWER, Sample size and Power in Scenario 4 (γ = 10)
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4.6.3.2 Scenario 4: Hwang-Shih-DeCani spending function with γ = 10
Scenario 4 also uses the Hwang-Shih-DeCani spending function with γ = 10. Figure 4.9
presents simulation results with the inputs of Setting 1. It shows that despite variation
of ρ12 and σ21 , the FWER is controlled with a minimum value of 0.01170 for ρ12 = 1
and a maximum value of 0.02515 for ρ12 = 0. The same figure shows that the sample
size increases in the same direction as ρ12 and σ22 with the minimum value 46 and the
maximum value 136. Finally the figure illustrates that the power is maintained and fairly
constant when ρ12 and σ21 increase with a minimum value of 0.7877 and a maximum value
of 0.8057.
4.6.3.3 Scenario 4: Summary and comments on the results
The results in scenario 4 show that the FWER is controlled but conservative as ρ12 in-
creases.
The results in Scenario 4 also show that sample sizes are increasing in the same di-
rection as ρ12 and σ21 and are about the same. However, the power for γ = 10 is maintained
compared to the one for γ = −10. This is because the Hwang-Shih-DeCani spending
function with γ = −10 gives a very conservative spending function. It spends less at the
beginning and more later on as illustrated in Figure 2.1. By having this type of spending
function, it is likely to go to a late look which means there is no effect of the sample size
re-estimation because the trial stops at the first look, consequently the power is reduced
despite a big sample size.
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4.7 Summary findings from the simulation results
This chapter described group sequential designs in the context of multiple endpoints. The
method uses specified stopping rules and a spending function based on the information at
each interim analysis. This information is adjusted to allow for the estimated correlation,
ρ, between test statistics at each stage. In Section 4.3, we illustrated how to implement this
method in practice and gave an example in Section 4.5.
Simulation results presented in Section 4.6 showed that, in most scenarios, the
FWER was controlled but became increasingly conservative as ρ12 increases. However,
we have observed that in Scenario 1 (Settings 1-5), the FWER was above the nominal level
of 0.025 for uncorrelated data, i.e. ρ12 = 0. Nevertheless, this slight increase in the FWER
of less than 0.001 was too small to be practically relevant. Therefore we concluded that for
the settings considered here, the GSD procedure controls the FWER.
In Section 4.6, we noticed that in most scenarios, the method maintains the power
and this was above the target power. However, if strange revision rules are used, the power
could not be maintained. For example, we showed in Scenario 3 that the GSD method does
not maintain the power when different effect sizes are used simultaneously. Figures 4.6
and 4.7 have shown this. The main findings for this scenario were that the magnitude of
the sample size for the GSD method was driven by the big effect size; and this (sample
size) was not large enough to detect two different effect sizes at the same time, hence the
reduction in power. To reiterate, we recommended to use the small effect size for sample
size calculation which is a guarantee that the sample size obtained would be large enough to
detect even the large effect size and maintain the power. We also showed in Figure 4.8 that,
the power for γ = −10 was not maintained. This was because the Hwang-Shih-DeCani
spending function with γ = −10 gives a very conservative spending function. By having
this type of spending function, it is likely to go to a late look which means there is no effect
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of the sample size re-estimation because the trial stops at the first look, consequently the
power is reduced despite a big sample size.
In Section 4.6, we finally observed that the sample size was increasing in the same
direction as ρ12, σ21 and σ22 , except in Scenario 3 where it was decreasing as ρ12 and σ21
increase. Normally, we would expect the sample size to increase in the same direction
as the nuisance parameters in other to maintain the power, but we did not observe this in
Scenario 3. That is why the power in this scenario was not maintained.
In the next chapter, we illustrate how the group sequential inverse normal designs,
described in Section 2.4, can be extended to the setting of multiple co-primary endpoints.
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Chapter 5
Group Sequential Design Inverse
Normal Combination tests with multiple
co-primary endpoints
This chapter illustrates how the group sequential inverse normal designs, described in Sec-
tion 2.4, can be extended to the setting of multiple co-primary endpoints. The principle
here is the full integration of the concept of inverse normal combination tests illustrated in
Section 2.4 into GSD described in Chapter 4. After an introduction in Section 5.1, Sec-
tion 5.2 presents a framework of analysis. Section 5.3 describes methodology for multiple
endpoints. Section 5.4 presents the implementation of the method followed by a worked
example in Section 5.5. Section 5.6 presents simulation results.
5.1 Introduction
For the case of early termination for efficacy, we reviewed statistics methods for multiple
outcomes in group sequential clinical trials in Section 4.1 and opted to consider multiple
hypothesis methods that allow the assessment of differential treatment effects in two or
more outcomes. We also reviewed methods allowing for reassessment of the sample size
after an interim analysis in group sequential trial with multiple co-primary endpoints in
181
Chapter 4. The aim of this chapter is to propose a method integrating the concept of inverse
normal combination test and multiple co-primary endpoints into group sequential testing.
In this setting, the sample size is re-estimated after an interim analysis in a classical group
sequential trial, the boundary at each stage is also calculated in the same way, however, the
hypothesis testing, assessing the evidence for efficacy of E and C at each stage is conducted
using the inverse normal combination test method.
5.2 General framework of analysis
In this section, we define an analysis framework for the GSD inverse normal combination
test approach in the context of multiple co-primary endpoints. It is a modified version of
the group sequential designs with multiple co-primary endpoints, described in Subsection
1.4.2, but this time, the test statistic is based on the evidence from the different stages of the
trial combined via the use of weighted inverse normal functions of the observed p-values
as described in more detail in Section 2.4. The reason we are doing this is to ensure the
FWER control. The general framework is defined in the following setting:
There are two treatments, experimental E and control C.
(i) To reiterate, let XkiEj be the random variable of the kth endpoint for the ith subject in
group E at stage j (k = 1, ..., K, i = 1, ..., nEj, j = 1, ..., J) and XkiCj be the random
variable of the kth endpoint for the ith subject in group C at stage j (k = 1, ..., K, i =
1, ..., nCj, j = 1, ..., J).
(ii) We develop one-sided tests as described in Subsection 1.2.5.
(iii) At each stage, we are interested in testing a null hypothesis that two K-dimensional
mean vectors of K endpoints are equal against an alternative hypothesis that the dif-
ference in mean vectors is a vector of positive K constants:
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H0k : θk = 0
H1k : θk > 0.
where θk is the k’th element of θ (a K x 1 column vector of true means) and we are
testing a family of k hypotheses.
(iv) we use the p-value defined in Eq. (3.14) to construct the p-value for this setting. Let
pkj now denote the p-value for endpoint k based on new data at stage j which we
write
pkj = 1− Φ(Zkj) (5.1)
where Zkj defined in Eq. (4.1) is now the standardised test statistics for endpoint k
based on new data at stage j.
(v) We also use Bj defined in Eq. (3.15) to define the test statistic in the setting of k
endpoints and j stages. Suppose Bkj now represents the inverse normal combination
test statistic for endpoint k at stage j.
(vi) Let cj be the critical value of the accumulating data at stage j calculated as in Sub-
section 2.3.3.
(vii) To reiterate, we assume that XijkE (XijkC) has a multivariate normal distribution
leading to the multivariate normal distribution for the test statistics Bkj with the vec-
tor θk = 0 and variance σ2k = 1.
(viii) At each stage j we consider the following stopping rules: ifBk1 ≥ c1 or . . . or Bk(j−1) ≥ c(j−1) or
Bkj ≥ cj , stop at stage j and reject H0k, otherwise continue to stage j + 1; where cj
represents a critical value at stage j defined in step (vi).
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(ix) We want to control the FWER in the strong sense, that is, to have
FWER = Pr(reject any true H0k) ≤ α, under any θk, which may combine true and
false hypotheses, with at least one true hypothesis.
5.3 Group Sequential Inverse Normal Combination test
Designs: Methodology for multiple co-primary end-
points
5.3.1 Definition of the problem
In this subsection, we consider methodology for situations where there are K co-primary
correlated endpoints in a clinical trial. The general setting for this problem is defined in
Section 5.2. Suppose that E and C are two treatments to be compared in a randomised
(phase III) clinical trial with parallel groups. After each group of 2N subjects has been ran-
domised in equal numbers to the two therapies and the response obtained, the nuisance pa-
rameters are re-estimated based on accumulated data at stage j; the sample size re-estimated
and the boundaries adjusted based on re-estimated sample size. However, in contrast to the
problem defined in Subsection 4.2.1, the data are now tested using a combination of inverse
normal tests of pkj-values defined in Eq. (5.1), that is, at the time of the j interim analysis,
the decision rule of a group sequential test can be represented as a combination rule for j
pkj-values, a series of pkj-values being derived from the data collected before all previous
stages and the other pkj-value being derived from the independent new data collected at
stage j. At each stage of the interim analysis, the further stage of the trial can be under-
stood as an independent new trial. The trial’s primary objective is to determine whether E
is more efficacious than C in terms of K continuous co-primary responses. This procedure
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is conducted at a sequence of up to J interim analyses, each involving a comparison of the
evidence for efficacy of E and C, with stopping occurring as soon as one of the interim
analyses is in some sense sufficiently convincing.
5.3.2 Test statistics
Suppose that we are interested in repeated looks at the accumulating data on the co-primary
endpoints with repeated hypothesis testing. At each interim analysis we will base inference
on some calculated test statistics. We need to think about these test statistics and their
distributions.
In this subsection, we define test statistics for the setting of K endpoints and J stages, derive
distributions and show how this relates to the canonical form as defined in Eq. (2.54) for
the setting of a single endpoint.
We use the inverse normal combination test statistic defined in Section 5.2, step (v), to
construct our test statistic, and at the design stage, we assume that σ2k is known. Let Bkj , k
= 1,..,K and j = 1,...,J now denote the inverse normal test for endpoint k combining the data
as a series of previous pkj-values from before the interim analysis j and the new data as the
pkj-value at the interim analysis point j, which we write as:
Bkj = w
j
1Φ
−1(1− pk1) + wj2Φ−1(1− pk2) + . . .+ wjjΦ−1(1− pkj) (5.2)
where
Bkj =
j∑
s=1
wjsΦ
−1(1− pks) (5.3)
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where pk1 denotes the p-value for endpoint k based on the data available at stage 1,
pkj represents the p-value for endpoint k based on the new data available at interim analysis
j and wjs denotes the pre-defined weight at each stage satisfying the following equation as
suggested by Lehmacher and Wassmer (1999):
j∑
s=1
(wjs)
2 = 1. (5.4)
UnderH0k,Bkj is normally distributed with mean θk = 0 and variance
∑j
s=1(w
j
s)
2 =
1; i.e., Bkj ∼ N(0, 1).
Suppose the covariance between inverse normal combination tests is:
Corr(Bkj, Bk′j) = ρkk′ , k
′
> k (5.5)
so that:
Cov(Bkj, Bk′j′ ) = w
j
sρkk′ , k
′
> k, j
′
> j, s = 1, . . . , j. (5.6)
As for Eq. (2.54) and under H0k, B11, . . . , BK1, . . . , B1J , . . . , BKJ has a multivariate nor-
mal distribution, which we write:

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B1J
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BKJ

∼ MVN


0
.
.
.
0
0
.
.
.
0
.
.
.
0
.
.
.
0

,


(w11)
2 (w21)
2 · · · (wJ1 )2
(w21)
2 + (w22)
2 · · · (wJ1 )2 + (wJ2 )2
.
.
.
.
.
.
(wJ1 )
2 + . . .+ (wJJ )
2

⊗

1 ρ12 · · · ρ1K
1 · · · ρ2K
.
.
.
.
.
.
1



(5.7)
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In the case of K = 2 and J = 3, Eq. (5.7) can be expressed as:

B11
B21
B12
B22
B13
B23

∼MVN


0
0
0
0
0
0

,


(w11)
2 (w21)
2 (w31)
2
(w21)
2 + (w22)
2 (w31)
2 + (w32)
2
(w31)
2 + (w32)
2 + (w33)
2
⊗
1 ρ12
1



(5.8)
5.3.3 Stopping boundaries
In the introduction we explained that the aim of this thesis was to construct tests in such a
way as to maintain the family-wise type I error rate in the context of K hypotheses.
Suppose that we have the same critical values {c1, ..cJ} calculated as in Subsection
2.3.3. We now need show that using these critical values, the distribution of the inverse
normal test statistics constructed under the null hypothesis in Eq. (5.7) controls the FWER
in the strong sense. The FWER is defined through the critical values {c1, ..cJ}, calculated
when B11, . . . , BK1, . . . , B1J , . . . , BKJ follow the null distribution as in Eq. (5.7) and
using the stopping rules defined in Section 5.2, step(viii).
So for one endpoint, we define the type I error rate to be
Pr(stop and reject H0 at or before stage j | θK = 0) =
Pr(B1 < c1, . . . , Bj−1 < cj−1, Bj ≥ cj). (5.9)
Now in the setting of K co-primary endpoints, we now have:
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Pr(stop and reject at least one H0k at or before stage 1 | θk = 0) =
Pr(B11 > c1 or B21 > c1 | θ=0) ≤ π1
Pr(stop and reject at least one H0k at or before stage 2 | θk = 0) =
Pr(B11 > c1 or B21 > c1 | θ=0) + Pr(B11 < c1, B21 < c1, B12 > c2 or
B22 > c2|θ = 0) ≤ π2
Pr(stop and reject at least one H0k at or before stage j | θk = 0) =
Pr(B11 > c1 or B21 > c1 | θ=0) + Pr(B11 < c1, B21 < c1, B12 > c2 or
B22 > c2|θ = 0) + ...+ Pr(B11 < c1, B21 < c1, B12 < c2, B22 < c2, ...,
B1(j−1) < cj−1, B2(j−1) < cj−1, B1j > cj or B2j > cj | θk = 0)
≤ πj (5.10)
πj represents the error spending function at stage j, j = 1,...,J. So, to control the
FWER, one must use cj , calculated as in Subsection 2.3.3, to satisfy Eq. (5.10) (i.e, calcu-
late cj using (4.9) and workout πj).
Power consideration is checked by simulations in Subsection 5.6 by using the sam-
ple size of the GSD method described in Chapter 4 and the GSD inverse normal combi-
nation test statistics described in Subsection 5.3.2. This is because the specification and
interpretation of alternative hypotheses is more difficult to define in general as explained
by Whitehead (2010).
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5.4 Implementation of the method
This section illustrates how the problem defined in Section 5.3.1 can be implemented in
practice. The general idea is that when the interim data are collected, the planned sample
size is re-calculated based on the estimate of the nuisance parameters and the test statistic
and the timing of the test are adjusted accordingly. However, the adjusted test statistic
is represented as a combination rule for j pkj-values. At each time point of the interim
analysis, pkj is independent of pk1,. . . ,pk(j−1) so the distribution of the test statistics is
unchanged. Furthermore the weights at each look are known and fixed in advance, and
they do not depend on the data observed. Details are given in the following subsections.
5.4.1 Design stage
At the design stage, we need to:
W0.1. Fix the maximum number of interim analyses J before the study commences.
W0.2. Determine spacing of analyses and
W0.3. Fix times of the interim analyses i.e., Tj0 = (t10 , t20 , ..., tj0), j = 1,...,J.
W0.4. Choose the overall significance level α and the target power.
W0.5. Specify the type of spending function to apply and use Eq. (2.46) to calculate πj (j =
1,...,J), the type I error probabilities for each stage.
W0.6. Guess ρkk′0 (k
′
> k) and σ2k0 .
W0.7. Calculate boundaries as described in more detail in Subsection 4.3.1 step (S0.7).
W0.8. Calculate the maximum sample size nmax0 as specified in more detail in Subsection
3.1.1(or Subsection 4.3.1 step S(0.8)).
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W0.9. Fix all weights as they do not depend on the data observed.
5.4.2 Stage 1
At this stage, interim data for stage 1 I1, which is a fraction of Nmax0, is used to estimate
the correlation ρkk′1 and the variance σ
2
k1
, which are then used to re-estimate the new maxi-
mum sample size Nmax1 or maximum information INmax1 . The new sample size Nmax1
is used to calculate the information fraction t1 at stage 1. t1 is used to calculate the type
I error π1 allocated to stage 1. π1 is used to find the boundary c1 at stage 1. c1 is then
compared to the test statistic Bk1 that results from the inverse normal method of combining
independent pkj-values, calculated based on interim data at stage 1, to stop the trial or not.
In short, the main point about this step is that based on a fraction of the data at the design
stage (before stage 1), we can re-estimate nuisance parameters ρkk′0 and σ
2
k0
, and modify
the sample size for stage 1 and, at the same time, we can stop the trial or not. The steps for
this stage are illustrated in more detail below:
W1.1. Simulate interim data for stage 1, i.e. I1 = t10Nmax0 observations.
W1.2. Use t10Nmax0 observations to estimate ρkk′1 as in Eq. (1.9).
W1.3. Estimate σ2k1 using the blinded method in Eq. (2.10), based on t10Nmax0 observa-
tions.
W1.4. Use boundaries calculated at the design stage (before stage 1) to estimate the maxi-
mum sample size Nmax1 as in step (W0.8).
W1.5. Calculate information fraction at stage 1: t1 = I1INmax1 =
t10Nmax0
Nmax1
.
W1.6. Use Eq. (2.46) to calculate the type I error π1 allocated to stage 1, i.e. π1 = f(t1).
W1.7. Use Eq. (2.50) to find boundary c11 at stage 1.
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W1.8. Use Eq. (1.27) to calculate the degrees of freedom based on the fraction of the data
at the design stage (before stage 1) : df1 = 2t10Nmax0-2.
W1.9. Use Eq. (1.23) to calculate t-statistics tk1 using the variance estimate in step (W1.3).
W1.10. Use Eq. (1.26) to calculate p-value pk1 from the t-distribution.
W1.11. Fix the weight in advance satisfying Eq. (5.4), that is: (w11)2 = ( 1√1)2 = 1.
W1.12. Use Eq. (5.3) to calculate the test statistic at stage 1 Bk1, calculated based on interim
data at stage 1 and the pre-defined weight defined in (W1.11), that is:
Bk1 =
1√
1
Φ−1(1− pk1). (5.11)
W1.13. Accept or reject H0k using the stopping rules defined in Section 5.2, step (viii) and
implemented in the program at appendix F: if B11 > c11 or...or Bk1 > c11 , reject
H0k and stop the trial.
W1.14. Otherwise, go to stage 2.
Before stage 2 begins, some adjustments need to be done to information fractions.
At stage 1, we have realised that the maximum sample size calculated before stage 1
Nmax0 has changed to Nmax1. This is because we have used the estimated correlation
ρ̂kk′1
and the estimated variance σ̂2k1 instead of ρkk′0 and σ
2
k0
. That is why we need to modify
the information time to reflect this change, that is Tj1 = (
t10Nmax0
Nmax1
,
t20Nmax1
Nmax1
, ...,
tJ0Nmax1
Nmax1
).
5.4.3 Stage 2
For stage 2, we need to estimate nuisance parameters based on stage 2 data and, at the
same time, we need to re-estimate the maximum sample size. The new maximum sample
size Nmax2 will be different to Nmax1, because we now are going to use the estimated
191
correlation ρ̂kk′2 and the estimated variance σ̂
2
k2
instead of ρ̂kk′1 and σ̂
2
k1
. This change will
imply that the boundary at stage 1 c1 would need to be changed to reflect the change in
maximum sample size from Nmax1 to Nmax2. However, we cannot to go back to stage 1
and change c1 based on the new maximum sample size Nmax2, because we have already
used it. We now need to construct stage 2 boundary c2, allowing for the fact that we have
already used the first boundary c1 at a different time. That is why it is important to modify
the information time to reflect this change before stage 2 begins. The steps for stage 2 are
as follows:
W2.1. Simulate interim data for stage 2, i.e. I22 = t20Nmax1 observations.
W2.2. Use t20Nmax1 observations to estimate ρkk′2 as in Eq. (1.9).
W2.3. Estimate σ2k2 using the blinded method as in Eq. (2.10), based on t20Nmax1 obser-
vations, representing the new data at stage 2.
W2.4. Repeat step (W2.3) but this time using new (t20Nmax1 − t10Nmax0) observations
for p-value calculation.
W2.5. Calculate boundaries based on the time of the interim analysis Tj1 as in step (W0.7).
W2.6. Estimate the maximum sample size Nmax2 as in step (W0.8) using correlation esti-
mated in step (W2.2) and variance estimate in step (W2.3).
W2.7. Calculate information fraction at stage 2: t2 = I2INmax2 =
t20Nmax1
Nmax2
.
W2.8. Use Eq. (2.46) to calculate the type I error π2 allocated to stage 2, i.e. π2 = f(t2).
W2.9. Use c11 calculated in step (W1.7) to find boundary c22 at stage 2 as illustrated in step
(W0.7) and Eq. (2.51).
W2.10. Use Eq. (1.27) to calculate the degrees of freedom based on the new fraction of data
at stage 2: df2 = 2(t20Nmax1 − t10Nmax0) - 2.
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W2.11. Use Eq. (1.23) to calculate t-statistics tk2 using variance estimate in step (W2.4).
W2.12. Use Eq. (1.26) to calculate p-value pk2 from the t-distribution.
W2.13. Fix the weight in advance satisfying Eq. (5.4), that is: (w21)2 + (w22)2 = ( 1√2)2 +
( 1√
2
)2 = 1.
W2.14. Calculate test statistic based on new data at stage 2, that is:
Φ−1(1− pk2). (5.12)
W2.15. Use Eq. (5.3) to combine test statistics calculated at step (W1.12) and step (W2.14),
with pre-defined weight defined in (W2.13):
Bk2 = w
2
1Φ
−1(1− pk1) + w22Φ−1(1− pk2). (5.13)
W2.16. Accept or reject H0 using the program at Appendix F: if B12 > c22 or...or Bk2 > c22 ,
reject H0k and stop the trial.
W2.17. Otherwise, go to stage J.
5.4.4 Stage J
Using the same rationale as in stage 2, we begin by making some adjustments to informa-
tion fractions T(j−1)j−1 = (
t10Nmax0
Nmaxj−1
,
t20Nmax1
Nmaxj−1
, ...,
tJ0Nmaxj−1
Nmaxj−1
). Now steps at stage J are:
WJ.1. Simulate interim data for stage J, i.e. IJ = tJ0Nmaxj−1 observations.
WJ.2. Use tJ0Nmaxj−1 observations to estimate ρkk′
J
as in Eq. (1.9).
WJ.3. Estimate σ2kJusing the blinded method as in Eq. (2.10), based on tJ0Nmaxj−1 obser-
vations.
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WJ.4. Repeat step (WJ.3) but this time using (tJ0Nmaxj−1 − t(J−1)0Nmaxj−2) observa-
tions, representing new data at stage J.
WJ.5. Calculate boundaries based on the time of the interim analysis T(j−1)j−1 as in step
(W0.7).
WJ.6. Estimate the maximum sample size NmaxJ as in step (W0.8) using correlation esti-
mated in step (WJ.2) and variance estimate in step (WJ.3).
WJ.7. Calculate information fraction at stage J: tJ = IJINmaxJ =
tJ0Nmaxj−1
NmaxJ
.
WJ.8. Use Eq. (2.46) to calculate the type I error πJ allocated to stage J, i.e. πJ = f(tJ).
WJ.9. Use c11 and c22 to find boundary cJJ at stage J as illustrated in step (W0.7) and Eq.
(2.51).
WJ.10. Use Eq. (1.27) to calculate the degrees of freedom based on the fraction of the data
at stage J: dfJ = (tJ0Nmaxj−1 − t(J−1)0Nmaxj−2)− 2.
WJ.11. Use Eq. (1.23) to calculate t-statistics tkJ using variance estimate in step (WJ.4).
WJ.12. Use Eq. (1.26) to calculate p-value pkJ from the t-distribution.
WJ.13. Fix the weight in advance satisfying Eq. (5.4), that is::
(wJ1 )
2 + (wJ2 )
2 + . . .+ (wJJ )
2
= (
1√
J
)2 + (
1√
J
)2 + . . .+ (
1√
J
)2 = 1.
WJ.14. Calculate test statistic at stage J, that results from the inverse normal method of com-
bining independent pkJ -value, calculated based on the interim new data at stage J ,
that is:
Φ−1(1− pkJ). (5.14)
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WJ.15. Use Eq. (5.2) to combine test statistics calculated, at step (W1.12.), step (W2.14),. . . ,
and step (WJ.14), with pre-defined weight as defined in (WJ.13):
BkJ = w
J
1 (Φ
−1(1− pk1) + wJ2Φ−1(1− pk2) + . . .
+wJJΦ
−1(1− pkJ). (5.15)
Scenario 1: if tJ >= 1:
WJ.16. Use the program in Appendix F to reject H0k and stop the trial if B1J > cJJ or...or
BkJ > cJJ .
WJ.17. Otherwise, stop and accept H0k.
Scenario 2: if tJ < 1:
WJ.18. If tJ < 1, the type I error πJ is less than α, i.e. πJ < α. This implies that we still
have a proportion of α to spend, so we need to go to stage J + 1 if H0k is not rejected
at stage J, that is:
WJ.19. Reject H0k and stop the trial if Bk1 > cJj or . . . or BkJ > cJj , using the program in
Appendix F.
WJ.20. Otherwise, go to stage J + 1.
5.4.5 Stage J + 1
This stage happens in Scenario 2 when H0k has not been rejected and tJ < 1. It gives us the
possibility to develop two options: either we proceed exactly as in stage J by calculating
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the information fraction tJ+1 and the type I error πJ+1 allocated to stage J + 1; or we force
the trial to stop by fixing the information fraction tJ+1 = 1 and πJ+1 = α. We have opted
for the last option and the steps for this stage are as follows:
As in stage J, we begin by making some adjustments on information fractions T(J)J
= (
t10Nmax0
NmaxJ
,
t20Nmax1
NmaxJ
, ...,
tJ0Nmaxj−1
NmaxJ
).
W(J+1).1. Simulate data for stage J + 1, i.e. IJ+1 = tJ0NmaxJ observations.
W(J+1).2. Use tJ0NmaxJ observations to estimate ρkk′
J+1
as in Eq. (1.9).
W(J+1).3. Estimate σ2J+1 using the blinded method as in Eq. (2.10), based on tJ0NmaxJ ob-
servations.
W(J+1).4. Calculate boundaries based on the time of the interim analysis T(J)J as in step (W0.7).
W(J+1).5. Estimate the maximum sample size NmaxJ+1 as in step (W0.8).
W(J+1).6. The information fraction is set to tJ+1 = 1, which implies that the type I error πJ+1
allocated to stage J + 1 is equal to α i.e. πJ+1 = α.
W(J+1).7. Use Eq. (2.52) to find boundary c(J+1) at stage J + 1 as illustrated in step (W0.7).
W(J+1).8. Use (NmaxJ+1− t(J−1)0NmaxJ−1) observations instead of (NmaxJ+1−NmaxJ )
to calculate inverse normal test statistic based on interim data at stage J+1. If we
consider (NmaxJ+1 − NmaxJ ) observations, we will not incorporate NmaxJ −
NmaxJ−1 observations which also form part of stage (J+1).
W(J+1).9. Repeat step (W(J+1).3) but this time using (NmaxJ+1− t(J−1)0NmaxJ−1) observa-
tions as explained in step (W(J+1).8).
W(J+1).10. Use Eq. (1.27) to calculate the degrees of freedom based on the fraction of data at
stage (J+1): dfJ+1 = (NmaxJ+1 − t(J−1)0NmaxJ−1)− 2.
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W(J+1).11. Use Eq. (1.23) to calculate t-statistics tk(J+1) using the variance estimate in step
(W(J+1).9).
W(J+1).12. Use Eq. (1.26) to calculate p-value pk(J + 1) from the t-distribution.
W(J+1).13. Fix the weight in advance satisfying Eq. (5.4), that is:
(w
(J+1)
1 )
2 + (w
(J+1)
2 )
2 + . . .+ (w
(J+1)
J+1 )
2
= (
1√
J + 1
)2 + (
1√
J + 1
)2 + . . .+ (
1√
J + 1
)2 = 1.
W(J+1).14. Calculate the test statistic at stage J+1, that results from the inverse normal method
of combining independent pk(J+1)-value, calculated based on the interim new data at
stage J+1 , that is:
Φ−1(1− pk(J+1)). (5.16)
W(J+1).15. Use Eq. (5.3) to combine the test statistics calculated at step (W1.12.), stage 1 and
step (W2.14), stage 2,. . . , step (WJ.14), stage J and step (W(J+1).14), stage (J+1):
Bk(J+1) = w
J+1
1 (Φ
−1(1− pk1) + wJ+12 Φ−1(1− pk2) + . . .+
wJ+1J−1Φ
−1(1− pk(J−1)) + wJ+1J Φ−1(1− pkJ) +
wJ+1J+1Φ
−1(1− pk(J+1)). (5.17)
W(J+1).16. If Bk(J+1) > cJ+1 or . . . or Bk(J+1) > cJ+1, reject H0k and stop the trial.
W(J+1).17. Otherwise, stop and accept H0k.
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Table 5.1: GSD: Implementation of the method
Stages Values
Before stage 1
Significance level α 0.025 (one sided)
Power 1− β 0.8
Endpoints K = 2
Assume ρ120 0.5
Assume σ210 1.5
Assume σ220 1
Number of stages 3
Assume t10 , t20 , t30 13 ,
2
3
, 3
3
Calculate Nmax0 72
Stage 1
Simulate t10Nmax0 data 24
Estimate ρ121 0.53
Estimate σ211 1.30
Estimate σ221 0.94
Estimate Nmax1 240
Info. fraction. : t1 =
t10Nmax0
Nmax1
0.10
Calculate c1 with t1 3.78
Calculate B11 and B12 0.84 and 1.20
Conclude B11 < c1 and B12 < c1 Continue to stage 2
Stage 2
Simulate t20Nmax1 data 160
Estimate ρ122 0.49
Estimate σ212 1.46
Estimate σ222 0.89
Estimate Nmax2 220
Info. fraction : t2 =
t20Nmax1
Nmax2
0.72
Calculate c2 with t2 2.84
Calculate B21 and B22 0.85 and 1.60
Conclude B21 < c2 and B22 < c2 Continue to stage 3
Stage 3
Simulate t30Nmax2 data 220
Estimate ρ123 0.45
Estimate σ213 1.47
Estimate σ223 0.93
Estimate Nmax3 250
Info. fraction : t3 =
t30Nmax2
Nmax3
0.88
Calculate c3 with t3 2.40
Calculate B31 and B32 0.16 and 1.61
Conclude B31 < c3 and B32 < c3 Continue to stage 4
Stage 4
Simulate t30Nmax3 data 250
Estimate ρ124 0.48
Estimate σ214 1.48
Estimate σ224 0.95
Estimate Nmax4 230
Fix the info. fraction : t4 1
Calculate c4 with t4 2.33
Calculate B41 and B42 0.51 and 2.35
Conclude B41 < c4 and B42 > c4 Stop and accept H02
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5.5 Example: Three-stage GSD inverse normal combina-
tion test procedure for multiple co-primary endpoints
This section considers the same example as in Section 4.5 to illustrate the GSD inverse
normal combination test procedures for multiple co-primary endpoints. Suppose that a
clinical trial is to be designed to compare an experimental drug E with a placebo control
C. Two co-primary endpoints are considered, i.e. K = 2. Patients are randomised in equal
numbers between E and C, and a normally distributed response is observed for each of
the endpoints. Suppose the parameters of interest representing the mean differences are
θ1 = θ2 = 0.5.
At the design stage (see Subsection 5.4.1 and Figure 5.1), the values considered
are summarized in Table 5.1. We assume (or guess) that the variance for endpoint 1 is
σ210 = 1.5, the variance for endpoint 2 is σ222 = 1 and the correlation between endpoints
is ρ120 = 0.5. A three-stage design (J = 3) is required to test H0k : θk = 0, k = 1,2, with
a one-sided test type I error rate of α = 0.025 and a power of 1 - β = 0.80 for θ = 0.5.
We consider the O’Brien and Fleming’s spending function as in Eq. (2.48) and the time of
interim analyses at tj0 = (1/3, 2/3, 3/3), j = 1,2,3. The first boundary c10 is found by using
the time t10 and its associated type I error rate π1, and also the normal distribution function.
For given c10 , t10 and the type I error rate π2 to spend at time t20 , the program in Appendix
F finds c20 . For given c10 , t10 ,c20 , t20 and the type I error rate to spend by time t30 , the
program in Appendix F finds c30 . The initial maximum sample size Nmax0 = 72 is then
calculated as described in more detail in step (W0.8).
At stage 1, the values simulated and estimated are summarized in Table 5.1. We
simulate stage 1 data as illustrated in step (W1.1): t10Nmax0 = 27. Based on the interim
data at stage 1, ρ̂121 , σ̂2k1 , k = 1,2 and Nmax1 are estimated following steps (W1.2) -
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(W1.4). Suppose the maximum sample size is now Nmax1 = 240 as in Figure 5.1. We
then use step (W1.5) to calculate the information fraction t1 and the corresponding type I
error π1 as in step (W1.6) to find the boundary c11 = 3.78 at stage 1 as described in step
(W1.7). Steps (W1.8)-(W1.10) are then used to calculate the degrees of freedom df1, t-test
statistics Tk1 and p-value pk1 respectively. We fix the weight w11 = 1 at stage 1 as in step
(W1.11) and calculate the inverse normal test statistics Bk1 as in step (W1.12). The test
statistic Bk1 is then compared to the boundary c11 to accept or reject H0k as described in
steps (W1.13) - (W1.14). Figure 5.1 and Table 5.1 show that H0k is not rejected, therefore
we proceed to stage 2.
Before we start stage 2, we need to modify the information time to reflect the change
in the maximum sample size from Nmax0 = 72 to Nmax1 = 240 as explained in Sub-
section 5.5.3. This step gives T1 in Figure 5.1. The values simulated and estimated at
this stage are summarized in Table 5.1. We continue and simulate interim data at stage 2,
t20Nmax1 = 160, as in step (W2.1) and Figure 5.1. We then estimate ρ̂122 and σ̂2k2 , k =
1,2 as in steps (W2.2) and (W2.3). We use step (W2.5) to calculate the boundaries based
on the information time T1 as in Figure 5.1, we do it by using step (W0.7). The maximum
sample size Nmax2 = 220 is estimated as in step (W2.6). We calculate the information
fraction t2 = 0.72 at stage 2 as in step (W2.7), the type I error π2 allocated to stage 2
as in step (W2.8) and the corresponding boundary c22 = 2.84 as in step (W2.9). We use
step (W2.4) to estimate the variance based on (t20Nmax1− t10Nmax0) new observations:
2Nmax1
3
− Nmax0
3
= 136. We use new observations at stage 2 to calculate the degrees of
freedom df2, the t-test statistics tk2 and the p-value pk2 as in steps (W2.10), (W2.11) and
(W2.12) respectively. We then fix the weight 1√
2
at stage 2 in advance and calculate the
test statistics as in steps (W2.13) and (W2.14) respectively. We combine test statistics cal-
culated in step (W1.12) and (W2.13), and calculate the inverse normal test Bk2 as in step
(W2.15), that is: Bk2 = 1√2Φ−1(1 − pk1) + 1√2Φ−1(1 − pk2). We then use step (W2.16) to
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accept or reject H0k. Figure 5.1 and Table 5.1 show that H0k is not rejected, hence we go
to stage J = 3, which is supposed to be the final stage.
At stage J = 3, we repeat the same process as in stage 2 to calculate the information
time to reflect the change in the maximum sample size from Nmax1 = 240 to Nmax2 =
220. This gives T2 in Figure 5.1. The values simulated and estimated at this stage are
summarized in Table 5.1. We continue and collect interim data at stage 3, t30Nmax2 =
220, as in step (WJ.1). We then estimate ρ̂123 and σ̂2k3 , k = 1,2 using steps (WJ.2) and
(WJ.3), and calculate the boundaries and the corresponding maximum sample size Nmax3
= 250 as described in steps (WJ.5), (WJ.6) and Figure 5.1 respectively. The information
fraction t3 = 0.88 and the type I error π3 allocated to stage J = 3 are then calculated using
steps (WJ.7) and (WJ.8). We use the same c11 , c22 calculated before to find c33 = 2.40
as in step (WJ.9). We use step (WJ.4) to estimate the variance based on (t30Nmax2 −
t(2)0Nmax1) new observations: 3Nmax23 − 2Nmax13 = 60. We use new observations at stage
3 to calculate the degrees of freedom df3, the t-test statistics Tk3 and the p-value pk3 as in
steps (WJ.10), (WJ.11) and (WJ.12) respectively. We then fix the weight 1√
3
at stage 3 in
advance, satisfying ( 1√
3
)2 + ( 1√
3
)2 + ( 1√
3
)2) = 1 and calculate the test statistics as in steps
(WJ.13) and (WJ.14) respectively. We combine test statistics calculated in step (W1.12),
(W2.14) and (WJ.14), and calculate the inverse normal test BJk as in step (WJ.15), that is:
Bk3 =
1√
3
Φ−1(1− pk1) + 1√3Φ−1(1− pk2) + 1√3Φ−1(1− pk3). Use step (WJ.19) to accept
or reject Hk0. Figure 5.1 and Table 5.1 show that H0k is not rejected.
We now need to proceed to the next stage, despite the fact that, at the design stage,
the plan was to conduct a three-stage GSD inverse normal combination test design. The
requirement to go to the next stage is justified by the fact that the information fraction t3
is less than 1. This implies that the type I error π3 allocated to stage 3 will be less than α.
This situation is equivalent to scenario 2 in Subsection 5.4.4.
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At stage (J + 1) = 4, the values simulated and estimated are summarized in Table
5.1. We set the information fraction to 1 i.e. t4 = 1, so the type I error π4 allocated
to stage 4 is equal to α, i.e. π4 = α. We repeat the same procedure as in stage 3 to
calculate the information time to reflect the change in the maximum sample size from
Nmax2 = 220 to Nmax3 = 250. This gives T3 in Figure 5.1. We then estimate ρ124 and
σ2k4 , k = 1,2 using steps (W(J+1).2) and (W(J+1).3) and t30Nmax3 = 32503 observations,
then we calculate the boundaries and the corresponding maximum sample size Nmax4
= 230 as described in steps (W(J+1).4), (W(J+1).5) and Figure 5.1. We use the same
c11 , c22 and c33 calculated before to find c44 = 2.33 as in step (W(J+1).7). We also use
new observations (Nmax4 − t(2)0Nmax2) = 83 at stage 4 described in step (W(J+1).8) to
calculate variance as described in step (W(J+1).9). We then use new observations at stage
4 to calculate the degrees of freedom df4, the t-test statistics tk4 and the p-value pk4 as in
steps (W(J+1).10), (W(J+1).11) and (W(J+1).12) respectively. We then fix the weight 1√
4
at stage 4 in advance, satisfying ( 1√
4
)2 + ( 1√
4
)2 + ( 1√
4
)2 + ( 1√
4
)2 = 1 and calculate the test
statistics as in steps (W(J+1).13) and (W(J+1).14) respectively. We combine test statistics
calculated in step (W1.12), (W2.14), (WJ.14) and (W(J+1).14), and calculate the inverse
normal test Bk4 as in step (W(J+1).15), that is: Bk4 = 1√4Φ−1(1−pk1)+ 1√4Φ−1(1−pk2)+
1√
4
Φ−1(1−pk3)+ 1√4Φ−1(1−pk4). We then proceed as in step (W(J+1).16) to compare Bk4
and c44 . If Hk0 is not rejected, we stop the trial as we do not have any α to spend anymore.
Table 5.1 shows that H0k is rejected.
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Figure 5.1: GSD Inverse Normal Designs with multiple co-primary endpoints: Implemen-
tation of the method
5.6 Simulation results
We explained at the beginning of this chapter that, this method consists of integrating the
concept of inverse normal combination tests into GSD with multiple endpoints. We now
need to show if using the same settings described in Section 4.6 (and reiterated in Tables
5.2 ad 5.3), we are going to obtain similar results in term of FWER, sample size and power.
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Table 5.2: Initial values considered in the simulation study.
Fixed parameters GSD inverse normal combination test
Significance level α 0.025 (one sided)
Standard error of estimate FWER 0.001
Target power 1− β 0.8
Standard error of estimate power 0.0025
Number of endpoints K = 2
Number of simulations 100,000
Number of looks = 3 1/3,2/3,3/3
Null hypothesis H0k θ1 = θ2 = 0
Guessed nuisance parameters
ρ120 0.5
σ210 1.5
σ220 1
However, here we know that the FWER is controlled, though it may still be conservative.
For all the scenarios considered, equal weights for each look are used as illustrated in more
detail in the previous section. For each scenario, the OBrien-Fleming spending function is
used except for scenario 4 where the Hwang-Shih-DeCani spending function is considered.
5.6.1 FWER, power and sample size in GSD Inverse Normal Combi-
nation tests with multiple co-primary endpoints
As for the three methods described previously, this subsection aims to check if the method
developed in this chapter controls the FWER and maintains the power if the nuisance pa-
rameters change as in the following settings:
5.6.1.1 Scenario 1 : Settings 1 - 5
5.6.1.1.1 Scenario 1 : FWER in Settings 1 - 5
Figure 5.2 presents GSD combination test FWER’s simulation results with the fixed
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Table 5.3: Scenarios considered in the simulation study.
Variable values GSD inverse normal combination test
Scenario 1 Common values for all settings
Alternative hypothesis θk = δk δ1 = δ2 = 0.5
Type of spending function O’Brien - Fleming
True nuisance parameters
ρ12 0,0.1,...,1
σ21 1,1.1,1.2,...,2
Setting 1
σ22 1
Setting 2
σ22 1.2
Setting 3
σ22 1.5
Setting 4
σ22 1.8
Setting 5
σ22 2
Scenario 2 Constant ρ12
Alternative hypothesis θk = δk δ1 = δ2 = 0.5
Type of spending function O’Brien - Fleming
True nuisance parameters
ρ12 0.5
σ21 1,1.1,1.2,...,2
σ22 1,1.1,1.2,...,2
Scenario 3 Different size effects
Type of spending function O’Brien - Fleming
Alternative hypothesis δ1 = 0.5, δ2 = 0.7
Alternative hypothesis δ1 = 0.7, δ2 = 0.5
Same true nuisance parameters as in Setting 3
Scenario 4 Different type of spending function
Type of spending function Hwang-Shih-DeCani
Same alternative hypothesis as in Setting 3 δ1 = δ2 = 0.5
Same true nuisance parameters as in Setting 3
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and variable values defined in Table 5.2 and Table 5.3 respectively. The figure shows
that this method effectively controls the overall FWER at the nominal 0.025 level despite
variation of ρ12 and σ21 in all five settings. In setting 1, the FWER has a minimum value
of 0.00895 for perfect correlated data i.e. ρ12 = 1 and a maximum value of 0.02301 for
uncorrelated data, i.e. ρ12 = 0. In setting 2, a minimum value of 0.00904 for ρ12 = 1 and
a maximum value of 0.02129 for ρ12 = 0 have been observed. In setting 3, the FWER has
a minimum value of .00961 for ρ12 = 1 and a maximum value of 0.02301 for ρ12 = 0.
In setting 4, a minimum value of 0.00943 for ρ12 = 1 and a maximum value of 0.02325
for ρ12 = 0 have been observed. Finally, in setting 5, the FWER has a minimum value of
0.00892 for ρ12 = 1 and a maximum value of 0.02339 for ρ12 = 0.
5.6.1.1.2 Scenario 1 : Sample size in Setting 1 - 5
Figure 5.3 presents GSD combination test sample size simulation results with the
fixed and variable values defined in Table 5.2 and Table 5.3 respectively. The results are
presented in all five settings of scenario 1. The figure shows that the sample size increases
as ρ12, σ
2
1 and σ22 increase. Again, this is an indication that the method is working.
5.6.1.1.3 Scenario 1 : Power in Settings 1 - 5
Figure 5.4 presents simulation results for the power with the fixed and variable val-
ues defined in Table 5.2 and Table 5.3 respectively. The figure illustrates that the method
does not maintain the power in all five settings.
5.6.1.2 Scenario 2 : Constant ρ12
The results in scenario 2 are presented in Figure 5.5. Its illustrates that despite variation of
σ21 and σ22 , the FWER is controlled with small values for σ21 = 1.2 and σ22 = 1, and fairly
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Figure 5.2: GSD combination FWER in Scenario 1; Settings 1 - 5
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Figure 5.3: GSD combination Sample size in Scenario 1; Settings 1 - 5
208
True correlation values
0.0
0.2
0.4
0.6
0.8
1.0
Tru
e 
va
ria
nce
1 v
alu
es
1.0
1.2
1.4
1.6
1.8
2.0
P
o
w
er
0.4
0.5
0.6
0.7
0.8
Power in setting 1 variance 2 = 1
True correlation values
0.0
0.2
0.4
0.6
0.8
1.0
Tru
e 
va
ria
nce
1 v
alu
es
1.0
1.2
1.4
1.6
1.8
2.0
P
o
w
er
0.60
0.65
0.70
0.75
0.80
Power in setting 2 variance 2 = 1.2
True correlation values
0.0
0.2
0.4
0.6
0.8
1.0
Tru
e 
va
ria
nce
1 v
alu
es
1.0
1.2
1.4
1.6
1.8
2.0
P
o
w
er
0.60
0.65
0.70
0.75
0.80
Power in setting 3 variance 2 = 1.5
True correlation values
0.0
0.2
0.4
0.6
0.8
1.0
Tru
e 
va
ria
nce
1 v
alu
es
1.0
1.2
1.4
1.6
1.8
2.0
P
o
w
er
0.70
0.72
0.74
0.76
0.78
0.80
Power in setting 4 variance 2 = 1.8
True correlation values
0.0
0.2
0.4
0.6
0.8
1.0
Tru
e 
va
ria
nce
1 v
alu
es
1.0
1.2
1.4
1.6
1.8
2.0
P
o
w
er
0.70
0.72
0.74
0.76
0.78
0.80
Power in setting 5 variance 2 = 2
Figure 5.4: GSD combination Power in Scenario 1; Settings 1 - 5
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Figure 5.5: GSD combination test FWER, Sample size and Power in Scenario 2
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constant values afterwards. The same figure illustrates that the sample size increases in
the same direction as σ21 and σ22 with the minimum value 33 and the maximum value 147.
Finally the same figure illustrates that the power is not maintained when σ21 and σ22 vary
with small values for σ21 = 1.2 and σ22 = 1, and fairly constant values afterwards.
5.6.1.3 Scenario 1 and 2: Summary and comments of the results
The results in scenario 1 shows that the FWER is controlled but becomes increasingly
conservative as ρ12 increases. We would expect this as the weights in this method are data-
dependent. In scenario 2 the results show that the FWER is controlled and fairly constant
when ρ12 is constant. In all the scenarios, the results obtained show that the FWER is more
conservative that in Chapter 4.
The results in scenarios 1 and 2 show that the sample size is increasing in the same
direction as ρ12, σ21 and σ22 , however, the power is decreasing in the opposite direction than
the nuisance parameters and this is below that target power. This is a known situation as
the weights used in these scenarios do not reflect the sample sizes.
5.6.2 Scenario 3 : Different size effect
5.6.2.1 Scenario 3 : δ1 = 0.5, δ2 = 0.7
Figure 5.6 presents simulation results in Scenario 3 with δ1 = 0.5 and δ2 = 0.7. It shows
that the FWER is maintained at the nominal 0.025 level despite variation of ρ12 and σ21
with the minimum value 0.00957 for perfect correlated data and 0.02088 for uncorrelated
data. The same figure shows that the sample size increases as ρ12 and σ21 increases with a
minimum value of 35 and maximum value of 68. Finally the same figure shows that the
power is not maintained but fairly constant when ρ12 and σ21 increase with a minimum value
of 0.6954 and a maximum value of 0.7178.
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Figure 5.6: GSD combination test FWER, Sample size and Power in Scenario 3 (δ1 = 0.5,
δ2 = 0.7)
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5.6.2.2 Scenario 3: δ1 = 0.7, δ2 = 0.5
Figure 5.7 presents a situation where δ1 = 0.7 and δ2 = 0.5. It shows that the FWER in this
setting is controlled with a minimum value of 0.00241 for ρ12 = 1 and a maximum value of
0.02148 for ρ12 = 0. The same figure shows that the sample size is increasing in the same
direction as ρ12 and σ21 with a minimum value of 15 and a maximum value of 104. Finally
the same figure shows that the power is not maintained and is increasing with σ21 and fairly
constant with ρ12, with a minimum value of 0.4002 and a maximum value of 0.7492.
5.6.2.3 Scenario 3: Summary and comments on the results
The results in Scenario 3 show that the FWER is controlled but conservative as ρ12 in-
creases. The results in Setting (0.7,0.5) are even more conservative for perfect correlated
data.
The results in Scenario 3 also show that sample sizes are increasing in the same
direction than ρ12 and σ21 . However they (sample sizes) are not large enough to detect
different effect sizes in both settings at the same time, hence reduction in power. For
example, the shape of the power seems to follow the variation of the sample size in Figure
5.7.
5.6.3 Scenario 4: Different spending function
5.6.3.1 Scenario 4: Hwang-Shih-DeCani spending function with γ = −10
Scenario 4 uses the Hwang-Shih-DeCani spending function with γ = −10 and Figure 5.8
presents the results with the same input values as in Setting 3. The figure shows that despite
variation of ρ12 and σ21 the FWER is controlled with a minimum value of 0.01070 and a
maximum value of 0.024377. The same figure shows that the sample size increases in the
same direction as ρ12 and σ21 with the minimum value 57 and the maximum value 125.
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Figure 5.7: GSD combination test FWER, Sample size and Power in Scenario 3 (δ1 = 0.7,
δ2 = 0.5)
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Figure 5.8: GSD combination test FWER, Sample size and Power in Scenario 4 (γ = −10)
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Finally the same figure illustrates that the power is not maintained but fairly constant when
ρ12 and σ21 increase with a minimum value of 0.7627 and a maximum value of 0.7798.
5.6.3.2 Scenario 4: Hwang-Shih-DeCani spending function with gamma = 10
Scenario 4 also uses the Hwang-Shih-DeCani spending function with γ = 10. Figure 5.9
presents its results. The figure shows that despite variation of ρ12 and σ21 , the FWER is
controlled with a minimum value of 0.01198 for ρ12 = 1 and a maximum value of 0.02585
for ρ12 = 0. The same figure shows that the sample size increases in the same direction as
ρ12 and σ21 with the minimum value 45 and the maximum value 84. Finally the same figure
illustrates that the power is maintained and fairly constant when ρ12 and σ21 increase with a
minimum value of 0.7840 and a maximum value of 0.8077.
5.6.3.3 Scenario 4: Summary and comments on the results
The results in Scenario 4 are similar to those in Subsection 4.6.1.8. They show that the
FWER is controlled but is over conservative as ρ12 increases.
They also show that sample sizes are increasing in the same direction as ρ12 and σ21 .
However, the power for γ = 10 is maintained compared to the one for γ = −10. This is
because Hwang-Shih-DeCani spending function with γ = −10 gives a very conservative
spending function. It spends less at the beginning and more later on as illustrated in Figure
2.1. To reiterate the conclusion of the findings in Subsection 4.6.3.3, by having this type
of spending function, it is likely to go to a late look which means there is no effect of the
sample size re-estimation because the trial stops at the first look, consequently the power is
reduced despite having a big sample size.
Simulation results for this method have shown that in all settings considered, the
power is not maintain, except for the setting with the Hwang-Shih-DeCani spending func-
tion and γ = 10. One of the solutions would be to use less conservative spending function
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Figure 5.9: GSD combination test FWER, Sample size and Power in Scenario 4 (γ = 10)
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(eg. Hwang-Shih-DeCani spending function with γ = 10) even if the weights are pre-
defined and fixed in advance. Figure 5.9 could be used as an example.
5.7 Summary findings from the simulation results
In this chapter, we described the GSD inverse normal combination tests procedure with
multiple co-primary endpoints. The method integrates the concept of an inverse normal
combination tests approach into the group sequential designs procedure described in Chap-
ter 4. In Section 5.4, we illustrated how to implement the method in practice and gave an
example in Section 5.5. Simulation results presented in Section 5.6 showed that the FWER
was controlled but became increasingly conservative as ρ12 increased. The results showed
no evidence of the inflation of the FWER for all the scenarios considered.
Simulation results presented in Section 5.6 also showed that the sample size was
increasing in the same direction as ρ12, σ21 and σ22; however the power was decreasing in
the opposite direction than the nuisance parameters and this was below that target power
in all settings. We observed similar results as in Chapter 4 regarding the use of different
effect sizes simultaneity. To reiterate, we observed that although the sample sizes were
increasing in the same direction in Scenario 3, they (sample sizes) were not large enough
to detect different effect sizes at the same time, hence reduction in power.
In Section 5.6, we finally showed that the power was not maintain, except for the
setting with the Hwang-Shih-DeCani spending function and γ = 10 (Scenario 4). We then
suggested to use this type of setting (Hwang-Shih-DeCani spending function with γ = 10)
if we would like to maintain the power even if the weights were pre-defined and fixed in
advance. However, the lack of power in the combination test approach is a known situation
because the weights used do not reflect the sample sizes. Authors such as Proschan (2009b)
and Lehmacher and Wassmer (1999) have shown this in the setting of a single endpoint.
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In the next chapter, we present a discussion and the conclusions of the simulation
results of all the methods described in this thesis.
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Chapter 6
Discussion and Conclusions
This thesis aimed to show how to adjust a sample size in clinical trials with multiple co-
primary continuous endpoints using adaptive and group sequential designs, and also how to
construct a test such as to control the FWER and maintain the power, even if the correlation
ρ between endpoints is not known. To achieve this, we used three different methods: group
sequential designs, sample size re-estimation and inverse normal combination tests.
In this chapter, we present a discussion and the conclusions of the simulation results
of the three methods previously described. Section 6.1 presents a discussion of the results,
Section 6.2 presents extensions and further work and Section 6.3 presents the conclusions.
6.1 Discussion
6.1.1 Sample size re-estimation method
The sample size re-estimation method was introduced in the context of a single endpoint in
Section 2.1, then extended in the context of multiple co-primary endpoints in Section 3.1.
We used the blinded method, and then considered the case of two co-primary endpoints
where the rejection of either is considered as proof that the new treatment is working. We
conducted two different tests each for one endpoint and at level α/K, and implemented the
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Internal Pilot Study design as developed by Wittes and Brittain (1990). The new features
for this method are: use of the Bonferroni correction to adjust for the FWER, steps to follow
when designing a clinical trial with multiple co-primary endpoints, steps to follow when
calculating sample size with multiple co-primary endpoints, what to do if different effect
sizes are needed in a clinical trial with multiple endpoints. Simulation results in Section
3.1.7 show that this method controls the FWER and maintains the power; and these results
are similar to the results obtained by Friede and Schmidli (2010). However, it is important
stress that the control of the FWER is not guaranteed analytically but appears to hold in
the SSR case. We also show that the power could not be maintained if strange revision
rules are used. For example, the interim evaluation performed when 10% of the patients
are in the internal pilot leads to inaccurate estimation of the nuisance parameters, with the
consequence that the power was not maintained. This also applies when different effect
sizes are used simultaneously.
6.1.2 SSR Inverse Normal Combination test method
The SSR Inverse Normal Combination test method was presented as a method integrating
the concept of the inverse normal combination test into sample size re-estimation. This
means that the same design as proposed by Wittes and Brittain (1990) was used to perform
sample size re-estimation, but the only difference was how the final analysis was conducted.
It was first introduced in the context of single endpoint in Section 2.2, followed by its ex-
tension in the context of multiple co-primary endpoints in Section 3.2. Here, we used the
inverse normal combination test method as proposed by Lehmacher and Wassmer (1999),
to construct the test statistics. The new features for this method are: use of the Bonferroni
correction to adjust for the FWER, steps to follow when designing a clinical trial with mul-
tiple co-primary endpoints and the application of the method in the context of the internal
pilot study design. Simulation results in Subsection 3.2.6 show that this method controls
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the FWER, but there is a cost, which is a loss of power, because the weights of the com-
bination test are not based on the observed sample size but on weights fixed in advance.
Although we would expect this method not to maintain the power for the reasons explained
earlier, simulation results show that by changing the timing of the interim intervention, this
method maintains the power even if it uses pre-defined weights fixed in advance. Simula-
tion ( analytically too ) results also show that changing the weights allocation has an impact
on maintaining the power, however, finding the optimal weights allocation is challenging
because they (weights) are defined before the trial begins.
6.1.3 Group Sequential Designs method
We first introduced the group sequential method in the context of a single endpoint in Sec-
tion 2.3, as described in more detail by Jennison and Turnbull (2000a). We then extended
it in the context of multiple co-primary endpoints in Chapter 4, where K group sequential
tests were conducted, each for one endpoint and at level α/K. We considered the case of K
co-primary endpoints where the rejection of any is taken into account as proof that the new
treatment is conclusive. We designed the method in such a way to allow for early stopping,
at the same time to monitor the information, which was adjusted at each stage to allow
for estimating the variance σ2. The solution that we propose to solve the problem defined
in Subsection 1.4.2, is an easy and simple option, it can be implemented in phase III of a
clinical trial without difficulties. It is also totally different to the solutions of Jennison and
Turnbull (1993) and Cook and Farewell (1994). The method proposed is flexible in such
a way that it allows a group sequential design planned with J stages to be modified to a
group sequential design with J + 1 stages. This is something new that neither Jennison and
Turnbull (1993) nor Cook and Farewell (1994) proposed. Simulation results showed that
the FWER was controlled but became increasingly conservative as ρ12 for large correlated
endpoints. The results also showed that the FWER was above the nominal level of 0.025
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for uncorrelated data, i.e. ρ12 = 0. Nevertheless, this slight increase in the FWER was less
than 0.001, hence too small to be practically relevant. Therefore we concluded that for the
scenarios considered here, the GSD procedure controls the FWER. Simulation results also
show that, although the method maintains the power reasonably well, it may lack power
depending on the spending function used. For example we showed that the power was not
maintained for the Hwang-Shih-DeCani spending function with γ = −10.
6.1.4 GSD Inverse Normal Combination test method
The GSD Inverse Normal Combination test method was presented as a method which inte-
grates the concept of inverse normal combination tests illustrated in Section 2.4 into GSD
as described in Chapter 4. It was first introduced in the context of single endpoint in Sec-
tion 2.2 and Section 2.4, followed by its extension in the context of multiple co-primary
endpoints in Chapter 5. The new features for this method are: use of the Bonferroni correc-
tion to adjust for the FWER, steps to follow when designing a clinical trial with multiple
co-primary endpoints and the application of the method in the context of GSD. Simulation
results in Section 5.6 show that this method controls the FWER, but there is a cost which
is a loss of power; however, the results show that one of the solutions for this would be to
use a less conservative spending function (eg. Hwang-Shih-DeCani spending function with
γ = 10) even if the weights are pre-defined and fixed in advance. It is important to high-
light that the FWER of this method becomes increasingly conservative as the correlation
between endpoints increases compared to the GSD method.
6.2 Extensions and future work
We presented different solutions for sample size re-estimation in phase III of a clinical
trial with multiple co-primary endpoints. We gave simulation examples for two continuous
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endpoints. The first possible extension for all the methods would be to consider an example
of more than two endpoints and investigate whether the FWER would still be controlled
and the power still maintained. The second extension would be to consider two sided-test
scenarios and check how this would affect the FWER and the power.
In Chapter 4, further work could be done on the GSD method with multiple co-
primary endpoints by adding lower boundaries into the design. Suppose cju and cjl repre-
sent the upper boundary and lower boundary, respectively. The stopping rules defined in
Eq. (2.39) are extended as follows:
After group j = 1, ..., J-1
if Zj ≥ cju stop, reject H0
if Zj < cjl stop, do not reject H0
otherwise continue to group j +1
after group J
if ZJ ≥ cJu stop, reject H0
if ZJ < cJl stop, do not reject H0
otherwise stop, accept H0
(6.1)
The type I error is defined through the critical values c1u, ..., cJu and c1l, ..., cJl as
described in Eq. (6.2) below for a single endpoint:
Pr(c1l < Z1 < c1u, ..., c(j−1)l < Zj−1 < c(j−1)u, cjl > Zj > cju|θ = 0) = πj/K (6.2)
calculated when the Z1, ..., ZJ follow the distribution of Eq. (2.38) and the stopping
rules of Eq. (6.1). Considering an example of two endpoints and j stages, the extension of
the FWER defined in Subsection 4.2.3 is now:
At stage 1, we have:
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Pr(stop and reject at least one H0k at or before stage 1 | θk = 0) =
P (Z11 > c1u or Z21 > c1u | θ=0) + P (Z11 < c1l and Z21 < c1l | θ=0) ≤ π1
At look 2, we have:
Pr(stop and reject at least one H0k at or before stage 2 | θk = 0) =
Pr(Z11 > c1u or Z21 > c1u | θ=0) + Pr(Z11 < c1l and Z21 < c1l | θ=0) +
Pr(c1l < Z11 < c1u, c1l < Z21 < c1u,Z12 > c2u or Z22 > c2u, Z12 < c2l
and Z22 < c2l,| θ = 0) ≤ π2
At look j, we have:
Pr(stop and reject at least one H0k at or before stage j | θk = 0) =
Pr(Z11 > c1u or Z21 > c1u | θ=0) + Pr(Z11 < c1l and Z21 < c1l | θ=0) +
Pr(c1l < Z11 < c1u, c1l < Z21 < c1u,Z12 > c2u or Z22 > c2u, Z12 < c2l
and Z22 < c2l,| θ = 0) + ...+ Pr(c1l < Z11 < c1u, c1l < Z21 < c1u,
c2l < Z12 < c2u,c2l < Z22 < c2u,...,c(j−1)l < Z1(j−1) < c(j−1)u,
c(j−1)l < Z2(j−1) < c(j−1)u, Z1j > cju or Z2j > cju, Z1j < cjl and
Z2j < cjl | θ = 0) ≤ πj (6.3)
πj represents the error spending function at stage j, j = 1,...,J. So, to control the
FWER, one must choose cju and cjl to satisfy Eq. (6.2) (i.e, calculate cju and cjl using Eq.
(6.2), and workout πj ).
225
The power defined in Eq. (4.11) is extended, so now we have:
Pr(stop and reject at least one H0k at or before stage j | θk = δ) =
Pr(Z11 > c1u or Z21 > c1u | θ = δ) + Pr(Z11 < c1l and Z21 < c1l | θ = δ) +
Pr(c1l < Z11 < c1u, c1l < Z21 < c1u,Z12 > c2u or Z22 > c2u, Z12 < c2l
and Z22 < c2l,| θ = δ) + ...+ Pr(c1l < Z11 < c1u, c1l < Z21 < c1u,
c2l < Z12 < c2u,c2l < Z22 < c2u,...,c(j−1)l < Z1(j−1) < c(j−1)u,
c(j−1)l < Z2(j−1) < c(j−1)u, Z1j > cju or Z2j > cju, Z1j < cjl and
Z2j < cjl | θ = δ) = 1− β (6.4)
For given values of j, α, β, cju and cjl, the maximum sample size can be found using
mvtnorm package in R to compute multivariate normal probabilities (see Subsection 3.1.4).
6.3 Conclusions
As a conclusion, in this thesis we consider statistical methods for dealing with interim data
in phase III of a clinical trial with multiple co-primary endpoints. They are: sample size
re-estimation, the group sequential approach and the inverse normal combination test pro-
cedure. We show that all the methods control the FWER and we explain in which settings
we would expect the inflation of the FWER. We also show that the SSR and GSD meth-
ods maintain the power and that the GSD seems to be more powerful, again highlighting
settings where the power is not maintained. We finally show that the power of the com-
bination test method is not maintained and explain the reasons for this. The conclusion
about the findings imply that what we can do with the GSD, we also can do with SSR and
combination test method. Simulations presented in this thesis have shown that even if the
results are more or less similar, we can do it in different ways, and the GSD has proven to
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be more powerful. The solutions we propose are either new methods to problems that have
not yet been solved, or approaches that are simpler to apply, and more efficient than ones
currently existing in the literature. We recommend our approaches (SSR and GSD) as they
are simpler to apply than existing ones.
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Appendix A: SSR simulation program
#############################################################################
## This program contains the mean vector, the variance covariance matrix
## and the multivariate normal probability function. The program computes
## the maximum sample size for SSR method and performs the test of hypothesis
## and append the results at the end.
#############################################################################
## Load the pachages below if needed
library(lattice)
library(ldbounds)
library(mvtnorm)
## Defining the function containing the non-centrality parameter, the
## variance covariance matrix and the multivariate normal probability function
sen <- function(n,stages,rho,diff,s1,s2){
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### variance covariance for look2 ##
sigma3 <- matrix(c(1,rho,
rho,1),
nrow=2,ncol=2)
#### Noncentrality parameter for look 2 ####
mean12 <- (diff/s1)*sqrt((2*n)/2)
mean22 <- (diff/s2)*sqrt((2*n)/2)
###DEFINING FUCNTION####
out <- 1 - pmvnorm(lower=c(-Inf,-Inf), upper=c(boundary[1],boundary[1]),
mean=as.numeric(c(mean12,mean22)),sigma=sigma3)-0.8
}
##### Set up the following parameters ######################
rho <- 0.5 # correlation betwen endpoints
s1 <- 1.5 # stadard deviation for endpoint 1
s2 <- 1 # stadard deviation for endpoint 1
diff <- 0.5 # clinically significant treatment difference
stages <- 2 # number of stage
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alpha <- 0.0125 # nominal alpha
mu1 <- matrix(c(diff,diff),nrow=1,ncol=2) # mean vector
mu0 <- matrix(c(0,0),nrow=1,ncol=2) # mean vector
## Calculate the initial maximum sample size
n1 <- floor(uniroot(sen,lower=1,upper=1000,stages=stages,rho=rho,
diff=diff,s1=s1,s2=s2)$root)
dfe1 <- (2*n1)-2 # degree of freedom
# simulation set-up
nsim <- 100000
set.seed(1)
#### set up a file where sigmas and maximum sample size and number
# of rejection are stored
results <- matrix(0,nrow=nsim,ncol=11)
colnames(results) <- c("Gesrho", "GesS1", "GesS2", "n1", "Trurho",
"Estrho", "EstS1", "EstS2", "TotalN", "efficacy")
# run simulations
for (i in 1:nsim){
results[i,1] <- rep(rho) # append guessed correlation
results[i,2] <- rep(s1) # append guessed sigma 1 for endpoint 1
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results[i,3] <- rep(s2) # append guessed sigma 2 for endpoint 2
results[i,4] <- rep(2*n1) # append initial sample size
# initiate
istop <- 0
# simulate sample of size n1
Trurho <- 0 # true correlation
Trus1 <- 1 # true sigma 1
Trus2 <- 1 # true sigma 2
results[i,5] <- rep(Trurho) # append true correlation
nsigma <- matrix(c(Trus1^2,Trus1*Trus2*Trurho,Trus1*Trus2*Trurho,Trus2^2),
ncol=2,nrow=2) # calculate variance covariance matrix
sample <- rmvnorm(n1,c(0,0),nsigma) # simulate sample for treatment group
Csample <- rmvnorm(n1,mu0,nsigma) # simulate sample for control group
nrho <- cor(c(Tsample[,1],Csample[,1]),c(Tsample[,2],Csample[,2]))
# estimate correlation
results[i,6] <- nrho # append estimated correlation
s11 <- sqrt(var(c(Tsample[,1],Csample[,1]))) # estimate variance for endpoint 1
results[i,7] <- s11 # append estimated variance 1
s22 <- sqrt(var(c(Tsample[,2],Csample[,2]))) # estimate variance for endpoint 2
results[i,8] <- s22 # append estimated variance 2
## Re-estimated maximum sample size
231
n2 <- round(uniroot(sen,lower=1,upper=1000,stages=stages,rho=nrho,
diff=diff,s1=s11,s2=s22)$root)
N <- 2*n2 # total re-estimated maximum sample szie
df <- (2*N)-2 # calculate degree of freedom
results[i,9] <- N # append maximum sample size
if (istop==0) {
if (n1>=N) {istop <- 1}
else {
# simulate sample of size N-n1
Tsamplev <- rmvnorm(N-n1,c(0,0),nsigma) # simulate sample of size N-n1 for
treatment group
Csamplev <- rmvnorm(N-n1,mu0,nsigma) # simulate sample of size N-n1 for
control group
Tsample <- rbind(Tsample,Tsamplev) # combine stage 1 data and stage 2 data
for treatment group
Csample <- rbind(Csample,Csamplev) # combine stage 1 data and stage 2 data
for control group
s1f <- sqrt(var(c(Tsample[,1],Csample[,1]))) # estimated variance 1 for
combined data for endpoint 1
s2f <- sqrt(var(c(Tsample[,2],Csample[,2]))) # estimated variance 1 for
combined data for endpoint 2
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cva <- qt(1-alpha,df) # critical value
# test statistics
z1 <- (mean(Tsample[,1])-mean(Csample[,1]))/(s1f*sqrt(2/N)) # calculate
t test for endpoint 1
z2 <- (mean(Tsample[,2])-mean(Csample[,2]))/(s2f*sqrt(2/N)) # calculate
t test for endpoint 2
efficacy <- as.numeric(z1>=(cva) | z2>=(cva)) # number of rejection H0
results[i,10] <- efficacy # append number of rejections
### end of final analysis ###
}# end if
} # end simulation
}
# append results
write.table(results,file="./Ztestguess05true00null.txt",
sep="\t",eol="\n",col.names=TRUE,na = "NA",row.names=FALSE)
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Appendix B: SSR inverse normal
combination test simulation program
#############################################################################
## This program contains the mean vector, the variance covariance matrix
## and the multivariate normal probability function. The program computes
## the maximum sample size for Inverse Normal Combination test method and
## performs the test of hypothesis and append the results at the end.
#############################################################################
## Load the pachages below if needed
library(lattice)
library(ldbounds)
library(mvtnorm)
## Defining the function containing the non-centrality parameter, the
## variance covariance matrix and the multivariate normal probability function
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sen <- function(n,stages,rho,diff,s1,s2){
### variance covariance for look2 ##
sigma3 <- matrix(c(1,rho,
rho,1),
nrow=2,ncol=2)
#### Noncentrality parameter for look 2 ####
mean12 <- (diff/s1)*sqrt((2*n)/2)
mean22 <- (diff/s2)*sqrt((2*n)/2)
###DEFINING FUCNTION####
out <- 1 - pmvnorm(lower=c(-Inf,-Inf), upper=c(boundary[1],boundary[1]),
mean=as.numeric(c(mean12,mean22)),sigma=sigma3)-0.8
}
##### Set up the following parameters ######################
rho <- 0.5 # correlation betwen endpoints
s1 <- 1.5 # stadard deviation for endpoint 1
s2 <- 1 # stadard deviation for endpoint 1
diff <- 0.5 # clinically significant treatment difference
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stages <- 2 # number of stage
alpha <- 0.0125 # nominal alpha
mu1 <- matrix(c(diff,diff),nrow=1,ncol=2) # mean vector
mu0 <- matrix(c(0,0),nrow=1,ncol=2) # mean vector
## Calculate the initial maximum sample size
n1 <- floor(uniroot(sen,lower=1,upper=1000,stages=stages,rho=rho,diff=diff,
s1=s1,s2=s2)$root)
dfe1 <- (2*n1)-2 # stage 1 degree of freedom
# simulation set-up
nsim <- 100000
set.seed(1)
#### set up a file where sigmas and maximum sample size and number
# of rejection are stored
results <- matrix(0,nrow=nsim,ncol=11)
colnames(results) <- c("Gesrho", "GesS1", "GesS2", "n1", "Trurho",
"Estrho", "EstS1", "EstS2", "TotalN", "efficacy")
# run simulations
for (i in 1:nsim){
results[i,1] <- rep(rho) # append guessed correlation
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results[i,2] <- rep(s1) # append guessed sigma 1 for endpoint 1
results[i,3] <- rep(s2) # append guessed sigma 2 for endpoint 2
results[i,4] <- rep(2*n1) # append initial sample size
# initiate
istop <- 0
# simulate sample of size n1
Trurho <- 0 # true correlation
Trus1 <- 1 # true sigma 1
Trus2 <- 1 # true sigma 2
results[i,5] <- rep(Trurho) # append true correlation
nsigma <- matrix(c(Trus1^2,Trus1*Trus2*Trurho,Trus1*Trus2*Trurho,Trus2^2),
ncol=2,nrow=2) # calculate variance covariance matrix
sample <- rmvnorm(n1,c(0,0),nsigma) # simulate sample for treatment group
Csample <- rmvnorm(n1,mu0,nsigma) # simulate sample for control group
nrho <- cor(c(Tsample[,1],Csample[,1]),c(Tsample[,2],Csample[,2]))
# estimate correlation
results[i,6] <- nrho # append estimated correlation
s11 <- sqrt(var(c(Tsample[,1],Csample[,1]))) # estimate variance for
stage 1 data endpoint 1
results[i,7] <- s11 # append estimated variance 1
s22 <- sqrt(var(c(Tsample[,2],Csample[,2]))) # estimate variance for
stage 1 endpoint 2
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results[i,8] <- s22 # append estimated variance 2
######### Combinatiion test stage 1 ##############
t1 <- (mean(Tsample[,1])-mean(Csample[,1]))/(s11*sqrt((1/n1)+(1/n1)))
# t test for endpoint 1
t2 <- (mean(Tsample[,2])-mean(Csample[,2]))/(s22*sqrt((1/n1)+(1/n1)))
# t test for endpoint 2
p1 <- (1-pt(t1,dfe1)) # p value for endpoint 1
p2 <- (1-pt(t2,dfe1)) # p value for endpoint 2
## Inverse Normal Combination
testcum11=(sqrt(0.5))*qnorm(1-p1) # stage 1 test for endpoint 1
testcum21=(sqrt(0.5))*qnorm(1-p2) # stage 1 test for endpoint 2
### End combination test#####
######### Combination test stage 2 ##############
n2 <- round(uniroot(sen,lower=1,upper=1000,stages=stages,
rho=nrho,diff=diff,s1=s11,s2=s22)$root) # maximum sample size re-estimated
N <- 2*n2 # total maximum sample size
dfe2 <- (2*(N-n1))-2 # stage 2 degree of freedom
results[i,9] <- N # append maximum sample size
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if (istop==0) {
if (n1>=N) {istop <- 1}
else {
# simulate sample of size N-n1
Tsamplev <- rmvnorm(N-n1,c(0,0),nsigma) # simulate sample of size N-n1 for
treatment group
Csamplev <- rmvnorm(N-n1,mu0,nsigma) # simulate sample of size N-n1 for
control group
s111 <- sqrt(var(c(Tsamplev[,1],Csamplev[,1]))) # estimate variance for
stage 2 endpoint 1
s222 <- sqrt(var(c(Tsamplev[,2],Csamplev[,2]))) # estimate variance for
stage 2 endpoint 2
# test statistics
t11 <- (mean(Tsamplev[,1])-mean(Csamplev[,1]))/(s111*sqrt((1/(N-n1))+
(1/(N-n1)))) # t test for endpoint 1
t22 <- (mean(Tsamplev[,2])-mean(Csamplev[,2]))/(s222*sqrt((1/(N-n1))+
(1/(N-n1)))) # t test for endpoint 2
p11 <- (1-pt(t11,dfe2)) # p value for endpoint 1
p22 <- (1-pt(t22,dfe2)) # p value for endpoint 2
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testcum12=(sqrt(0.5))*qnorm(1-p11) # stage 2 test for endpoint 1
testcum22=(sqrt(0.5))*qnorm(1-p22) # stage 2 test for endpoint 2
############### End combination test ############
######### Final Analysis ############
test1 = testcum11 + testcum12 # combined test for stage 1 and stage 2 data
endpoint 1
test2 = testcum21 + testcum22 # combined test for stage 1 and stage 2 data
endpoint 2
efficacy <- as.numeric(test1>=(boundary[1]) | test2>=(boundary[1]))
# number for accepting or rejection H0
results[i,10] <- efficacy # append number of rejections
}# end if
} # end simulation
}
# append results
write.table(results,file="./Ztestguess05true02null.txt",sep="\t",eol="\n",
col.names=TRUE,na = "NA",row.names=FALSE)
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Appendix C: Program to compute the
boundaries of a GSD
##############################################################################
#This program contains the main program to compute the boundaries using
Simpson method
##############################################################################
simpson<-function(f,dx){
# Approximates integrals using Simpsons rule.
# f is a vector of function values at 2m+1 equally spaced x
# values (comprising 2m intervals of length dx).
m<-(length(f)-1)/2
evens<-2*(1:m);
odds<-2*(1:m)+1;
last<-2*m+1
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int<-(4*sum(f[evens])+2*sum(f[odds])+f[1]-f[last])*(dx/3) return(int) }
updt<-function(datavec){
# updt gives P(Z_1\le c_1,...,ldots,Z_prev\le c_prev,
# Zcur=zcur);
# datavec consists of:
# First dim1 components contain fprev=P(Z_1\le c_1,\ldots,
# Z_{prev-1}\le c_{prev-1},Z_prev=zprev) for a vector prevgrid.
# Next dim1 components contain the vector prevgrid.
# Next 2 components contain information times of previous and current looks.
# The last component contains zcur.
dimmy<-length(datavec);
dim1<-(dimmy-3)/2;
dim1p<-dim1+1
dim2<-2*dim1
dim2p<-dim2+1;
dim2pp<-dim2+2;
dim2ppp<-dim2+3
fprev<-datavec[1:dim1];
prevgrid<-datavec[dim1p:dim2]
tprev<-datavec[dim2p]
tcur<-datavec[dim2pp];
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zcur<-datavec[dim2ppp]
temp<-(zcur*sqrt(tcur)-prevgrid*sqrt(tprev))/sqrt(tcur-tprev)
y<-sqrt(tcur/(tcur-tprev))*exp(-temp^2/2)/sqrt(2*pi)*fprev
dx<-prevgrid[2]-prevgrid[1] return(simpson(y,dx)) }
distrib<-function(tt,cc){
# Gives P(Z(t_1)\le c_1,...Z(t_k)\le c_k), where
# cc=(c_1,\ldots,c_k),
# tt=(t_1,\ldots,t_k)
if(length(tt)!=length(cc)){return("dimensions of t and c do not match")}
if(max(tt)>1 | min(tt)<=0){return("t_i not in (0,1] for all i")}
if(min(cc)<-7){return(0)}
k<-length(tt)
numint<-50
lengthz<-numint+1
if(k==1){return(pnorm(cc[1],0,1))}
zgrid<-seq(-7,cc[1],length=lengthz)
tprev<-tt[1]
fprev<-exp(-zgrid^2/2)/sqrt(2*pi) for(i in 2:k){
zcur<-seq(-7,cc[i],length=lengthz)
tprev<-tt[i-1]
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tcur<-tt[i]
datmat<-matrix(rep(c(fprev,zgrid,tprev,tcur),lengthz), nrow=lengthz, byrow=T)
datmat<-cbind(datmat,zcur)
ww<-apply(datmat,MARGIN=1,updt)
fprev<-ww
zgrid<-zcur }
dz<-zcur[2]-zcur[1]
ans<-simpson(ww,dz) return(ans) }
#############################################################
rename<-function(cccur,otherstuff){
# Re-parameterizes the distribution function P(Z(t_1)\le c_1,
# \ldots,Z(t_k)\le c_k) so that first variable is c_k and the
# last variable is the cumulative alpha spent.
kminus1<-(length(otherstuff)-2)/2
i1<-kminus1+1;
i2<-kminus1+2;
i3<-2*kminus1+1;
i4<-2*kminus1+2
ttcur<-otherstuff[1];
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ttprev<-otherstuff[2:i1]
ccprev<-otherstuff[i2:i3]
alphacum<-otherstuff[i4]
return(distrib(c(ttprev,ttcur),c(ccprev,cccur))-(1-alphacum)) }
findroot<-function(f,low,high,otherstuff){
# Finds root in interval (low,high) for the increasing (in x) pending Functions
# function f(x,otherstuff).
lower<-low;
higher<-high
if(f(lower,otherstuff)>0 | f(higher,otherstuff)<0){return
("findroot find the root")} for(i in 1:20){
midpoint<-(lower+higher)/2
if(f(midpoint,otherstuff) > 0){higher<-midpoint}
else{lower<-midpoint} }
return((lower+higher)/2)}
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Appendix D: Program containing the
mean vector, the covariance matrix and
the multivariate probability function
#############################################################################
## This program contains the mean vector, the variance covariance matrix
## and the multivariate normal probability function
#############################################################################
gs2.power <- function(n,stages,rho,diff,bound,s1,s2){
################################## set-up stuff ############################
if(stages<2 | stages>5){
stop("Stages must be <=5 and >1")
} # end if
b <- bound
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##### Noncentrality parameter for look 1 ####
mean11 <- (diff/s1)*sqrt(n/2)
mean21 <- (diff/s2)*sqrt(n/2)
#### Noncentrality parameter for look 2 ####
mean12 <- (diff/s1)*sqrt(2*n/2)
mean22 <- (diff/s2)*sqrt(2*n/2)
#### Noncentrality parameter for look 3 ####
mean13 <- (diff/s1)*sqrt((3*n)/2)
mean23 <- (diff/s2)*sqrt((3*n)/2)
### variance covariance for look3 ##
sigma3 <- matrix(c(1,rho,sqrt(1/2),sqrt(1/2)*rho,sqrt(1/3),sqrt(1/3)*rho,
rho,1,sqrt(1/2)*rho,sqrt(1/2),sqrt(1/3)*rho,sqrt(1/3),
sqrt(1/2),sqrt(1/2)*rho,1,rho, sqrt(2/3),sqrt(2/3)*rho,
sqrt(1/2)*rho,sqrt(1/2),rho,1,sqrt(2/3)*rho,sqrt(2/3),
sqrt(1/3),sqrt(1/3)*rho,sqrt(2/3),sqrt(2/3)*rho,1,rho,
sqrt(1/3)*rho,sqrt(1/3),sqrt(2/3)*rho,sqrt(2/3),rho,1),
nrow=6,ncol=6)
############################## Defining functions ###########################
if(stages==3){
out <- 1 - pmvnorm(lower=c(-Inf,-Inf,-Inf,-Inf,-Inf,-Inf), upper=c(bound[1],
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bound[1],bound[2],bound[2],bound[3],bound[3]),
mean=as.numeric(c(mean11,mean21,mean12,mean22,mean13,mean23)),sigma=sigma3)
} ### end if stages=3
out
} ### end gs2.power
ngs2.power <- function(n,stages,rho,diff,bound,power,s1,s2){
gs2.power(n=n,stages=stages,rho=rho,diff=diff,bound=bound,s1=s1,s2=s2)[1]-power
} ### end ng2.power
248
Appendix E: GSD simulation program
##########################################################################
##This program computes the boundaries at each stage and the maximum sample
##sample size. It also performs the test of hypothesis and append the results
##at the end.
##########################################################################
## Load the packages below if needed
library(lattice)
library(mvtnorm)
## The program uses the source file "call" which contains the mean vector,
## the variance covariance matrix and the multivariate normal probability
## function. The progran also uses the source file "coded" which contains
## the main program to compute the boundaries
source("./coded.R") # see appendix A
source("./call.R") # see Appendix B
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##### Before stage 1 the following parameters are set up ####################
stages <- 3 # number of stages
rho <- 0.5 # correlation
diff <- 0.5 # treatement effect
alpha <- 0.0125 # nominal alpha
s1 <- 1.5 # sigma 1
s2 <- 1 # sigma 2
cv <- qnorm(1-alpha/2) # calculate crical value
power <- 0.8 # target power
t10 <- 1/3 # initial time at stage 1
t20 <- 2/3 # initial time at stage 2
t30 <- 3/3 # initial time at stage 3
######### calculate boundaries before stage 1################################
## calculate boundary at stage 1
spendfunct1 <- 2 - 2*pnorm(cv/sqrt(t10))
B10 <- qnorm(1-spendfunct1)
## calculate boundary at stage 2 using program "coded"
# Input
#############################################################
tcur<- t20 # Current value of t
tprev<-c(t10) # Previous values of t go in
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# parentheses.
cprev<-c(B10) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t20)) # Cumulative alpha up to current look,
# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B20 <- findroot(rename,-7,7,other)
## calculate boundary at stage 3 using program "coded"
# Input
#############################################################
tcur<-t30 # Current value of t
tprev<-c(t10,t20) # Previous values of t go in
# parentheses.
cprev<-c(B10,B20) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t30)) # Cumulative alpha up to current look,
# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B30 <- findroot(rename,-7,7,other) # boundary
boundary0 <- c(B10,B20,B30) # initial boundaries
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## Calculate the initial maximum sample size
n0 <- try(round(uniroot(ngs2.power,lower=1,upper=10000,stages=stages,rho=rho,
diff=diff,bound=boundary0,power=power,s1=s1,s2=s2)$root,0),silent=TRUE)
nmax0 <- n0*3
############ Simulate data for stage 1 ############################
################# simulation set-up ###############################
nsim <- 100000 ### number of simulation
set.seed(1) ### number of seeds
results <- matrix(0,nrow=nsim,ncol=8) #### append file set up
###set up a file where number of rejection and expected sample size at each
stage are stored
colnames(results) <- c("efficacy1","expsample1","efficacy2","expsample2",
"efficacy3","expsample3","efficacy5","expsample5")
#### set up a file where sigmas and maximum sample size are stored
results1 <- matrix(0,nrow=nsim,ncol=21)
colnames(results1) <- c("i","rho","s1","s2","nmax0","nrho1","ns11","ns21",
"nmax1","nrho2","ns12","ns22","nmax2","nrho3","ns13","ns23","nmax3","nrho4"
,"ns14","ns24","nmax4")
############################## Run simulations ######################
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for (i in 1:nsim){
results1[i,1] <- i
results1[i,2] <- rho
results1[i,3] <- s1
results1[i,4] <- s2
results1[i,5] <- nmax0
#### initiate ####
istop <- 0
if (istop==0){
############################ stage 1 ###################
trurho <- 0.5 # true correlation
trus1 <- 1.5 # true sigma 1
trus2 <- 1.5 # true sigma 2
nsigma <- matrix(c(trus1^2,trus1*trus2*trurho,trus1*trus2*trurho,
trus2^2),nrow=2,ncol=2) # true variance-covariance matrix
Tsample1 <- rmvnorm(nmax0/3,c(0.5,0.5),nsigma) # simulated data for E group
Csample1 <- rmvnorm(nmax0/3,c(0,0),nsigma) # simulated data for C group
## Estimate nuisance parameters
nrho1 <- cor(c(Tsample1[,1],Csample1[,1]),c(Tsample1[,2],Csample1[,2]))
# estimate rho
ns11 <- sqrt(var(c(Tsample1[,1],Csample1[,1]))) # estimate sigma 1
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ns21 <- sqrt(var(c(Tsample1[,2],Csample1[,2]))) # estimate sigma 2
results1[i,6] <- nrho1 # append results
results1[i,7] <- ns11 # append results
results1[i,8] <- ns21 # append results
## Estimate sample size at stage 1
n1 <- try(round(uniroot(ngs2.power,lower=1,upper=10000,stages=stages,rho=nrho1,
diff=diff,bound=boundary0,power=power,s1=ns11,s2=ns21)$root,0),silent=TRUE)
nmax1 <- n1*3 # maximum sample size
results1[i,9] <- nmax1 # append results
## calculate information fraction and type I error spent at stage 1
t11 <- nmax0/(3*nmax1) # information fraction at stage 1
spendfunct11 <- 2 - 2*pnorm(cv/sqrt(t11)) # type I error at stage 1
B11 <- qnorm(1-spendfunct11) # boundary at stage 1
## perform test of hypotheses
z11 <- (mean(Tsample1[,1])-mean(Csample1[,1]))/(ns11*(sqrt(2/(nmax0/3))))
# z test endpoint 1
z21 <- (mean(Tsample1[,2])-mean(Csample1[,2]))/(ns21*(sqrt(2/(nmax0/3))))
# z test endpoint 2
efficacy1 <- as.numeric(z11>=(B11)|z21>=(B11)) # compare Z and boundary B11
results[i,1] <- as.numeric(z11>=(B11)|z21>=(B11))
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if(efficacy1==1){
results[i,2] <- nmax0/3
istop <- 1
} #accept or reject
else {
################################# stage 2 ################################
# simulate more data
Tsample22 <- rmvnorm(((2*nmax1)/3)-(nmax0/3),c(0.5,0.5),nsigma)
Csample22 <- rmvnorm(((2*nmax1)/3)-(nmax0/3),c(0,0),nsigma)
Tsample2 <- rbind(Tsample1,Tsample22)
Csample2 <- rbind(Csample1,Csample22)
#Estimate nuisance parameters
nrho2 <- cor(c(Tsample2[,1],Csample2[,1]),c(Tsample2[,2],Csample2[,2]))
ns12 <- sqrt(var(c(Tsample2[,1],Csample2[,1])))
ns22 <- sqrt(var(c(Tsample2[,2],Csample2[,2])))
#caculate z statistics
z12 <- (mean(Tsample2[,1])-mean(Csample2[,1]))/(ns12*(sqrt(2/((2*nmax1)/3))))
z22 <- (mean(Tsample2[,2])-mean(Csample2[,2]))/(ns22*(sqrt(2/((2*nmax1)/3))))
results1[i,10] <- nrho2
results1[i,11] <- ns12
results1[i,12] <- ns22
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###################Adjusting Old boundary ##############################
t12 <- nmax0/(3*nmax1)
cond1a <- as.numeric((t12 < 0.091))
if (cond1a==1){t12 <- 0.091}
spendfunct12 <- 2 - 2*pnorm(cv/sqrt(t12))
B12 <- qnorm(1-spendfunct12)
t22 <- (2*nmax1)/(3*nmax1) # information fraction at stage 2
cont <- as.numeric(t22>=1)
if (cont==1) {
t22 <- 1
istop <- 1
}
else {
# Input
#############################################################
tcur<-t22 # Current value of t
tprev<-c(t12) # Previous values of t go in
# parentheses.
cprev<-c(B12) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t22)) # Cumulative alpha up to current look,
# alpha_*(tcur)
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#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B22 <- findroot(rename,-7,7,other) # boundary at stage 2
t32 <- nmax1/nmax1
# Input
#############################################################
tcur<-t32 # Current value of t
tprev<-c(t12,t22) # Previous values of t go in
# parentheses.
cprev<-c(B12,B22) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t32)) # Cumulative alpha up to current look,
# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B32 <- findroot(rename,-7,7,other)
boundary1 <- c(B12,B22,B32) # adjusted boundaries
##### calculate sample size at stage 2 ########
n2 <- try(round(uniroot(ngs2.power,lower=1,upper=10000,stages=stages,rho=nrho2,
diff=diff,bound=boundary1,power=power,s1=ns12,s2=ns22)$root,0),silent=TRUE)
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nmax2 <- n2*3 # max sample size
results1[i,13] <- nmax2 # append results
efficacy2 <- as.numeric(z12>=(B22)|z22>=(B22)) # compare z and boundar B22
results[i,3] <- as.numeric(z12>=(B22)|z22>=(B22)) # append
if(efficacy2==1){
results[i,4] <- (2*nmax1)/3
istop <- 1
} # accept or reject
else {
############################# stage 3 ###############################
######Adusting of old boundaries##########
t13 <- nmax0/(3*nmax2)
spendfunct13 <- 2 - 2*pnorm(cv/sqrt(t13)) # type I erro spent
B13 <- qnorm(1-spendfunct13)
t23 <- (2*nmax1)/(3*nmax2)
t23 <- (2*nmax1)/(3*nmax2)
# Input
#############################################################
tcur<-t23 # Current value of t
tprev<-c(t13) # Previous values of t go in
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# parentheses.
cprev<-c(B13) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t23)) # Cumulative alpha up to current look,
# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B23 <- findroot(rename,-7,7,other)
#print(B23)
t33 <- nmax2/nmax2
# Input
#############################################################
tcur<-t33 # Current value of t
tprev<-c(t13,t23) # Previous values of t go in
# parentheses.
cprev<-c(B13,B23) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t33)) # Cumulative alpha up to current look,
# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B33 <- findroot(rename,-7,7,other)
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boundary2 <- c(B13,B23,B33) # adjusted boundaries at stage 3
# simulate data sta stage 3
Tsample33 <- rmvnorm(nmax2-(2*nmax1)/3,c(0.5,0.5),nsigma)
Csample33 <- rmvnorm(nmax2-(2*nmax1)/3,c(0,0),nsigma)
Tsample3 <- rbind(Tsample2,Tsample33)
Csample3 <- rbind(Csample2,Csample33)
#Estimate nuisance parameters
nrho3 <- cor(c(Tsample3[,1],Csample3[,1]),c(Tsample3[,2],Csample3[,2]))
# estimate rho
ns13 <- sqrt(var(c(Tsample3[,1],Csample3[,1]))) # estimate sigma
ns23 <- sqrt(var(c(Tsample3[,2],Csample3[,2]))) # estimate sigma
# z statistics
z13 <- (mean(Tsample3[,1])-mean(Csample3[,1]))/(ns13*(sqrt(2/(nmax2))))
# z statistic for endpoint 1
z23 <- (mean(Tsample3[,2])-mean(Csample3[,2]))/(ns23*(sqrt(2/(nmax2))))
# z statistic for endpoint 2
# append estimate results
results1[i,14] <- nrho3
results1[i,15] <- ns13
results1[i,16] <- ns23
n3 <- try(round(uniroot(ngs2.power,lower=1,upper=10000,stages=stages,rho=nrho3,
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diff=diff,bound=boundary2,power=power,s1=ns13,s2=ns23)$root,0),silent=TRUE)
nmax3 <- n3*3 # max sample size
results1[i,17] <- nmax3
################ Adjust old Boundary ###############
t14 <- nmax0/(3*nmax3)
cond3 <- as.numeric(((t20 -t14) < 0.091) | (t14 < 0.091))
if (cond3==1) {t14 <- 0.091}
spendfunct14 <- 2 - 2*pnorm(cv/sqrt(t14))
B14 <- qnorm(1-spendfunct14)
t24 <- (2*nmax1)/(3*nmax3)
conti <- as.numeric(t24>=1)
if (conti==1) {
t24 <- 1
istop <- 1
}
else {
# Input
#############################################################
tcur<-t24 # Current value of t
tprev<-c(t14) # Previous values of t go in
# parentheses.
cprev<-c(B14) # Previous boundary values go in
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# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t24)) # Cumulative alpha up to current look,
# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B24 <- findroot(rename,-7,7,other)
t34 <- (3*nmax2)/(3*nmax3)
# Input
#############################################################
tcur<-t34 # Current value of t
tprev<-c(t14,t24) # Previous values of t go in
# parentheses.
cprev<-c(B14,B24) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t34)) # Cumulative alpha up to current look,
# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B34 <- findroot(rename,-7,7,other)
boundary3 <- c(B14,B24,B34) # new boundaries to use at stage 4
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efficacy3 <- as.numeric(z13>=(B34) | z23>=(B34))
results[i,5] <- as.numeric(z13>=(B34) | z23>=(B34))
if (efficacy3==1){
results[i,6] <- nmax2
istop <- 1
}
else {
if (t34==1) {
istop <- 1
}
else {
#####################################stage 4###############################
#simulate data
Tsample44 <- rmvnorm((nmax3-nmax2),c(0.5,0.5),nsigma)
Csample44 <- rmvnorm((nmax3-nmax2),c(0,0),nsigma)
Tsample4 <- rbind(Tsample3,Tsample44)
Csample4 <- rbind(Csample3,Csample44)
#Estimate nuisance parameters
nrho4 <- cor(c(Tsample4[,1],Csample4[,1]),c(Tsample4[,2],Csample4[,2]))
# estimate rho
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ns14 <- sqrt(var(c(Tsample4[,1],Csample4[,1]))) # estimate sigma 1
ns24 <- sqrt(var(c(Tsample4[,2],Csample4[,2]))) # estimate sigma 2
results1[i,18] <- nrho4
results1[i,19] <- ns14
results1[i,20] <- ns24
# Sample size at stage 4
n4 <- try(round(uniroot(ngs2.power,lower=1,upper=10000,stages=stages,rho=nrho4,
diff=diff,bound=boundary3,power=power,s1=ns14,s2=ns24)$root,0),silent=TRUE)
nmax4 <- n4*3 # max sample size
results1[i,21] <- nmax4
t4 <- 1 # information time
# Input
#############################################################
tcur<-t4 # Current value of t
tprev<-c(t14,t24,t34) # Previous values of t go in
# parentheses.
cprev<-c(B14,B24,B34) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t4)) # Cumulative alpha up to current look,
# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
264
B4 <- findroot(rename,-7,7,other) # boundary at stage 4
z14 <- (mean(Tsample4[,1])-mean(Csample4[,1]))/(ns14*(sqrt(2/(nmax4))))
z24 <- (mean(Tsample4[,2])-mean(Csample4[,2]))/(ns24*(sqrt(2/(nmax4))))
efficacy4 <- as.numeric(z14>=(B4) | z24>=(B4))
results[i,7] <- as.numeric(z14>=(B4) | z24>=(B4))
if(efficacy4==1){
results[i,8] <- nmax4
istop <- 1}
} # end sim
} # end istop
} # end of look 1
} # end t22
} # end look 2
} # end of t23
} # end of t24
} # end of stage 3
################## append results and results1 ##############
write.table(results,file="./guess05true05alt.txt",sep="\t",eol="\n",
col.names=TRUE,na = "NA",row.names=FALSE)
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write.table(results1,file="./guess05true05alt1.txt",sep="\t",eol="\n",
col.names=TRUE,na = "NA",row.names=FALSE)
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Appendix F: GSD inverse normal
combination test simulation program
library(lattice)
#library(ldbounds)
library(mvtnorm)
source("./call.R")
source("./coded.R")
#setwd("H:/IPS/Results")
stages <- 3
rho <- 0.5
diff <- 0.5
alpha <- 0.0125
s1 <- 1.5
s2 <- 1
cv <- qnorm(1-alpha/2)
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power <- 0.8
t10 <- 1/3
t20 <- 2/3
t30 <- 3/3
## calculate boundary at look 1###
spendfunct1 <- 2 - 2*pnorm(cv/sqrt(t10))
B10 <- qnorm(1-spendfunct1)
## calculate boundary at look 2##
# Input
#############################################################
tcur<- t20 # Current value of t
tprev<-c(t10) # Previous values of t go in
# parentheses.
cprev<-c(B10) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t20)) # Cumulative alpha up to
current look,
# alpha_*(tcur)
#############################################################
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other<-c(tcur,tprev,cprev,cumulal)
B20 <- findroot(rename,-7,7,other)
## calculate boundary at look 3##
# Input
#############################################################
tcur<-t30 # Current value of t
tprev<-c(t10,t20) # Previous values of t go in
# parentheses.
cprev<-c(B10,B20) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t30)) # Cumulative alpha up to
current look,
# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B30 <- findroot(rename,-7,7,other)
boundary0 <- c(B10,B20,B30)
#print(boundary2)
## Sample size
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#n0 <- round(uniroot(gs2.power,lower=1,upper=100000,rho=rho,
diff=diff,bound=boundary0,stages,s1,s2)$root)
n0 <- try(round(uniroot(ngs2.power,lower=1,upper=10000,
stages=stages,
rho=rho,diff=diff,bound=boundary0,power=power,s1=s1,
s2=s2)$root,0),silent=TRUE)
nmax0 <- n0*3
# simulation set-up
nsim <- 100000
set.seed(1)
results <- matrix(0,nrow=nsim,ncol=8)
colnames(results) <- c("efficacy1","expsample1",
"efficacy2","expsample2",
"efficacy3","expsample3","efficacy5","expsample5")
results1 <- matrix(0,nrow=nsim,ncol=21)
colnames(results1) <- c("i","rho","s1","s2","nmax0",
"nrho1","ns11","ns21",
"nmax1","nrho2","ns12","ns22","nmax2","nrho3","ns13",
"ns23","nmax3","nrho4","ns14","ns24","nmax4")
# run simulations
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for (i in 1:nsim){
results1[i,1] <- i
results1[i,2] <- rho
results1[i,3] <- s1
results1[i,4] <- s2
results1[i,5] <- nmax0
# initiate
istop <- 0
if (istop==0){
############################ Look1 ###################
trurho <- 0
trus1 <- 1
trus2 <- 1.5
nsigma <- matrix(c(trus1^2,trus1*trus2*trurho,
trus1*trus2*trurho,trus2^2),nrow=2,ncol=2)
Tsample1 <- rmvnorm(nmax0/3,c(0,0),nsigma)
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Csample1 <- rmvnorm(nmax0/3,c(0,0),nsigma)
##Blinded Sample Size##
nrho1 <- cor(c(Tsample1[,1],Csample1[,1]),
c(Tsample1[,2],Csample1[,2]))
ns11 <- sqrt(var(c(Tsample1[,1],Csample1[,1])))
ns21 <- sqrt(var(c(Tsample1[,2],Csample1[,2])))
condit11 <- as.numeric(nrho1>1)
if (condit11==1) { nrho1 <- 1}
results1[i,6] <- nrho1
results1[i,7] <- ns11
results1[i,8] <- ns21
n1 <- try(round(uniroot(ngs2.power,lower=1,
upper=10000,
stages=stages,rho=nrho1,diff=diff,bound=boundary0,
power=power,s1=ns11,s2=ns21)$root,0),silent=TRUE)
nmax1 <- n1*3
dfe1 <- (2*(nmax0/3))-2
results1[i,9] <- nmax1
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t11 <- nmax0/(3*nmax1)
cond1 <- as.numeric(((t20 - t11) < 0.091)|
(t11 < 0.091))
if (cond1==1){t11 <- 0.091}
spendfunct11 <- 2 - 2*pnorm(cv/sqrt(t11))
B11 <- qnorm(1-spendfunct11)
Tsample11 <- rmvnorm(nmax1/3,c(0,0),nsigma)
Csample11 <- rmvnorm(nmax1/3,c(0,0),nsigma)
z11 <- (mean(Tsample11[,1])-mean(Csample11[,1]))
/(ns11*(sqrt(2/(nmax1/3))))
z21 <- (mean(Tsample11[,2])-mean(Csample11[,2]))
/(ns21*(sqrt(2/(nmax1/3))))
dfe11 <- (2*(nmax1/3))-2
p1 <- (1-pt(z11,dfe11))
p2 <- (1-pt(z21,dfe11))
zz11= qnorm(1-p1)
zz21= qnorm(1-p2)
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efficacy1 <- as.numeric(zz11>=(B11)|zz21>=(B11))
#futility1 <- as.numeric(zz11<(-B11) & zz21<(-B11))
results[i,1] <- as.numeric(zz11>=(B11)|zz21>=(B11))
if(efficacy1==1){
results[i,2] <- nmax0/3
istop <- 1
}
else {
################################# Look 2 #####################
ttt <- ((2*nmax1)/3)-(nmax0/3)
kat <- as.numeric(ttt<5)
if (kat==1) {ttt <-7}
Tsample2 <- rmvnorm(ttt,c(0,0),nsigma)
Csample2 <- rmvnorm(ttt,c(0,0),nsigma)
#Tsample2 <- rmvnorm(((2*nmax1)/3)-(nmax0/3),c(0,0),nsigma)
#Csample2 <- rmvnorm(((2*nmax1)/3)-(nmax0/3),c(0,0),nsigma)
274
#J <- ((2*nmax1)/3)-(nmax0/3)
#Tsample2 <- rbind(Tsample1,Tsample22)
#Csample2 <- rbind(Csample1,Csample22)
#########################Blinded Sample Size##
nrho2 <- cor(c(Tsample2[,1],Csample2[,1]),c(Tsample2[,2],
Csample2[,2]))
ns12 <- sqrt(var(c(Tsample2[,1],Csample2[,1])))
ns22 <- sqrt(var(c(Tsample2[,2],Csample2[,2])))
condit22 <- as.numeric(nrho2>1)
if (condit22==1) { nrho2 <- 1}
#condit222 <- as.numeric(nrho2<0)
#if (condit222==1) { nrho2 <- 0}
#z12 <- (mean(Tsample2[,1])-mean(Csample2[,1]))/(ns12*
(sqrt(2/((2*nmax1-nmax0)/3))))
#z22 <- (mean(Tsample2[,2])-mean(Csample2[,2]))/(ns22*
(sqrt(2/((2*nmax1-nmax0)/3))))
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z12 <- (mean(Tsample2[,1])-mean(Csample2[,1]))/(ns12*
(sqrt(2/((ttt)))))
z22 <- (mean(Tsample2[,2])-mean(Csample2[,2]))/(ns22*
(sqrt(2/((ttt)))))
#### calculate degree of freedom, p-values and IVN tests ####
#dfe2 = 2*((2*nmax1-nmax0)/3)-2
#dfe2 = 2*ttt-2
#p11 <- (1-pnorm(z12))
#p22 <- (1-pnorm(z22))
#zz12=(1/sqrt(2))*(qnorm(1-p1)+qnorm(1-p11))
#zz22=(1/sqrt(2))*(qnorm(1-p2)+qnorm(1-p22))
results1[i,10] <- nrho2
results1[i,11] <- ns12
results1[i,12] <- ns22
###################Adjusting Old boundary ###############
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t12 <- nmax0/(3*nmax1)
cond1a <- as.numeric((t12 < 0.091))
if (cond1a==1){t12 <- 0.091}
spendfunct12 <- 2 - 2*pnorm(cv/sqrt(t12))
B12 <- qnorm(1-spendfunct12)
t22 <- (2*nmax1)/(3*nmax1)
cont <- as.numeric(t22>=1|t22<=t12|(t22 - t12) < 0.091)
if (cont==1) {
#t22 <- 1
istop <- 1
}
else {
# Input
#############################################################
tcur<-t22 # Current value of t
tprev<-c(t12) # Previous values of t go in
# parentheses.
cprev<-c(B12) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t22)) # Cumulative alpha up
to current look,
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# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B22 <- findroot(rename,-7,7,other)
t32 <- nmax1/nmax1
# Input
#############################################################
tcur<-t32 # Current value of t
tprev<-c(t12,t22) # Previous values of t go in
# parentheses.
cprev<-c(B12,B22) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t32)) # Cumulative alpha up
to current look,
# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B32 <- findroot(rename,-7,7,other)
boundary1 <- c(B12,B22,B32)
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n2 <- try(round(uniroot(ngs2.power,lower=1,upper=10000,
stages=stages,rho=nrho2,diff=diff,bound=boundary1,
power=power,s1=ns12,s2=ns22)$root,0),silent=TRUE)
nmax2 <- n2*3
tttt <- ((2*nmax2)/3)-(nmax1/3)
katt <- as.numeric(tttt<5)
if (katt==1) {tttt <-7}
Tsample22 <- rmvnorm(tttt,c(0,0),nsigma)
Csample22 <- rmvnorm(tttt,c(0,0),nsigma)
z12 <- (mean(Tsample22[,1])-mean(Csample22[,1]))
/(ns12*(sqrt(2/((tttt)))))
z22 <- (mean(Tsample22[,2])-mean(Csample22[,2]))
/(ns22*(sqrt(2/((tttt)))))
dfe22 = 2*tttt-2
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p11 <- (1-pt(z12,dfe22))
p22 <- (1-pt(z22,dfe22))
zz12=(1/sqrt(2))*(qnorm(1-p1)+qnorm(1-p11))
zz22=(1/sqrt(2))*(qnorm(1-p2)+qnorm(1-p22))
kkk <- nmax2- ((2*nmax1)/3)
condaaa <- as.numeric(kkk <= 5)
if (condaaa==1) {kkk <- 10}
#else{
results1[i,13] <- nmax2
efficacy2 <- as.numeric(zz12>=(B22)|zz22>=(B22))
#futility2 <- as.numeric(z12<(-B22) & z22<(-B22))
results[i,3] <- as.numeric(zz12>=(B22)|zz22>=(B22))
if(efficacy2==1){
results[i,4] <- (2*nmax1)/3
istop <- 1
}
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else {
############################# Look 3 ###############
######Adusting of old boundaries##########
t13 <- nmax0/(3*nmax2)
cond2 <- as.numeric(((t20 - t13) < 0.091) |
(t13 <0.091))
if (cond2==1) {t13 <- 0.091}
spendfunct13 <- 2 - 2*pnorm(cv/sqrt(t13))
B13 <- qnorm(1-spendfunct13)
t23 <- (2*nmax1)/(3*nmax2)
conda <- as.numeric(t23>=1 | t23<=t13|(t23 - t13)
< 0.091)
if (conda==1) {istop <- 1}
else {
#condabis <- as.numeric(((t23 - t13) < 0.091) |
(t23 <0.091))
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#if (condabis==1) {t23 <- 0.091}
# Input
#########################################################
tcur<-t23 # Current value of t
tprev<-c(t13) # Previous values of t go in
# parentheses.
cprev<-c(B13) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t23)) # Cumulative
alpha up to current look,
# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B23 <- findroot(rename,-7,7,other)
#print(B23)
t33 <- nmax2/nmax2
# Input
#############################################################
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tcur<-t33 # Current value of t
tprev<-c(t13,t23) # Previous values of t go in
# parentheses.
cprev<-c(B13,B23) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t33)) # Cumulative
alpha up to current look,
# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B33 <- findroot(rename,-7,7,other)
boundary2 <- c(B13,B23,B33)
Tsample3 <- rmvnorm(kkk,c(0,0),nsigma)
Csample3 <- rmvnorm(kkk,c(0,0),nsigma)
#Tsample3 <- rmvnorm(nmax2-(2*nmax1)/3,c(0,0),nsigma)
#Csample3 <- rmvnorm(nmax2-(2*nmax1)/3,c(0,0),nsigma)
#Tsample3 <- rbind(Tsample2,Tsample33)
#Csample3 <- rbind(Csample2,Csample33)
##Blinded Sample Size##
nrho3 <- cor(c(Tsample3[,1],Csample3[,1]),
c(Tsample3[,2],Csample3[,2]))
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ns13 <- sqrt(var(c(Tsample3[,1],Csample3[,1])))
ns23 <- sqrt(var(c(Tsample3[,2],Csample3[,2])))
condit33 <- as.numeric(nrho3>1)
if (condit33==1) {nrho3 <- 1}
#condit333 <- as.numeric(nrho3<0)
#if (condit333==1) { nrho3 <- 0}
#z13 <- (mean(Tsample3[,1])-mean(Csample3[,1]))
/(ns13*(sqrt(2/(kkk))))
#z23 <- (mean(Tsample3[,2])-mean(Csample3[,2]))
/(ns23*(sqrt(2/(kkk))))
#z13 <- (mean(Tsample3[,1])-mean(Csample3[,1]))
/(ns13*(sqrt(2/(nmax2-((2*nmax1)/3)))))
#z23 <- (mean(Tsample3[,2])-mean(Csample3[,2]))
/(ns23*(sqrt(2/(nmax2-((2*nmax1)/3)))))
#dfe3 = 2*(nmax2-(2*nmax1)/3)-2
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#dfe3 = 2*kkk-2
#p13 <- (1-pt(z13,dfe3))
#p23 <- (1-pt(z23,dfe3))
#zz13=(1/sqrt(3))*(qnorm(1-p1)+qnorm(1-p11)+qnorm(1-p13))
#zz23=(1/sqrt(3))*(qnorm(1-p2)+qnorm(1-p22)+qnorm(1-p23))
######
results1[i,14] <- nrho3
results1[i,15] <- ns13
results1[i,16] <- ns23
n3 <- try(round(uniroot(ngs2.power,lower=1,upper=10000,
stages=stages,rho=nrho3,diff=diff,bound=boundary2,
power=power,s1=ns13,s2=ns23)$root,0),silent=TRUE)
nmax3 <- n3*3
results1[i,17] <- nmax3
kkkk <- nmax3- ((2*nmax2)/3)
condaaaa <- as.numeric(kkkk <= 5)
if (condaaaa==1) {kkkk <- 10}
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Tsample33 <- rmvnorm(kkkk,c(0,0),nsigma)
Csample33 <- rmvnorm(kkkk,c(0,0),nsigma)
z13 <- (mean(Tsample33[,1])-mean(Csample33[,1]))
/(ns13*(sqrt(2/(kkkk))))
z23 <- (mean(Tsample33[,2])-mean(Csample33[,2]))
/(ns23*(sqrt(2/(kkkk))))
#z13 <- (mean(Tsample3[,1])-mean(Csample3[,1]))
/(ns13*(sqrt(2/(nmax2-((2*nmax1)/3)))))
#z23 <- (mean(Tsample3[,2])-mean(Csample3[,2]))
/(ns23*(sqrt(2/(nmax2-((2*nmax1)/3)))))
#dfe3 = 2*(nmax2-(2*nmax1)/3)-2
dfe33 = 2*kkkk-2
p13 <- (1-pt(z13,dfe33))
p23 <- (1-pt(z23,dfe33))
zz13=(1/sqrt(3))*(qnorm(1-p1)+qnorm(1-p11)
+qnorm(1-p13))
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zz23=(1/sqrt(3))*(qnorm(1-p2)+qnorm(1-p22)
+qnorm(1-p23))
################New Boundary###############
t14 <- nmax0/(3*nmax3)
cond3 <- as.numeric(((t20 -t14) < 0.01)
| (t14 < 0.091))
if (cond3==1) {t14 <- 0.091}
spendfunct14 <- 2 - 2*pnorm(cv/sqrt(t14))
B14 <- qnorm(1-spendfunct14)
t24 <- (2*nmax1)/(3*nmax3)
conti <- as.numeric(((t24 -t14) < 0.091)
| (t24>=1) | t24 <=t14)
if (conti==1) {
#t24 <- 1
istop <- 1
}
else {
# Input
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########################################################
tcur<-t24 # Current value of t
tprev<-c(t14) # Previous values of t go in
# parentheses.
cprev<-c(B14) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t24)) # Cumulative
alpha up to current look,
# alpha_*(tcur)
#########################################################
other<-c(tcur,tprev,cprev,cumulal)
B24 <- findroot(rename,-7,7,other)
t34 <- (3*nmax2)/(3*nmax3)
contii <- as.numeric(t34>=1 |((t34 - t24) < 0.10))
#contii <- as.numeric(t34>=1)
if (contii==1) {
t34 <- 1
}
# Input
#############################################################
tcur<-t34 # Current value of t
tprev<-c(t14,t24) # Previous values of t go in
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# parentheses.
cprev<-c(B14,B24) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t34)) # Cumulative
alpha up to current look,
# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B34 <- findroot(rename,-7,7,other)
boundary3 <- c(B14,B24,B34)
efficacy3 <- as.numeric(zz13>=(B34) | zz23>=(B34))
#futility3 <- as.numeric(z13<(-B34) & z23<(-B34))
results[i,5] <- as.numeric(zz13>=(B34) | zz23>=(B34))
if (efficacy3==1){
results[i,6] <- nmax2
istop <- 1
}
else {
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if (t34==1) {
istop <- 1
}
else {
#####################Look 4################################
ppp <- nmax3-nmax2
condit444 <- as.numeric(ppp < 5)
if (condit444==1) {ppp <- 7}
Tsample4 <- rmvnorm(ppp,c(0,0),nsigma)
Csample4 <- rmvnorm(ppp,c(0,0),nsigma)
#Tsample4 <- rmvnorm((nmax3-nmax2),c(0,0),nsigma)
#Csample4 <- rmvnorm((nmax3-nmax2),c(0,0),nsigma)
#Tsample4 <- rbind(Tsample3,Tsample44)
#Csample4 <- rbind(Csample3,Csample44)
#Tsample4 <- rmvnorm(nmax3,c(0.5,0.5),nsigma)
#Csample4 <- rmvnorm(nmax3,mu0,nsigma)
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#Blided sample size
nrho4 <- cor(c(Tsample4[,1],Csample4[,1]),c
(Tsample4[,2],Csample4[,2]))
ns14 <- sqrt(var(c(Tsample4[,1],Csample4[,1])))
ns24 <- sqrt(var(c(Tsample4[,2],Csample4[,2])))
#condit444 <- as.numeric(nrho4<0)
#if (condit444==1) {nrho4 <- 0}
condit44 <- as.numeric(nrho4>1)
if (condit44==1) { nrho4 <- 1}
results1[i,18] <- nrho4
results1[i,19] <- ns14
results1[i,20] <- ns24
#cojeka <- as.numeric((nmax3-nmax2)<=3)
# if (cojeka==1) {istop <- 1}
#else{
n4 <- try(round(uniroot(ngs2.power,lower=1,upper=10000
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,stages=stages,rho=nrho4,diff=diff,bound=boundary3
,power=power,s1=ns14,s2=ns24)$root,0),silent=TRUE)
nmax4 <- n4*3
results1[i,21] <- nmax4
#cond333 <- as.numeric(nmax3<=nmax2)
# if (cond333==1) {istop <- 1}
#else {
###
t4 <- 1
#print(t4)
# Input
#############################################################
tcur<-t4 # Current value of t
tprev<-c(t14,t24,t34) # Previous values of t go in
# parentheses.
cprev<-c(B14,B24,B34) # Previous boundary values go in
# parentheses.
cumulal<- 2 - 2*pnorm(cv/sqrt(t4)) # Cumulative
alpha up to current look,
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# alpha_*(tcur)
#############################################################
other<-c(tcur,tprev,cprev,cumulal)
B4 <- findroot(rename,-7,7,other)
sss <- nmax4-nmax3
condit4444 <- as.numeric(sss <= 3)
if (condit4444==1) {istop <- 1}
else {
Tsample44 <- rmvnorm(sss,c(0,0),nsigma)
Csample44 <- rmvnorm(sss,c(0,0),nsigma)
z14 <- (mean(Tsample44[,1])-mean(Csample44[,1]))
/(ns14*(sqrt(2/(sss))))
z24 <- (mean(Tsample44[,2])-mean(Csample44[,2]))
/(ns24*(sqrt(2/(sss))))
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#z14 <- (mean(Tsample4[,1])-mean(Csample4[,1]))
/(ns14*(sqrt(2/(nmax3-nmax2))))
#z24 <- (mean(Tsample4[,2])-mean(Csample4[,2]))
/(ns24*(sqrt(2/(nmax3-nmax2))))
########calculate p-value,
#dfe4 = 2*(nmax3-nmax2)-2
dfe4 = 2*sss-2
p14 <- (1-pt(z14,dfe4))
p24 <- (1-pt(z24,dfe4))
zz14= (1/sqrt(4))*(qnorm(1-p1)+qnorm(1-p11)
+qnorm(1-p13)+qnorm(1-p14))
zz24= (1/sqrt(4))*(qnorm(1-p2)+qnorm(1-p22)
+qnorm(1-p23)+qnorm(1-p24))
efficacy4 <- as.numeric(zz14>=(B4) | zz24>=(B4))
futility4 <- as.numeric(zz14<(-B4) & z24<(-B4))
results[i,7] <- as.numeric(zz14>=(B4) | zz24>=(B4))
if(efficacy4==1){
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results[i,8] <- nmax4
istop <- 1}
} #end sim
} #end istop
} # end of look 1
} #end t22
} #end look 2
} #end of t23
} #end of t24
} #end of stage 3
}
}
#}
#}
#}
write.table(results,file="./guess05true00null.txt"
,sep="\t",eol="\n",col.names=TRUE,na = "NA",row.names=FALSE)
write.table(results1,file="./guess05true00null1.txt"
,sep="\t",eol="\n",col.names=TRUE,na = "NA",row.names=FALSE)
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